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A: General Introduction 
From studies described in literature, it has become clear that many 
industrial aromatic halogenated hydrocarbons (AHHs) may pose a threat to 
the health of humans, particularly of those in the occupational environment. 
These compounds have found a broad environmental distribution and are 
contaminating food at low levels. The AHHs share the property of a high fat 
and low water solubility, a high persistancy to biodegradation and a low 
turnover rate. Hence, they are deposited in the body in adipose (fatty) tissue, 
and accumulate in the food chain (plants, fish, mammalian species). The 
group of AHHs (Table 1), consist of the halogenated benzenes, halogenated 
biphenyls, halogenated dibenzo-p-dioxins and halogenated dibenzofurans 
(Fig. 1). 
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00 Table 1, Toxic accidents with halogenated aromatic hydrocarbons (AHHs) 
Chemical class Toxic Source Loca\!on Naura- Thyrold- References 
compounds loxlcity toxicity 
Polychlorinated Hexachloro- Contaminated grain Turkey + + Pelers el al (1982) 
benzenes benzene + Cripps el al (198~) 
Polychlorinated PCB mixture Rice oil Yusho (Japan) + Kuratsune 
biphenyls (PCBs) (1972,1976,1980) 
+ Mural el al (1987) 
YuCheng (Taiwan) + Hsu el al (1984) 
+ Rogan at al 
(1988,1992) 
Polybromlnaled (Firemaster food supplement Michigan (US) + Dunckel (1975) 
biphenyls (PBBs) BP-6) + Bahn el al (1986) 
Polychlorinated TeDO') 2,4,5- Weesp (Netherlands) + Hay (1979) 
dibenzo-p-dloxins Irichlorophenol Seveso (ilaly) + Bertazzi at al 
(PCDDs) Wesl Virginia (US) (1989) 
TeDO') Contaminated Missouri (US) 
-
- Regglanl (1980) 
horse arenas + Ashe el al (1953) 
1) 2,3,7,8-tetrachlorodibenzo-p-dloxin 
Fig 1. Chemical structures of AHHs 
Chemical Structure 
BackboneI'") 
3 2 2' 3' 
4Q-U'\( Ij '\( 4' 
1 l' 
- -
m o o m 5 6 6' 5' 
Chlorinated benzenes' 1 x x 
x~ ~x 
x x 
Polychlorinated biphenyls'l x x x x 
x~ H ~x 
x x x x 
Polychlorinated dibenzo-p-dioxins'l 
Polychlorinated dibenzofurans'l 
r) The structures indicate the possible positions ofthe chlorines 'In terms of ortho (0), meta (m), 
or para (p) site, and of 1, 2, 3, 4, 5 and 6 positions. 1): X=chlorine. 
9 
Toxic episodes with sometimes large-scale exposure of people to AHHs 
have revealed a number of different signs and symptoms of toxicity, such as 
dermal lesions (chloracne, e.g hyperkeratosis of the epidermis), hepato-
megaly, thymus involution, and alopecia. Neuro- and thyroid-toxicity were 
found to be associated with the major part of the AHHs (Table 1). All taken 
together it appears that, despite the differences in chemical backbone of the 
various AHHs, the signs and symptoms of intoxication with these compounds 
share a great deal of homology. Apart from the acute toxic effects of these 
chemicals, there is concern about the long-term effects on human health. In 
particular, toxicity of AHHs with respect to carcinogenesis, reproduction and 
development (of the nervous system) are the subject of a number of recently 
completed or ongoing investigations in the Netherlands and internationally. 
In the following sections, information on occurrence, toxicokinetics and 
toxicodynamics of AHHs is given with special emphasis on polychlorinated 
biphenyls (PCBs), polychlorinated dibenzo-p-dioxins (PCDDs) and 
hexachlorobenzene (HCB). In the outline of this thesis, the aim of the study 
is presented. 
B: Toxicology of aromatic halogenated hydrocarbons with an emphasis 
on thyroid-and neuro-toxicity: a review 
Polychlorinated biphenyls (PCBs) and polychlorinated dibenzo-p-dioxins 
(PCDDs) 
Occurrence 
Industrial chemicals which have become widespread contaminants ofthe 
environment are PCBs and PCDDs (see reviews of Safe, 1984, George et ai, 
1988, McFarland et ai, 1989, Sale et ai, 1990). PCBs were used for over 50 
years in numerous industrial processes as additives to open systems, such 
as paints, plastics, rubber, carbonless paper, printing inks, and insecticides. 
In addition, PCBs were also extensively applied as insulating materials in 
electrical capacitors and as coolants in closed systems, such as transformers 
and condensators (Hutzinger et ai, 1974). Theoretically, 209 PCB isomers are 
possible, and they are classified according to the number and position of 
chlorine-atoms (Ballschmiter et ai, 1980, McFarland et ai, 1989). 
PCBs have not been produced or used since the end of the seventies, 
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but the properties that guaranteed their usefulness to industry (i.e., 
resistance to fire, acids and bases, and oxidation, including suitable 
viscosity-temperature relationships and low vapour pressure), has resulted 
in occurrence of considerable amounts in the environment (Tanabe, 1988). 
Major routes by which PCBs enter the environment are inadequate 
destruction of PCB containing materials by incineration, leakage from 
landfills, and leaking cooling water used in transformer manufacturing. 
Dioxins (PCDDs) are formed as unwanted by-products during the 
synthesis of PCBs, chlorophenols (pentachlorophenol, 2,4,5-trichlorophenol), 
and herbicides. Furthermore, PCDDs are predominantly introduced into the 
environment as by-products of incinerations, such as fly ash and flue gases 
(Olie et ai, 1977). 
Toxicokinetics 
PCBs accumulate in skin and muscle, but mainly in adipose tissue, due 
to their low solubility in water and high accumulation coefficients. PCBs leave 
the body slowly. Animal species of the aquatic environment (fish, marine 
mammals, fish eating birds), and land living mammals (also humans) contain 
large quantities of PCBs, which has often been ascribed to their IipophiliCity 
and stability . 
. PCBs and other compounds belonging to the AHHs are metabolized by 
the so- called phase 1- and phase II (conjugation) enzymes. The former 
introduce polar groups into lipophilic substrates by oxidation, reduction or 
hydrolysis, and the latter couple hydrophylic compounds to the polar group, 
leading to more water soluble molecules. When highly reactive intermediate 
(arene) oxides and/or hydroxylated compounds are produced, toxicity may 
be increased (bioactivation). Xenobiotics with more polar character will be 
mainly metabolized by phase II enzymes. The phase I enzymes include the 
hepatic and extrahepatic aryl hydrocarbon-metabolizing mixed function 
oxidases (MFOs). These are hemoproteins which are localised in membranes 
of the smooth endoplasmatic reticulum of the cell. 
One of the most important enzymes with mono-oxygenase activity, i.e., 
the capacity to reduce molecular oxygen to water and to insert a second 
oxygen atom in the substrate, is cytochrome P450. There exist various iso-
enzymes, which all possess the capacity to transform various types of 
substrates (Hahn et ai, 1988). Roughly, two classes of MFO inducers, based 
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on their degree and capacity of induction of different types of cytochrome 
P450, resembling phenobarbital (PB) or 3-methylcholanthrene (MC) are 
known. 
The oxidative metabolic pathways for PCBs and related compounds are 
catalyzed by various types of MFOs (see review McFarland et al; 1989). The 
induced type of MFO and the toxicity of PCBs depends on the structure of 
the PCB congener. It has been suggested that PCB congeners with strong 
MC-inducible activity, such as most non-ortho-coplanar PCB congeners with 
at least two halogen atoms in lateral positions, have the greatest toxic 
potential (Goldstein, 1979, Poland et ai, 1979, Safe, 1984). These congeners 
mainly induce activities of enzymes, such as arylhydrocarbonhydroxylase 
(AHH) or ethoxyresorufin-O-deethylase (EROD), both associated with 
cytochrome P450-1A1 (Sawyer et ai, 1982, Kimbrough, 1987). PCB-
congeners with the less toxic ortho-chlorine substituents, for instance the non 
planar di-ortho PCBs, however, do not induce cytochrome P450-1 A 1 (Safe, 
1984, 1987, 1990), but mainly cytochrome P450-2B1/2, like phenobarbital. 
High levels of induction of cytochrome P450-1 A 1 and P450-1 A2 were 
observed in rats exposed to dietary mixtures of PCBs (Aroclor 1254), 
(Dragnev et ai, 1994). 
Elimination of PCBs is dependent on their degree of lipophilicity and its 
rate of metabolism. The latter occurs in several organs, but the liver is 
considered as the major organ of biodegradation of PCBs. From many 
studies with PCB isomers, it became evident that the degree and position of 
chlorination on the biphenyl ring, as well as the animal species, determine 
the extent of metabolism and rate of excretion. Congeners with less 
chlorination do not tend to accumulate and are readily metabolized and 
eliminated (Goldstein et ai, 1977). For instance, 50 % of 3,3',4,4'-
tetrachlorobiphenyl (TCB) is metabolized in rats within three days, while 
3,3' ,4,4' ,5,5' hexachlorobiphenyl is hardly metabolized at all. In addition, it 
appeared in dogs that the excretion percentage of 2,2',3,3',6,6'-
hexachlorobiphenyl after three days was about 17 -fold higher than 
2,2'3,3'5,5'-hexachlorobiphenyl (Safe, 1987). 
Dioxins (PCDDs) are hardly metabolized in animal species. If dioxins are 
metabolized, it will mainly occur by hydroxylations at lateral (2,3,7,8) positions 
(as with PCBs), presumably with arene oxides as intermediates. In addition, 
the presence of two non-substituted carbon atoms accelerates metabolism. 
Biotransformation studies with PCDDs have mainly been carried out with 
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2,3,7,8-tetrachloro-dibenzo-p-dioxin (TCDD). This type of dioxin is one of the 
most toxic congeners of PCDDs in animals and an extremely strong inducer 
of MC-like MFOs. 
Hexachlorobenzene (HeB) 
Occurrence 
HCB has been extensively manufactured in the past as a fungicide. 
However, HCB may still be unintentially produced as a by-product in the 
manufacturing of many chlorinated hydrocarbons (Menzie, 1986, Tobin, 1986, 
Jacoll et ai, 1986). For instance, HCB may be formed as an impurity during 
the production of perchloroethylene, trichloroethylene, vinyl chloride and 
pentachloronitro-benzene (Blackwood et ai, 1979). In addition, release of 
HCB may occur during combustion processes such as municipal 
incinerations (Carpenter et ai, 1986). Former applications of HCB were its use 
as an additive for pyrotechnic compositions for the military, as an 
intermediate in dye manufacturing and as a wood preservative. 
In most Western countries the production and use of HCB as a pure 
compound is banned (Morris et ai, 1986). There is evidence that it has not 
been commercially available since the late 1970s (Carpenter et ai, 1986). 
However, in the U.S, 4130 tons of HCB are still produced annually as a 
contaminant in the production of pesticides or chlorinated solvents according 
to an estimation 9f the Environmental Protection Agency (EPA). 
The physico-chemical properties of HCB include a high lipophilicity 
(Verschueren, 1983), a high persistency (Beall, 1976, Mansour et ai, 1986), 
and a slight photosensitivity. Evidence for release of HCB from chemical 
industries into the water and air, and deposition in soil has been established 
(Schoch et ai, 1985, Spigarelli et ai, 1986, SloolI et ai, 1991). 
Toxicokinetics 
The major route of human exposure to HCB is contamination via food, 
since HCB can be taken up by plants and further transported through the 
food cycle (EPA, 1987). After intestinal uptake, HCB is transported in the 
bloodstream to adipose tissue (Robinson et ai, 1990). Estimates of exposure 
of humans to HCB from the general environment, using the exposure 
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commitment method, showed a daily dietary intake of 0.2 ",9 by ingestion, 
and an accumulation of 0.047 mg/year in fatty tissue (Bennett, 1981, Cam et 
ai, 1963, Burton et ai, 1987). In addition, the body burden of HCB in humans 
appeared to be 0.7 mg, based on a concentration of 0.04 mg/kg in fatty 
tissue. 
In several laboratory animals exposed to HCB, adipose tissue contained 
the greatest concentration of HCB, although bone marrow, skin and intestinal 
tract were also shown to contain HCB (Avrahami, 1975, Mehendale et ai, 
1975, latropoulos et ai, 1975, Ingebrigtsen et ai, 1983). A number of studies 
showed evidence for accumulation of HCB in fetal tissue, particularly brain, 
after placental transfer in several species of laboratory animals (Villeneuve et 
ai, 1974, 1975, Courtney 1979, Courtney et ai, 1985a, 1985b, Cripps, 1990, 
Goldey et ai, 1991, 1992. Furthermore, rapid transfer of HCB from maternal 
adipose tissue via the milk to suckling neonatal rats and mice has been 
demonstrated (Courtney et ai, 1985b, Goldey, 1991). In addition, placentas 
and cord blood of pregnant Japanese women contained levels of HCB (Ando 
et ai, 1985). 
HCB is a MC- and PB-like type inducer of MFOs (Goldstein et ai, 1982). 
The preferential induction of rats exposed to HCB involves MC-inducible 
forms of cytochrome P450, namely cytochrome P450-1A2 and P450-1A 1, with 
a preference for the former (Linko et ai, 1986, Li et ai, 1986, Goldstein et ai, 
1986, Nebert et ai, 1989). Rozman et al (1986) obtained evidence for HCB 
also as a potent inducer of cytochrome P450-2B1 in rats, which is associated 
with PB-inducible forms of cytochrome P450. Recently, it was found that 
cytochrome P450-1 A 1 and P450-1A2 were highly induced in female F344 rats 
that were exposed to HCB for 30 weeks (Smith et ai, 1990). 
Several in vitro and in vivo metabolic studies indicate that the conversion 
of HCB to pentachlorophenol (PCP) and tetrachlorohydroquinone (TCHQ) is 
a major metabolic route, and that cytochrome P450-3A 1 and/or cytochrome 
P450-3A2 mediate this metaboliC pathway (Van Ommen et ai, 1985, 1989). 
Den Besten et al (1993) found evidence in support of the latter pathway as 
subchronic co-treatment of rats with triacetyloleandomycin (TAO), a selective 
inhibitor of the oxidative biotransformation of HCB, did result in diminished 
levels of PCP and TCHQ in urine. On the other hand, a high degree of PCP 
urinary excretion correlated well with the degree of HCB-induced porphyria. 
Earlier studies also showed that the microsomal oxidation of HCB to PCP 
and TCHQ was related to the porphyrinogenic action of HCB (Debets et ai, 
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1980, Carpenter et ai, 1986, Van Ommen et ai, 1986, 1989). Koss et al (1986) 
demonstrated that 80-90 % of daily urinary PCP in man appeared to be 
formed from HCB. Kinetic studies with ['4C]HCB in rats demonstrate that 
almost half of the amount of HCB was excreted as metabolites over a period 
of 4 weeks after administration (Koss et ai, 1976), and that 20% of the 
metabolites were identified as PCP, while 3% and 16% were TCHQ and the 
sulphur-containing metabolite pentachlorothiophenol (PCTP) respectively. 
PCTP arises from a conjugation reaction of HCB to glutathione (GSH) as a 
phase II detoxification pathway for HCB, resulting in subsequent formation 
of the intermediate N-acetyl-S-(pentachlorophenyl)cysteine (PCPNAc), which 
is hydrolyzed to PCTP (Den Besten, 1992). 
There are indications that the elimination of HCB by GSH conjugation is 
sex-dependent. For instance, D'Amour and Charbonneau (1992) 
demonstrated that male Sprague-Dawley rats treated with five doses of HCB 
(500 mg/kg) over 3 days had decreased hepatic GSH levels compared with 
controls, while in female rats no differences were observed. Furthermore, in 
male rats dosed with HCB, a higher biliary excretion of PCTP compared with 
females was observed. However, urinary concentrations of PCTP were higher 
in female rats after treatment with HCB. In F344/N rats, urinary excretion of 
PCTP, PCP, and 2,3,5,6-tetrachlorobenzene-1.4-diol was higher in females 
than in males after 10 weeks of HCB-treatment by intubation (Rizzardini et ai, 
1982). 
Besides PCP, other chlorophenols have been demonstrated as 
metabolites of HCB. For instance, 2,3.4,6-tetrachlorophenol, 2,3,5,6-
tetrachlorophenol and 2,4.5-trichlorophenol were detected in urine of Wistar 
rats orally treated with HCB for 19 days (Engst et ai, 1976). Urine of Sprague 
Dawley rats that received ['4C] HCB in oil orally, contained 0.85% of the 
original dose, with 2.4,5-trichlorophenol, PCP and several unidentified 
chlorinated benzenes as metabolites (Mehendale et ai, 1975). A daily 
treatment of RhesuS monkeys with ['4C]HCB for 78 weeks resulted in about 
50 % urinary excretion of PCP, but pentachlorobenzene (25 %) was also 
found (Rozman et ai, 1977). In feces, 99 % of the label was found as HCB, 
and 1 % as pentachlorobenzene. From most studies which involve elimination 
of HCB, it has become clear that the route of administration of HCB (i.p, 
orally, i.v.) , the period of treatment and the species caused the enormous 
variations in its half-life (weeks-years), (see Roper, 1990). 
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Toxicity of PCBs and PCDDs 
PCBs and PCDOs 
In contrast to the relative lack of data on toxicity of HCB in humans, the 
toxic effects of PCBs on different organ systems in animals have been well 
characterised. The toxicity of PCBs is dependent on the compound, dose, 
duration of exposure and the species involved (see reviews McConnell 1980, 
George et ai, 1988, McFarland et ai, 1989, Safe et ai, 1990). Important 
indications of their systemic and, particularly, skin toxicity (chloracne) in 
humans became clear from examining people in Japan and Taiwan 
(respectively Yusho and YuCheng episodes) who were exposed to PCBs via 
contaminated cooking rice oil (Kuratsune et ai, 1972, 1976, Urabe et ai, 1977, 
Hsu et ai, 1984, Kunita et ai, 1984). Skin lesions also were clearly observed 
in humans involved in the manufacture of PCBs (Umeda et ai, 1978). 
Symptoms observed in several species of animals chronically exposed 
to PCBs include tumours, immunosuppression, hepatomegaly, porphyria and 
impairment of reproduction (Strik et ai, 1980, McConnell, 1980, George et ai, 
1988, Gray et ai, 1993). With respect to skin lesions, it appeared that rodents 
were rather insensitive, while monkeys were highly sensitive to (mixtures of) 
PCBs (Brouwer, 1987, Van den Berg et ai, 1988a, 1988b, Arnold et ai, in 
press). 
It is thought that PCB congeners which induce both the MC- and PB type 
MFOs are toxic (yoshimura et ai, 1979, McFarland et ai, 1989), with the 
former primarily responsible for the carCinogenic or mutagenic response. 
These signs of toxicity are related to formation of highly reactive, electrophilic 
epoxides that arise from oxygen insertion into conformationally hindered sites 
of planar molecules (Parke, 1985). Co-planar PCBs, with at least two chlorine 
substituents at the meta positions and at the para site appear to be the most 
toxic forms. This phenomenon is related to the fact that this conformation 
facilitates binding to the intracellular cytosolic aryl hydrocarbon (Ah) receptor 
(Nebert et ai, 1979), which can result in a greatly increased MFO activity. A 
good correlation was also found between immuno- and hepato-toxic potency 
of coplanar PCBs and induction of cytochrome-P450-1 A 1 in rodents (Safe et 
ai, 1990). 
Most studies involving the toxicity of dioxins have been done with 2,3,7,8-
tetrachlorodibenzo-p-dioxin (TCDD) as a prototype. TCDD is one of the most 
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toxic coplanar congeners of the PCDDs, and a very potent inducer of various 
types of MFOs, particularly cytochrome P4501 A 1 in mammals (Safe et ai, 
1990). The symptoms that indicate the toxic action of TCDD closely resemble 
those induced by PCBs. In humans who were exposed to unknown levels of 
TCDD after an industrial accident, chronic symptoms such as porphyria, 
chloracne, and hepatic damage were observed (Ashe et ai, 1953). Acute 
symptoms included respiratory tract irritation, dyspnea and nausea. In 
exposed animals, reproductive disturbances including fetotoxicity and 
teratogenicity are the major signs, although hepatic damage, 
immunosuppression and an increased tumour incidence have also been 
shown (IARC vol 15, 1977, Poland et ai, 1984). 
As with PCBs, the toxic properties of PCDDs and structurally related 
compounds may be associated with an interaction with the Ah receptor 
(Roberts et ai, 1985), the coplanarity of the phenyl rings of TCDD facilitating 
this binding. An excellent relationship has been observed between binding 
affinity of TCDD for this receptor (Safe et ai, 1984) and its potency as an 
inducer of mono-oxygenase activities associated with cytochrome P450-1 A 1 
(AHH and EROD). 
Neurotoxicity in adults 
Neurotoxic symptoms from the episode in Japan (Yusho) included 
headaches, numbness and weakness in limbs and lowered peripheral nerve-
conduction velocities (Kuratsune et ai, 1972). Various signs of neurotoxicity 
similar to those of PCBs appeared several specific types of halogenated 
aromatiCS, such as phenoxy-acids, dithiocarbamates, organochlorines and 
various solvents (Bainova, 1982). 
Experimental animal studies also reported neurotoxic effects of PCBs, 
and it appeared that particularly dopaminergic related systems were highly 
sensitive to PCBs. For instance, pig-tailed-macaques that were treated daily 
with the PCB mixture Aroclor-1016 for 20 weeks had decreased levels of 
neurotransmitters (mainly of dopamine) in various brain regions, (Seegal et 
ai, 1991). In addition, evidence was obtained that the degree of chlorination 
of the PCBs determined whether dopamine levels altered (Seegal et ai, 
1988). Studies with cultured rat pheochromocytoma-cells (PC 12), which are 
capable of dopamine and noradrenaline synthesis, including the release and 
uptake of dopamine, indicated that PCBs induce decreases in cell dopamine 
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content (Seegal et ai, 1989). 
From a variety of in vivo studies, including those using cultured cells (see 
review Seegal et ai, 1992) it could be concluded that the ortho-substituted 
PCB-congeners were mainly responsible for the decrease in dopamine 
concentrations in the brain. This phenomenon may be due to a direct action 
on tyrosine hydroxylase, the rate-limiting enzyme in dopamine synthesis. 
Neurotoxic effects of PCDDs in humans are hardly reported in literature. 
A study of birth defects in TCDD-polluted areas in Seveso indicated a 
possible association of neural tube defects and TCDD occurence (BrUZZi, 
1983). In West Virginia, people became exposed to TCDD after an industrial 
accident (Ashe et ai, 1953) and showed acute symptoms of neurotoxicity, 
such as headache, dizziness, fatigue, nervousness, decreased libido, and 
intolerance to cold. Chronic symptoms were mainly polyneuropathies. 
A central action of TCDD was proposed from animal studies (rats) since 
serotonin and histamine levels were increased in brain regions directly 
involved in regulation of food intake (Rozman et ai, 1991, Tuomisto et ai, 
1991). Recently, Stahl et al (1990) could not find evidence in rats for direct 
effects of TCDD on areas in the brain which regulate food intake, and 
suggested that TCDD is more likely to be a peripherally acting anorectic 
agent. 
Neurotoxicity during development 
From. the episode in Taiwan and Japan, it has become clear that infants 
who were exposed to PCBs either in utero or during breast feeding had a 
delayed psychomotor activity, decreased visual recognition memory and 
intelligence scores, and impaired mental functions (Rogan et ai, 1988, Tilson 
et ai, 1990, Lin Yu et ai, 1991, Rogan et ai, 1992, Seegal et ai, 1992). 
Hypotonia and hyporeflexia were also observed in these children. Jacobson 
et al (1984) reported abnormally weak reflexes, low responsiveness, and 
uncoordinated movements in children born to mothers who had eaten fish 
products from Lake Michigan (U.S). Furthermore, these children had impaired 
visual memory recognition at 7 months of age (Fagan et ai, 1986). 
In animal behavioral and related biochemical studies evidence was found 
for neurotoxicity of PCBs, particularly with respect to dopaminergic changes. 
For instance, exposure of mice to 3,3' ,4,4' -tetrachlorobiphenyl (rCB) induced 
in the pups an altered response to dopaminergic agonists and antagonists 
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(Chou et ai, 1979). These pups developed a syndrome of a rapid, 
uncoordinated circling. Agrawal et al (1981) found in 1 year old offspring of 
TCB-treated pregnant mice lowered levels of dopamine and dopamine 
receptors in brain. In 6-week old rat pups born to dams that were exposed 
to mixtures of PCBs (PCB 169 and 77), increased levels of metabolites of 
dopamine were found. These effects disappeared after 12 months (Sloot, 
personal communication). Behavioral studies after amphetamine challenge, 
however, indicated latent differences in the dopaminergic neuronal system 
after 12 months (Jaspers, personal communication). 
A further remarkable finding is a dramatic reduction in the reproductive 
capacity in offspring of rats, both males and females, after perinatal exposure 
(Smits van Prooije et ai, 1993). Furthermore, exposure of 10-day old mice to 
TCB resulted in effects on the development of the chOlinergic system 
(Eriksson, 1988), a system involved in processes such as memory and 
learning, hearing, vision and aggression (Karczmar, 1975). Studies with 
monkeys exposed to mixtures of PCBs also indicated that behavioral and/or 
cognitive deficits occurred in the offspring (Schantz et ai, 1989). Recently, it 
had been demonstrated that prenatal exposure of Wistar WU rats to Aroclor 
1254 did result in increased levels of astrocytic proteins in cerebellum of 90-
days old male offspring (Morse et ai, 1993a). 
In another recent study (Morse et ai, 1993b), it was proposed that PCB-
induced neurotoxic responses during development (fetal and neonatal stage) 
could be due to reductions of thyroid hormones, since the latter are essential 
for brain maturation. 
Toxicity of HCB 
HCB 
The first indications of toxicity of HCB in humans became evident from 
an inCident in Turkey in the early fifties (Cam et ai, 1963, Courtney, 1979, 
Peters et ai, 1982, Cripps et ai, 1984), when HCB-treated grain was 
consumed during a period of crop failure. The amount of HCB consumed 
was 0.05-0.2 g per day per person during one month. About 5000 people 
suffered from a disease resembling porphyria cutana tarda, which is 
characterised by blistering and fragility of the skin, frequently associated with 
porphyria. The latter is characterised by accumulation and excretion of 
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intermediate products of the hepatic heme synthesis, caused by a selective 
inhibition of the enzyme uroporphyrinogen decarboxylase (Elder et ai, 1976, 
Kerklaan et ai, 1977, Strik et ai, 1980, Debets et ai, 1981). Other symptoms 
were bone abberations, such as arthritis, osteomyelitis and osteoporosis of 
the limbs. These symptoms were obs.erved in 76 % of exposed males and 
in 81 % of exposed children between 4 and 14 years of age. A mortality rate 
of 95 % was observed in suckling infants. These children were probably pre-
and postnatally exposed to extremely high levels of HCB by placental 
transfer and breast milk. Persistent dermatic, hepatic, arthritic, and porphyritic 
effects of HCB became clear from symptoms twenty to thirty years after the 
HCB incident, such as hyperpigmentation, hirsutism, fragile skin, painless 
arthritis, hepatomegaly, jaundice and elevated uroporphyrin excretion in urine 
and faeces. 
Comparable symptoms were seen in animal studies. For instance, 
(sub)chronic exposure of rats to HCB induced hepatomegaly often in 
combination with porphyria (Ockner et ai, 1961, Strik et ai, 1980, Rozman et 
ai, 1986, Kleinman De Pisarev et ai, 1989, 1990, Rizzardini et ai, 1990), skin 
lesions and neurological dysfunctioning (Koss et ai, 1978). Furthermore, HCB 
can be a carcinogenic, mutagenic, immunotoxic, or teratogenic compound 
depending on the species used (Khera, 1974, Cabral et ai, 1977, 1979, 1986, 
Brusick, 1986, Vos, 1986, Barnett et ai, 1987). 
Neurotoxicity in adults 
HCB may induce neurotoxic symptoms in humans as became apparent 
from an incident in Turkey, where people became exposed to HCB by food 
(see previous page). The symptoms included weakness, myotonia, 
paraesthesia, and sensory shading, and some of these were still observed 
twenty to thirty years after the initial exposure. 
Signs of neurotoxicity observed in laboratory animals (mainly rodents) 
subchronically exposed to HCB by diet included tremors, alopecia, scabbing, 
ataxia, and convulsions. Brain lesions (hyperaemia and haemorrhage) have 
also been seen (Kuiper-Goodman et ai, 1977, Cabral et ai, 1979, Headly et 
ai, 1981). Female beagle dogs that daily received HCB for 3 weeks showed 
physiologic alterations in the brain, as appeared from dysrhytmias in the 
electroencephalogram (Sundlof et ai, 1981). In female ferrets, who received 
HCB in their diet for 47 weeks, signs of abnormal aggressiveness and 
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hyperexcitability were obselVed Gust prior to death) (Bleavins et ai, 1984). In 
the same study, elevated levels of neurotransmitters, such as serotonin, 
norepinephrine, and dopamine in various brain regions were obselVed. 
Neurotoxicity during development 
There are indications that the developing nelVous system may also be 
a target for HCB. For instance, a recent study indicated that oral exposure 
of pregnant Sprague Dawley rats to HCB at two weeks before partus, 
resulted in hyperactive behaviour in pups screened over a period of at least 
6 days postnatally (PND 6) (Goldey et ai, 1992). The hyperactivity was 
obselVed for negative geotaxis (PND 6-10), olfactory discrimination (PND 9-
11), and exploratory behaviour (PND 15-20). Furthermore, it was suggested 
that there was a relationship between the neurotoxic action of HCB and the 
induced deficits of myelin in the brain. It was also postulated that human 
fetuses and suckling infants exposed to HCB via placental transfer and 
breast milk, respectively, are at risk for development of HCB neurotoxicity 
(Goldey et ai, 1992). 
Thyroid hormones 
Structure, function and action of thyroid hormones. 
The thyroid gland secretes two hormones, thyroxine (3,3' ,5,5' -tetraiodo-L-
thyronine; T 4) and 3,3' ,5-triiodo-L-thyronine; T3. T 4 is considered as a 
prohormone, while T3 is the active form in most animal species and in 
humans (Oppenheimer et ai, 1976). The chemical structures of these 
hormones are presented in figure 2. 
Thyroid hormones are essentially factors for maintenance of homeostasis 
in warm-blooded mammals by regulating cellular metabolic processes. For 
instance, these hormones stimulate Na+/K+ ATPase activity which result in 
heat production (calorigenesis) and increased respiratory oxygen 
consumption in several organs (Van Hardeveld, 1986, Bjorkman et ai, 1990, 
Kvetney et ai, 1990). Other actions include osmoregulation, and stimulation 
of production and breakdown of proteins, carbohydrates and fatty acids. In 
general, the stimulating effect of thyroid hormone on breakdown of these 
compounds is greater than the production. Increased levels of serum lipids 
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and cholesterol are usually detected in patients with hypothyroidism (Abrams 
et ai, 1981). Symptoms that might be observed in these patients are fatigue, 
slowness, cold -intolerance, dry skin, heavy weight, hypertensy, bradycardia, 
and, in severe cases, an alveolar hypoventilation (Laurberg, 1990). 
For thyroid hormones to get access to target organs, they have to pass 
cellular membranes. The latter occurs by sodium and energy dependent 
Fig 2. Structure of thyroxine IT 4) and 3,3' ,5-triiodo-L-thyronine (T3) 
T4 
T3 
active transport systems (Docter et ai, 1990, Pontecorvi et ai, 1989). Effect 
on cellular differentiation, growth and energy consumption are mainly due to 
T3 (and much less to T4) via binding to specific, limited capacity, binding 
sites within the chromatin of the cell nucleus in the target tissues (nuclear 
receptors), (Eberhardt et ai, 1976; Oppenheimer et ai, 1983, 1986; Silva et 
ai, 1986; Nikodem et ai, 1990). Binding of thyroid hormones to proteins in cell 
membranes, cytosol and mitochondria have also been described (see review 
Ichikawa et ai, 1991). 
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Role in cerebral functions 
Thyroid hormones are crucial for normal growth, differentiation and 
development of tissues of higher vertebrates (Dratman, 1978), and are 
particularly involved in maintenance of a normal development and functioning 
of the central nervous system during the fetal and neonatal stage of 
mammalian development (Morreale de Escobar et ai, 1983, 1986). Therefore, 
an adequate and efficient transport of these hormones to the brain is 
indispensable. An insufficient thyroid activity during the early years of life 
can result in dwarfism, often combined with mental retardation (cretinism). 
Learning and memory deficITs were observed in young infants WITh congenital 
hypothyroidism (Maenpaa, 1972, Macfaul et ai, 1978, Sutan-Assin, 1990). 
Other characteristics of this syndrome are behavioral abnormalities such as 
lethargy and loss of initiative and energy. 
Disturbance of cerebral functions in adult humans with severe 
hypothyroidism can also develop, such as psychosis, delusions, hearing loss 
and visual hallucinations, and disorientation (see review of Laurberg, 1990). 
Relationships of hypothyroidism with depression have also been established 
(Gold et ai, 1981, Tappy et ai, 1987). 
From micro anatomical studies it appeared that thyroid hormone 
deficiency may lead to disturbed maturation of several types of organelles 
(see for review Dussault et ai, 1987). For instance, in rats with 
hypothyroidism, the maturation of synaptosomes and nuclear T3 receptors 
of the brain were altered (Mussa et ai, 1990). During the critical period of rat 
brain development, the maturation of neuronal synaptic plasma membranes 
is highly dependent on thyroid hormones. Reductions in neuronal 
interactions or neurite outgrowth were observed in neonatal rats with 
inadequate thyroid hormone levels (Eayrs 1964, Legrand, 1977). Rats WITh 
hypothyroidism at an age of 12 days, i.e. the period of rapid brain maturation 
and of maximal uptake of T 4 by the brain, developed delayed 
myelinogenesis (Dalal et ai, 1971, Eberhardt et ai, 1976). Neurological 
impairment was also detected in rats when intracellular T3 levels were 
insufficient during the 'critical period' for brain development, which starts in 
utero and ends about 10-12 days after birth (Hendrich et ai, 1984). Table 2 
summarizes specific effects of hypothyroidism on the developing brain of 
laboratory animals. 
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Table 2. Biochemical effects of hypothyroidism in the developing brain. 
Parameter Observations') References 
Energy Delay in developmental changes in Moore et ai, 1973 
metabolism glucose transport rate and ketone Patel,1979 
body metabolizing enzymes alter 
weaning 
Microtubules Decreased tubulin-tyrosine ligase. Gonzalez et ai, 1978 
Decreased content of tubulin. Takahashi et ai, 
Defect of assembly. 1981 
Myelin Decreased content. Delay in Balazs et ai, 1969 
development of myelin associated Valcana et ai, 1975 
enzymes. 
Cellular Delay in maturation of Purkinje cells Legrand 1979, 1986 
types of cerebellum. 
Receptors Delay of developmental changes in Patel et ai, 1980 
GABA-ergic, muscarinic and B- Smith et ai, 1980 
adrenergic receptors. Mussa et ai, 1990 
Delay in T3 receptors in brain. 
1) See reviews of Nunez (1984) and Dussault et al (1987). 
Regulation of thyroid hormone activity 
Thyroglobulin synthesis, colloidal uptake of thyroglobulin by the follicular 
cells of the thyroid gland, and the rate of proteolysis of thyroglobulin for se-
cretion of thyroid hormones, are processes that are under control of 
thyrotropin (TSH), which is produced by the mammalian adenohypophysis 
(see review Wilber et ai, 1990). If there is a temporary depletion of (free) 
thyroid hormone supply to tissue, an increase of the secretion of TSH by the 
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pituitary follows (Emerson et ai, 1989). When normal plasma levels of (free) 
thyroid hormones are reached, the pituitary suppresses TSH production via 
a coordinated feedback relationship between the pituitary and the thyroid 
The TSH release is controlled by the thyrotropin-releasing hormone (TRH) , 
a tripeptide produced by the hypothalamus. It is thought that TSH binds 
receptors on the thyroid membranes, followed by stimulation of adenyl-
cyclase and formation of cyclic adenosine monophosphate (cAMP). The latter 
mediates processes involved in production of thyroid hormones. 
Under conditions of hypothyroidism (for instance via iodine deficiency, 
iodine overdose, treatment with thyreostatic drugs, auto-immune thyroiditis, 
strumectomy, defects in incorporation of iodine in the thyroid gland, direct 
damage of the thyroid, pituitary tumours, insensitive thyroid etc), an 
increased TSH delivery from the pituitary results in an increased 
vascularisation and hypertrophic enlargement (goitre) of the thyroid gland. 
Determination of plasma TSH levels is a reliable indirect method to detect 
disturbances of thyroid homeostasis. A slight increase of plasma TSH level, 
in combination with normal plasma T3 or T4 levels, without complaints and 
symptoms is characterised as subclinical hypothyroidism. Clinical 
hypothyroidism is diagnosed when decreased plasma T4 levels as well as 
increased TSH levels are detected, in combination with complaints and 
symptoms. 
Transport of thyroid hormones 
Nearly all of circulating thyroid hormone is noncovalently bound to 
transport proteins (Glinoer et ai, 1985, De Nayer et ai, 1985). The unbound 
hormone fraction is generally considered as the active hormones at the level 
of target organs (Oppenheimer, 1968). The primary function of thyroid 
hormone binding proteins is to act as a buffer system to prevent sudden 
changes in free thyroid hormone levels. 
Three human T 4-binding proteins have been described: T 4-binding 
globulin (TBG) , transthyretin (TTR) and albumin. Binding characteristics, 
concentrations and hormone distribution of these proteins, including plasma 
concentrations in humans are presented in Table 3 and Table 4. The major 
human thyroid hormone binding protein in plasma is TBG, an acidic 
glycoprotein which carries about 70 % of all T3 (TT3) and all T4 (TT4) in 
plasma under physiological conditions (Hollander et ai, 1963, Robbins et ai, 
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1978, 1986a, 1986b, Cheung 1985, Murata et ai, 1986). The L-alanine side 
chain conformation, the presence of the phenolic hydroxyl group, and 
iodines in the inner-and outer ring of thyroid hormones appeared to be 
essential for optimal binding to TBG (Snyder et ai, 1976). TBG is a protein 
with a molecular weight of 57,000 and an electrophoretic mobility between 
the alpha 1 and alpha 2-globulins (Oppenheimer, 1968). TBG appears to be 
composed of a single polypeptide chain with one binding site for thyroid 
hormones per molecule (Sterling et ai, 1971, Cheng, 1977, Gershengorn et 
ai, 1977). For a long time, it was thought that TBG is not present in the 
circulation of rats. However, Savu et al (1991) found expression and re-
expression of the TBG gene during postnatal development and senescence 
respectively. In this study, TBG was detected in the circulation during 
postnatal maturation and in old animals. Under hypothyroidic or starvation 
conditions in young rats, plasma TBG levels increase (Visser, personal 
communication). 
In humans, about 10-15 % of plasma T 4 is transported by thyroxine-
binding prealbumin (TBPA) , also known as transthyretin (TTR). The name 
TTR was used instead of TBPA to indicate its role in the transport of thyroid 
hormones in plasma, and to avoid possible confusion with the precursorform 
of albumin, proalbumin. Not only thyroid hormone, but also retinol-binding 
protein is transported in plasma by TTR (Kanai et ai, 1968). 
Human TTR is a stable tetrameric protein (Mw 55 Kd) consisting of four 
identical subunits (Blake et ai, 1974), which are connected by hydrogen 
bonding and hydrophobic interactions. High-resolution X-ray crystallographic 
analysis gave insight into the tertiary and quaternary structures of human 
TTR. With the same technique, analysis of complexes of TTR with thyroid 
hormones indicated that T4 as well as T3 exclusively interact with two 
symmetrical sites located deeply within a central channel (Blake et ai, 1977, 
1978). By allosterical effects, T4 reduces the affinity of the second site for T4 
and it is actually suggested that only one T4 molecule binds (Ferguson et ai, 
1975, De Nayer et ai, 1985). Andrea et al (1980) found by using halogen 
substituents that all four iodine atoms favourably contributed to binding, and 
suggested a hydrogen-bonding and/or charge transfer interaction between 
the halogen and TTR. Recently, the interaction of T4 with the T4-binding site 
of TTR had been described according to a "forward" and a "reverse" binding 
model (de la paz et ai, 1992). The forward model suggests that interactions 
are possible between water molecules and the phenolic ring inside the 
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Table 3. Affinity constants (Kal and bound percentages for T4 and T3 to 
human TBG, TTR and albumin. 
Plasma- Ka for T4 % bound Ka for T3 % bound 
protein (M") T4 (M") T3 
TBG 1.0-2.3 x 1010 ± 65-75 5.0-6.0 x 1 rf 80 
TTRo 0.7-1.0 x 10· ± 10-15 0.9-1.4 x 107 10 
(k,) (k,) 
7.0-9.5 x 105 6.0 x 105 
(k,) (k,) 
albu- 5.0-7.0 x 105 ± 10-20 1.0x105 10 
min# (k,) (k,) 
5.0 x 10· 5.0 X 10' 
(k,J (k,) 
"": Two values are represented since DR has me identical binding sites for thyroid hormones. 
#: The k1 values correspond to one binding site for T4 and T3, and the ~ values correspond to 
the other (two to six) binding sites. The presented data have been derived from Nilsson et al 
(1975), Robbins (1976), Robbins et al (1979, 1986a, 1986b) and from Hennemann et al (1990). 
protein, under the condition that the phenOlic ring is deeply hidden into the 
TTR-binding site, and the phenyl ring with the amino side chain close to the 
binding site entrance. The "reverse" model suggests that the hydrogen atoms 
of the phenolic ring interact with charged residues at the entrance, and that 
the amino side chain is positioned near the core of the binding site. 
The major sites of synthesis of TTR are the liver, the choroid plexus of 
the brain (Dickson et ai, 1985a,b, 1986a,b, Herbert et ai, 1986, Kato et ai, 
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1986), the visceral yolk sac (Soprano et ai, 1985), and the pancreatic islets 
(Jacobsson et ai, 1979). In rats, the liver is the major organ of TTR 
degradation, accounting for 36-38% of total body TTR degradation, followed 
by muscle and skin which account for 12-15% and 1-8% respectively of the 
total body TTR degradation (Makover et ai, 1988). 
Table 4. Plasma concentrations of human TBG. TTR and albumin, including 
of hormone bound complexes 
Plasma protein 
or hormone [nmol/I] 
binding complex 
TBG 280-510 
TTR 2250-4300 
albumin 6.4 x 10' 
T4 110 
TBG-T4 82.5 
TTR-T4 16.5 
Albumin-T4 11 
T3 2.3 
TBG-T3 1.84 
TTR-T3 0.23 
Albumin-T3 0.23 
The presented data have been derived from Robbins (1976), Robbins et al (1986a, 1986b). and 
from Hennemann et al (1990). 
Besides TBG and TTR, a less specific binding protein that interacts with 
the thyroid hormones is albumin. It has one strong binding site for T 4 and 
T3 with different K.. values compared with the other (two to six) binding sites 
28 
(Table 3). The high concentration of albumin in human plasma results in the 
binding of about 15 % of circulating T4 (Table 3). 
Little information is available about affinities of T4 or T3 for serum binding 
proteins in laboratory animals. Sutherland et al (1976) found that rat albumin 
(K. = ± 6.1 x 10' M") bound T 4 significantly more strongly than rabbit 
albumin (K. = ± 2.3 x 10' M·'). In Table 5, the K. values for the thyroid 
hormone binding proteins of the rat are presented. cDNA nucleotide 
sequence analysis demonstrated 83 % similarity between the primary 
structures of human and rat TTR (Sundelin et ai, 1985) and 73 % between 
human- and rat albumin (Sargent et ai, 1981, Dugaiczik et ai, 1982). In rats, 
TTR is the major T 4 carrying plasma protein since it binds 70 % of all T 4 
(Sutherland et ai, 1976). 
Table 5. Affinity constants (Ka)" for binding ofT4 and T3 to ratTBG, TTR and 
albumin". 
Plasma-
protein 
TBG 
TTR 
Ka forT4 
(M") 
>1 X 109 
0.4-3.5 x 10' (k,) 
9.5 x 10' (I<,) 
albumin 6.1 x 10' 
Ka for T3 
(M") 
1 X 109 
0.9 X 105 (#) 
*: See Ferguson et at (1975), Sutherland et al (1976) and Savu et al (1989). 
(#) = estimated value. 
With affinity chromatography on thyroxine-Sepharose, a new thyroxine 
binding protein was isolated from human blood plasma, namely a 25 Kda 
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apo-Iipoprotein A-1 (apo A-1), a component of high-density lipoproteins. 
Various forms of apo A-1 had different T4-binding activity (I<,.'s 4-7.5. 107 M·'). 
The interaction of apo A-1 with T 4 involves mechanisms that differ from the 
complex formation of iodothyronines with albumin, TTR,and TBG (Sviridov et 
ai, 1991). 
Metabolism of thyroid hormones by glucuronyltransferases and deiodinases 
The metabolism of thyroid hormones occurs through a variety of 
pathways in several organ systems. In mammals, conjugation of the 
phenolic hydroxyl group with glucuronic acid or sulphate are important 
metabolic routes of T 4 and T3 (Visser, 1988a, Visser 1990a, Visser et ai, 
1990b). These processes are dependent on UDP-glucuronyltransferase 
(UDPG1) generating glucuronide derivates. The thyroid hormone-UDPGTs 
are homologous enzymes that vary in their substrate specificities and their 
activity after treatment with microsomal enzyme inducers, such as 3-
methyl cholanthrene, phenobarbital, PCBs, and dioxins (Visser et ai, 1993b, 
Curran et ai, 1991). 
Recent studies suggest that T4 is glucuronidated by both clofibrate-
inducible bilirubin and MC-inducible phenol UDPGT, and that androsterone-
UDPGT is responsible for the glucuronidation of T3 (Visser et ai, 1993a, 
Beetstra et ai, 1991). Visser et al (1993b) discovered three different classes 
of UDPGT-isozymes responsible for glucuronidation of thyroid hormone. Type 
1-UDPGT conjugates T4, rT3 (3,3',5'-triiodothyronine, reverse T3) and 
bilirubin, and is induced in vivo by clofibrate and in vitro by the detergent Brij 
56. Type 2-UDPGT has conjugation activity towards T 4, rT3 and phenols, and 
is induced in vivo by MC-type compounds but inhibited in vitro by Brij 56. 
Type 3-UDPGT conjugates androsterone and T3, and is hardly influenced by 
comparable in vivo or in vitro treatments. 
The metabolic reactions that use UDPGTs with thyroid hormones as a 
substrate, occur mainly in the liver and kidney and lead to inactivation and 
facilitation of excretion of the hormones by increasing their water solubility. 
A part of the produced thyroid hormone glucuronides are hydrolyzed by 
microbial gut flora, whereafter free hormones become available again via 
enterohepatic circulation (Rutgers et ai, 1989). Besides glucuronidation, 
sulfation of the phenolic hydroxylgroup is possible. T3-sulfate (T,S) is rapidly 
deiodinated, resulting in a biliary excretion of T3 mainly as T3-glucuronide 
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(TaG). 
Another route of metabolism of thyroid hormones is the conversion of T4 
to T3 by the hepatic type 1 deiodinase that accounts for approximately 80 
% of T3 production in humans, the remainder being produced by the thyroid 
gland (Engler et ai, 1984, De Nayer et ai, 1985, Visser et ai, 1988b). In the 
central nervous system at least 50% of intracellular T3 is derived from local 
deiodination of T 4, while in liver and kidney circulating T3 is the major source 
of intracellular T3 (Davies et ai, 1991). Another product of deiodination of T4 
is reverse T3, which is produced by removal of an iodine in the 5' -position. 
Deiodination of T3 and rT3 forms three possible diiodothyronines (T2); 3,3'-
T2, 3',5'-T2 and 3.5-T2 (Engler et ai, 1984). 
At least three different iodothyronine deiodinases occur in rats: type 1 
is capable of deiodination of both the inner and outer ring of T 4 and is 
susceptible to inhibition by 6-propyl-2-thiouracil (PTU), type 2 has only outer 
ring deiodinase activity and is not sensitive to PTU while type 3 facilitates 
only inner ring deiodination and is not sensitive to PTU (Visser et ai, 
1990a,b). Sulfation of T3 seems to be a prerequisite before it is deiodinated 
(De Herder et ai, 1988, Visser et ai, 1990a,b). 
Metabolism of T4 orT3 by oxidative deamination and decarboxylation of 
the alanine chain leads to acetic acid analogues (tetraiodothyroacetic acid 
and triiodothyroacetic acid), but there is no evidence that they are 
physiological relevant. The metabolic pathway via cleavage of the ether 
bridge, yielding diiodotyrosine, occurs mainly during infections (Burger et ai, 
1981). Under normal conditions this route is of minor importance compared 
with conjugation and deiodination (Engler et ai, 1984). 
Transport mechanisms of thyroid hormones with brain as target 
General aspects 
The brain is an important target for thyroid hormones (Shambaugh, 
1986), especially during embryonal development (Morreale de Escobar, 1983, 
1986). Thyroid hormones enter the brain through the blood brain barrier, 
which can be divided into a cerebral capillary barrier on the one hand, and 
a barrier formed by cerebroventricular organs on the other. The latter is 
formed for a major part by the epithelial cells of the choroid plexus (CPl. In 
mammals, including humans, the CP is able to produce cerebrospinal fluid 
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(CSF), (Cserr, 1971, Nilsson et ai, 1992) and possesses highly specific 
mechanisms for the transport of essential nutrients required for adequate 
brain function (Neuwelt, 1989). In humans, the production of CSF occurs for 
30 % in the walls of the subarachnoidal space, for 33 % at the ependymal 
surface of the ventricles, and for 37 % at the CP (Cserr, 1971). In figure 4, 
the structural and functional relationships of blood supply, CSF and 
extracellular and intracellular fluid compartments of the brain are presented. 
In the CP of many animal species, several highly specific mechanisms 
for transport (active, carrier-mediated, facilitated transport) of compounds 
essential for brain function, such as vitamins, nucleosides, purines and amino 
acids, have been identified (Spector, 1989, Neuwelt, 1989). In addition, the 
CP also possesses a specific carrier-mediated system for removal of toxic 
organic acids out of the brain (Rapoport, 1 976). A few in vivo studies 
involving mechanisms of transport of thyroid hormones from blood to the 
brain are known. 
With respect to the fast uptake of T3 into the brain by cerebral 
capillaries( < 15 s), using bolus injections into the carotid arteries of rats, a 
saturable, facilitated (not active) transport mechanism for T3 operating at the 
capillary blood-brain barrier was found (Pardridge, 1979). It has been 
suggested that this route of transport is very important, since the surface 
area of the cerebral capillaries is 50DD-fold higher compared with those of the 
cerebroventricular organs (Crone, 1971). 
Several studies indicate that T 4 and T3 pass also blood-CSF barriers. For 
instance, indications were found for a saturable carrier-mediated transport 
using infusions of [,251]T4 in dogs (Hagen et ai, 1974), based on an influx 
from blood into CSF against a concentration gradient. The latter was based 
on much higher levels of free T 4 in CSF compared with plasma. However, 
Banks et al (1985) demonstrated in mice carrier-mediated systems for the 
transport of T4 from CSF to blood, and no carrier-mediated system was 
found for the opposite route. Recently, a saturable uptake of [1251]T3 at the 
blood - and CSF side of perfused sheep CP was demonstrated (Preston et 
aI1992). 
Role of choroid plexus and TTR in thyroid hormone transport 
A special role for TTR as a carrier protein for transport of T 4 from blood 
to the brain has been suggested. Various studies indicated de novo 
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synthesis of TIR in the rat and human brain, independent of hepatic TIR, 
and this particularly occurs in the CP (Soprano et ai, 1985, Kato et ai, 1986, 
Dickson et ai, 1985a, b, 1986a). High levels of mRNA coding forTIR or could 
be identified in the CP of rats (Dickson et ai, 1985a, b, 1986a, Stauder et ai, 
1986) and humans (Dickson et ai, 1986b). In addition, CSF collected from the 
surface of perfused sheep CP was shown to contain highly radioactive TTR 
after addition of [14Clleucine to the perfusion medium. Furthermore, TIR was 
released at the apical side (towards the brain, and not at the blood side) of 
the epithelial cells of the CP. These phenomena indicated a high-capacity 
uptake of T4 in the CP, and an unidirectional transport of TIR from the CP 
Fig. 4. Relationships between the major compartments of the brain 
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to the CSF (Schreiber et ai, 1990). An earlier study (Dickson et ai, 1987) 
demonstrates that Lv. administered [, 251JT4 in rats not only accumulated in 
the liver, blood, kidney and pituitary, but also in the CPo Furthermore, a delay 
in uptake of T4 in several brain structures was observed compared with CPo 
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No accumulation of label was observed in CP or brain after an intravenous 
injection of [, 25I]T3. Isolated CP of rabbits also accumulated T 4, but not T3, 
from CSF medium (Spector et ai, 1975). 
Fig.5. Model for transport of thyroxine IT 4) via choroid plexus. 
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Such observations led to several assumptions involving transport of T 4 
to the brain (Schreiber et ai, 1990). Firstly, the fenestrated capillaries of the 
CP give access of T4 or T4-TTR complexes to the interstitium of the CP, 
where available free T4 passes membranes of the epithelial cells of the CPo 
In the CP, T4 binds to newly synthesized TTR (Fig. 5). The exact place of 
binding, i.e intracellular, near membranes or extracellular, has still to be 
identified. The TTR-T 4 complex is further transported by the flow of CSF 
through the ventricles and the sub-arachnoidal space of the brain. 
TTR derived from the CP (and probably also TTR in CSF) has a similar 
primary structure as hepatic TTR (Duan et ai, 1989). The amounts of TTR-
bound thyroid hormone in CSF are essentially different from plasma. For 
instance, in euthyroid persons, 12 % of T3 and 44 % of T 4 is bound to TTR 
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in the CSF, while 3% of T3 and 17% of T4 is bound to plasma TTR (Hagen 
et ai, 1973). It is interesting to mention that patients with central 
hypothyroidism and severe depression had lowered levels of TTR in CSF 
(Hatterer et ai, 1993). 
Chanoine et al (1992) found experimental support for TTR in CSF of rats 
being primarily derived from CP, and not from plasma. In addition, it was 
shown that transfer of T4 from plasma via CP to CSF was determined by the 
free T4 levels in plasma and the amount of binding ofT4 to TTR derived from 
the CPo 
From a toxicological point of view, a TTR-mediated transport system for 
T4 in the choroid plexus may be of interest since a number of industrial 
aromatic compounds have affinity for the T 4-binding site of TTR. Therefore, 
T 4 transport to the brain may be disturbed by these compounds. In the 
thesis, this aspect is elucidated in Chapter VIII and IX. 
Toxicity of PCBs and PCDDs for thyroid homeostasis 
Human studies 
Information about an altered thyroid hormone status in humans induced 
by PCBs or PCDDs is scarce, but in industrial workers chronically exposed 
to organochloropesticides, or polybrominated biphenyls (PBBs), evidence for 
disturbed thyroid physiology was found (Wassermann et ai, 1971, Bahn et 
ai, 1986, Marshall et ai, 1968). Many subjects showed decreases in plasma 
total T4 (TI4) and increases in TSH levels. Significant decreases in serum 
TT 4 levels were also observed in transformer maintenance workers exposed 
to Aroclor 1260 for 4 years (Emmett et ai, 1988). However, examination 01 
thyroid function in subjects 16 years after the incident in Yusho revealed 
significantly raised serum levels of both total T3 (TI3) and TT 4 with no 
differences in TSH and TBG levels in serum (Murai et ai, 1987). Ten years 
after an accident in Seveso (Italy), where a wide area became contaminated 
with 2,3,7,8-tetrachlorodibenzo-p-dioxin (rCDD) by an explosion in a 
chemical factory, an increased incidence of thyroid cancer has been 
observed in women who lived in the neighbourhood of the accident (Bertazzi 
et al1989). 
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Animal studies 
A direct sign of thyroid toxicity in non-human primates (marmoset 
monkeys) was the dramatic reduction in serum TT4 levels (99 %) (over the 
whole exposure period) during repeated dosing of 3,3',4,4'-
tetrachlorobiphenyl (TCB) for 18-23 weeks (Van den Berg et ai, 1988a,b). 
Other indicative parameters of thyroid hormone status, such as the free T 4 
index and serum TT3 levels, were decreased, while TSH and T3 resin uptake 
were increased. The follicular cells of the thyroid glands of exposed animals 
appeared highly hyperplastic, and this phenomena was closely correlated 
with decreased serum TT4 and increased TSH levels. These effects took 
place at relative low doses and occurred early after exposure (Van den Berg, 
1988a,b). Tryphonas et al (1986) demonstrated also histopathological 
alterations in thyroids of Rhesus monkeys exposed to Aroclor 1254 (a 
mixture of PCBs) for two years. 
Reduced thyroid hormone and/or vitamin A levels in plasma were also 
observed in rodents exposed to PCBs or PBBs (Sleight et ai, 1978, Brouwer 
et ai, 1985, 1986a, 1986b, Brouwer, 1987, 1989). Studies with eight week old 
male Osborne-Mendel rats exposed to Aroclor 1254 for 12 weeks indicated 
ultrastructural lesions in thyroid follicular cells associated with lowered serum 
TT4 levels (Collins et ai, 1977, 1980). A post-exposure period of 35 weeks 
was necessary to get TT 4 values back to base levels and follicular cells in a 
normal condition. Enlarged thyroids induced by PCBs were also observed in 
fish-eating animals such as salmon and seagulls (Barsano, 1989). Other 
wildlife species, such as cormorant chicks and harbour seals, that lived in 
Dutch areas contaminated with PCBs, had decreased plasma thyroid 
hormone levels (Craane et ai, 1990, Brouwer 1991). Pups derived from 
Sprague-Dawley rats daily exposed to 2,3',4,4' -5-pentachlorobiphenyl or 
2,2',4,4',5,5'-hexachlorobiphenyllkg/day had decreased serum TT4 levels in 
conjunction with increased follicular cell vacuolization and nuclear 
vesiculation within thyroids (Ness et ai, 1993). Daily exposure of 31-day old 
Fisher rats to a very low dose of Aroclor 1254 (0.1 mg/kg) for 15 weeks 
resu~ed in highly signmcant decreases of TT 4 levels in serum (Gray et ai, 
1993). In general, determination of TT4 levels in serum may possibly be a 
suitable and/or sensitive biomarker for (sub)chronic exposure of living 
organisms to PCBs. Direct evidence for thyroid toxicity was also found in 
rodents that were exposed to PBSs or pesticides (Gupta et ai, 1983, Bainova, 
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1982). Furthermore, prenatal exposure of pregnant rats to PCBs 
(3,3',4,4',5,5'-hexachlorobiphenyl) resulted in decreased plasma levels ofTT4 
and free T4 (FT4) in maternal and neonatal animals (day 21 postpartum), 
(Morse et ai, 1993b). 
Indications of disturbed thyroid physiology by 2,3,7,8-tetrachlorodibenzo-
p-dioxin (TCDD) have been derived from many animal experimental studies. 
For instance, a single oral dose of TCDD (25 "g/kg) to rats resulted in 50 % 
reduction of serum TT 4 levels, and in elevated serum TSH concentrations, 
nine days after treatment (Bastomsky, 1977). Male Sprague Dawley rats and 
male Syrian golden hamsters, which were exposed to several i.p doses of 
TCDD (0-500 "g/kg), developed changes in serum TT4 levels (Henry et ai, 
1987). The response of serum TT41eveis appeared species dependent, since 
in hamsters these levels were increased, and in rats decreased by TCDD. 
Furthermore, rats appeared more sensitive to TCDD-induced alterations in 
TT4 levels. Potter et al (1983) demonstrated that one week after 
administration of TCDD to male Sprague Dawley rats, serum TT4 levels 
declined to 46 % of controls. In this study, a possible relationship existed 
between the TCDD-induced hypothermia and lowered serum TT 4 levels. 
These observations could not account for the observed lowered food uptake 
by TCDD. 
Rozman et al (1984) showed that thyroid hormones may mediate TCDD-
induced toxicity. This finding was based on the observations that male 
thyroidectomised Spraque Dawley rats, exposed to TCDD, developed a much 
slower loss of body weight than nonthyroidectomised-euthyroid rats or 
thyroidectomised, T 4-substituted rats. These results suggest that 
thyroidectomy may be protective against lethal effects of TCDD. 
Disturbances of thyroid homeostasis by PCBs or PCDDs, in particular the 
reductions of plasrna TT4 levels, may have consequences for proper brain 
function of adults, and for the development of the brain of growing animals. 
Toxicity of HCB for thyroid homeostasis 
Human studies 
Most information about disturbed thyroid physiology in humans has been 
obtained from an incident in Turkey, where people had eaten food 
contaminated with HCB (Table 1). In addition to other toxic signs, reduced 
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plasma TT 4 levels were found in conjunction with enlarged thyroids (Peters 
et ai, 1982). The latter occurred in 60 % of the screened females, and in 27 
% of the men. In 50 % of the females, very low values of serum TT 4 were 
detected. Recently, Grimalt et al (1994) found possible indications for HCB-
induced thyroid neoplasms. 
Animal studies 
Enlarged thyroids were observed in pigs exposed to HCB for 8 weeks 
(Den Tonkelaar et ai, 1978). In Syrian golden hamsters, that were daily 
exposed to HCB by diet, thyroid adenomas were observed at the end of life 
(Cabral et ai, 1977, 1986). Increased thyroid weights were observed when 
Syrian golden hamsters received HCB for 6 weeks in the diet (Smith et ai, 
1987). Reduced TT4 and TT31eveis in blood were also detected in Sprague-
Dawley rats, which received dietary HCB for 55 days (Rozman et ai, 1986). 
Termination of the treatment did not result in a return to normal serum TT4 
values. Significant reductions of TT4 and free T4 (FT4) plasma levels were 
observed in female Wistar rats exposed to HCB (0.03 % in diet) for 5 or 13 
weeks (Den Besten et ai, 1993). Compounds structurally similar to HCB, such 
as 1 ,2-dichlorobenzene, 1 ,4-dichlorobenzene, 1 ,2,4-trichlorobenzene, 1 ,2,4,5-
tetrachlorobenzene and pentachlorobenzene also induced a reduction in 
plasma TT 4 levels in male Wistar rats alter a single dose (Den Besten et ai, 
1992). In addition, subchronic oral exposure of rats to several 
trichlorobenzene isomers (Cote et ai, 1988) or tetrachlorobenzene isomers 
(Chu et ai, 1984) led to an altered thyroid morphology. 
Mechanisms of toxicity of aromatic halogenated hydrocarbons (AHHs) 
Interaction with the Ah receptor 
An important non-specific cellular mechanism underlying the capacity of 
AHHs to induce MFOs by AHHs is the interaction with the Ah (Aryl 
hydrocarbon) receptor (Brunstrom, 1992). The latter is an intracellular protein 
that is produced by a structural gene, associated with the Ah locus. Alter 
binding of ax encbi otic compound (e.g. a halogenated aromatic carbon) to 
the Ah receptor, a set of regulatory, structural and possibly temporal genes, 
involved in controlling many species-dependent and tissue-specific 
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responses (Poland et ai, 1976, Safe, 1985, Safe et ai, 1990) may become 
simultaneously activated. Thereafter, a number of toxic responses may be 
induced (pleiotropic response), (Safe, 1984). In detail, the Ah-receptor-Iigand 
complex translocates to the nucleus and interacts with the so called dioxin 
responsive element (DRE), localised in the 5' upstream region of genes, 
which become activated (Denison et ai, 1989, Safe et ai, 1990). This is 
followed by enhanced transcription and translation of mRNAs that code for 
proteins (mainly MFOs) that are capable of biotransformation of the 
xenobiotic compound involved (Nebert et ai, 1979, Roberts et ai, 1985, Safe 
et ai, 1990). 
Binding of AHHs with the Ah receptor is highly dependent on their 
structure. For instance, coplanar dioxins or PCBs show in general a much 
stronger interaction than non-coplanar structures. In case of binding of 
coplanar PCBs or TCDD, conversion of the parent compound to less or 
rather more toxic metabolites occurs primarily by cytochrome P450-1A1. 
Interference of AHHs with thyroid and/or vitamin-regulated systems has 
been suggested to be a mechanism of induction of various toxic responses 
(Neal et ai, 1979, Poland et ai, 1982, Rozman et ai, 1984, Thunberg et ai, 
1984). It appeared that most signs of toxicity, mainly observed in exposed 
rodents and non-human primates, closely resembled clinical symptoms 
observed under thyroid hormone or vitamin A-deficient conditions. For 
instance, PCBs and PCDDs are efficient inducers of body weight loss by 
reduced feed intake (wasting syndrome), heart beat disturbances, skin 
lesions (this symptom is species dependent), increases of serum total lipid 
levels, and reductions of vitamin A and thyroid hormone levels in plasma 
(Innamini et ai, 1974, McConnell, 1980, Brouwer et ai, 1986a,1986b, Van den 
Berg et ai, 1988a,b, Brouwer, 1991). 
Prolonged reductions of thyroid hormone levels may pose a threat to 
maintenance of important physiological processes in fetal, neonatal, and 
adult organisms, such as growth and differentiation, organ development 
(brain), and reproduction (SChwartz, 1983, Legrand 1977, 1986). 
Furthermore, induced hypothyroidism may contribute to enhancement of the 
neurotoxic effects of AHHs, since major clinical symptoms in patients include 
behavioral changes (depression), psychological abnormalities and even 
seizures (Laurberg, 1990). 
Numerous studies indicate increased thyroid hormone metabolism by 
AHHs via induction of phase II enzymes as an important event for 
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explanation of decreased thyroid hormone levels in blood. With respect to 
PCBs and PCDDs, increases in several metabolic parameters, such as 
hepatic T4-glucuronyltransferase activity, biliary T4 glucuronide production, 
bile flow, and biliary hormone clearance had been demonstrated in exposed 
animals (Bastomsky, 1974, 1976a,b, Henry et ai, 1987, Beetstra et ai, 1991). 
Similar effects were also observed in animals dosed with HCB. For 
instance, female Wistar rats that were treated with high doses of HCB (1000 
mg/kg) for 4 weeks (Kleinman de Pisarev et ai, 1989) showed a 6-fold 
increase in the metabolic clearance of T4. In addition, serum thyrotropin 
(TSH) levels and 1251_thyroidal uptake were also highly increased and 
indications of interference with deiodinative metabolism of T 4 were obtained. 
Recently, Van Raaij et al (1993) found a relationship between HCB-induced 
reductions of TT 4 levels in serum and increased activity of T 4-
glucuronyltransferase. In another study, HCB-induced reductions of TT4 
levels were not correlated with an impaired thyroid hormone syntheSis, 
indicating an extrathyroidal effect on thyroid homeostasis (Kleinman De 
Pisarev et ai, 1990). 
Also mixtures of PCBs enhance T 4 metabolism. For instance, reductions 
of TT 4 and FT 4 levels in serum were observed in thyroidectomised Sprague 
Dawley rats that received replacement therapy with T 4 and T3 to normal 
euthyroid levels following a dose of Aroclor 1254 (Barter et ai, 1992). These 
observations indicated enhanced activity of T 4 metabolizing enzymes. 
Bastomsky (1977) obtained evidence for a rapid increase of biliary clearance 
of plasma [,251JT 4 after a single dose of 2,3,7,8-dibenzo-p-dioxin (TCDD) to 
rats. In contrast, TCDD did not alter biliary excretion of T3. One study of 
Byrne et al (1987) indicated evidence that exposure of rats to Aroclor 1254 
for 5 months induced decreases of TT4 and TT3 levels in serum over the 
whole exposure period, due to damage of the thyroid itself. An increased 
hepatic or peripheral catabolism of T4 was not involved since the T4 
metabolic clearance rates were not altered by this treatment. 
Interaction with thyroid hormone binding proteins 
During the past few years, interactions of AHHs with thyroid hormone 
binding proteins as a possible mechanism by which disturbances of thyroid 
homeostasis could be induced have become of interest. Special attention 
has been paid to transthyretin (TTR), a transport protein for thyroid 
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hormones and the retinol-retinol binding (retinol-RBP) complex in mammals, 
including humans (Brouwer et ai, 1986a, 1986b, Brouwer, 1987). 
The structure 01 TTR consists of four identical subunits, which form a 
central channel. Two identical T 4-binding sites lined with hydrophobic amino 
acid side chains form polarizable pockets for halogenated benzene 
interactions. Van den Berg (1990) showed with respect to the chlorophenols 
that affinity for the T4-binding site of TTR was predominantly determined by 
the position and number of chlorine atoms. The most efficient binding 
occurred when chlorine was present in both ortho positions to the hydroxyl 
group. Furthermore, according to Scatchard analysis it appeared that the 
interaction 01 pentachlorophenol (PCP) with TTR was competitive with T 4. It 
was concluded that the combination of hydroxyl and chlorine groups did 
result in a higher affinity for the T 4-binding site of TTR than each separate 
group. Within the chlorophenols, PCP had the highest relative affinity for this 
site. Den Besten et al (1991) confirmed the latter phenomenon, and showed 
a correlation between relative binding affinities of phenolic metabolites of 
various chlorinated benzenes for the T 4-binding site of TTR and the 
magnitude of plasma TT 4 reduction in male Wistar rats. A clear increase in 
affinity forTTR was demonstrated from dichlorobenzene, via trichlorobenzene 
to HCB. No interaction was detectable for monochlorophenol or 
pentachlorobenzene (PECB). Furthermore, it was suggested that cysteine 
residues were not involved in binding 01 T4 to TTR, since tetrachloro-
benzoquinone, that possess a strong affinity for protein thiols, had no affinity 
for T 4-binding sites on TTR. Figure 6 shows a PCP molecule fitted into the 
T 4-binding pocket 01 a TTR tetramer using a molecular modelling program 
and crystallographic data from Blake and coworkers (1974, 1978). 
Also with respect to PCBs, there is evidence that interactions of the 
hydroxylated metabolites with T4-binding sites of plasma proteins playa role 
in the mechanism responsible for reductions of plasma TT 4 or vitamin A 
levels. This has become apparent from studies with rats that were exposed 
to one of the most toxic coplanar PCB congeners, i.e. 3,3',4,4'-
tetrachlorobiphenyl (fCB). It could be demonstrated that the 5-monohydroxy-
derivative (5-0H-TCB) had a relative high affinity for the T 4-binding site of 
TTR. In addition, serum TT4 levels in marmoset monkeys exposed to TCB, 
remained lowered as long as 5-0H-TCB was present (Brouwer, 1987). It 
further became clear that hydrolytic dechlorination at the meta or para 
position of a phenyl ring facilitated the interaction as was demonstrated with 
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hydroxylated metabolites of TCB (Brouwer et ai, 1990). Rickenbacher et al 
(1986) demonstrated that the interaction of hydroxylated PCBs with TTR was 
3-8 times more effective compared with the interaction of T4 itself, and that 
the highest binding affinity was observed for the laterally substituted PCBs 
(3,3',5,5'-), which closely matched the structure of the diiodophenolic ring of 
T4. Chlorine substitution on nonlateral (2,2',6,6'-) positions resulted in a 
decrease in binding capacity. A planar structure of PCBs, with a hydroxyl-
group and chlorines in lateral positions appeared an ideal condition to 
interact with the T 4-binding site of TTR. 
Fig. 6. Interaction of pentachlorophenol (PCP) with the T4-binding site ofTTR 
Front view Side view 
With data from computer molecular modelling studies using X-ray 
crystallographic measurements, and from experimentally measured binding 
affinities, it was also demonstrated that hydroxylated derivatives of dioxins 
and dibenzofurans, or PCB isomers and hydroxy-derivatives of PCBs, fitted 
42 
well into the T4-binding-pocket of TTR (McKinney et ai, 1985a,b, 
Rickenbacher et ai, 1986). It was generally demonstrated that AHHs 
containing one phenyl ring, or linear molecules with multiple rings, had a 
much higher affinity for TTR than normal angular diphenyl-ether bridged 
thyroid hormone analogues. Comparable phenomena were observed when 
hepatic nuclear extracts were tested for binding of PCBs (McKinney et ai, 
1987). From a recent study that used competitive binding assays (Lans et ai, 
1993), it has become apparent that interaction of hydroxy-PCBs with the T 4-
binding site of human TTR was most favourable under the following 
conditions; 1) the hydroxygroup substituted on the meta/para positions, and 
2) one or more chlorine atoms substituted adjacent to the hydroxy group on 
either or both aromatic rings. In the same study, hardly any difference was 
observed in T4-displacement potency between the non-ortho-, mono-ortho-
as well as di-ortho-hydroxy-PCBs, and coplanarity was not an essential 
condition for competitive binding of hydroxy-PCBs to TTR. 
Since TTR has a T4-binding site that is complementary to the DNA 
double helix (Blake et ai, 1977), it has been postulated that the thyroid 
hormone agonistic and/or antagonistic properties of PCDDs, TCDD in 
particular, were due to interactions with nuclear thyroid hormone receptors 
in tissue (Blake et ai, 1977, McKinney et ai, 1985b). This event might be an 
additional mechanism underlying toxicity besides their high potency to 
interact with the Ah receptor. A later study however, indicated that TCDD has 
no intrinsic thyromimetic activity (Roth et ai, 1988). Not only hydroxylated 
PCBs or chlorophenols, but also other types of industrial halogenated 
aromatiCS, such as chlorophenoxyacids and dichloro-diphenyl-
trichloroethanes (DOTs) appeared to be effective competitors for the T4-
binding pocket of TTR (this thesis). 
Information about interactions of AHHs with other thyroid hormone-
binding proteins, such as albumin or thyroxine-binding globulin (TBG) is 
scarce. Van den Berg (1990) demonstrated competitive interactions of PCP 
for the T 4-binding site of TBG and albumin, although the affinity was much 
lower compared with TTR (relative affinities amounted to 0.001, 0.25 and 1.7 
respectively). Furthermore, interactions of o,p'-DDD with TBG were 
demonstrated (Marshall et ai, 1968). Equilibrium dialysis experiments showed 
that some benzene derivatives, such as phenols and benzoates were able 
to displace T4 from the low-affinity T4 site on human serum albumin (HSA) , 
which was dependent on 1) the presence of highly polarizable substituents, 
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such as iodine atoms, and 2) the presence of anionic groups (fabachnick 
et ai, 1970). In addition, the interaction of phenols with T4-binding sites on 
HSA increased with the number of halogen substituents associated with 
reduction of the pKa value. The herbicide 3,5-diiodo-4-hydroxybenzonitrile 
(ioxynil) interacts with TIR, but no affinity for TBG or albumin was found 
(Ogilvie et ai, 1988) 
The observations described above led to the hypothesis that interaction 
of hydroxylated AHHs with TIR are for a large part responsible for reductions 
of T4 or vitamin A levels in plasma (Brouwer et ai, 1986a,1986b). Brouwer 
(1987) suggests that the plasma T 4 reductions are the result of binding of 
the hydroxylated metabolite with the T 4-binding site of TIR and a rapid 
removal of T 4 levels from the circulation. The reductions of plasma vitamin 
A levels may be due to subsequent conformational changes of the TIR 
bound retinol-RBP complex (Brouwer et ai, 1988), destabilization of binding 
and finally loss of this complex. 
Outline and aim of the thesis 
From various previous sections (part B), it is clear that exposure of 
several mammalian species, including humans, to aromatic halogenated 
hydrocarbons (AHHs) may cause toxic effects. In particular, symptoms of 
neurotoxicity in exposed juveniles and adults may be induced. In addition, 
studies report altered thyroid homeostasis induced by AHHs. This results 
mainly in reductions of thyroxine levels in blood. Since thyroid hormones are 
required for proper brain function and for development of brain during 
neonatal and early life, inadequate thyroxine levels may contribute to various 
neurotoxic responses. 
In this thesis, hexachlorobenzene (HCB) was chosen as a model 
compound for AHHs to give insight in 1) mechanisms underlying altered 
thyroid hormone levels by HCB in the Circulation, 2) the relative contribution 
of enhanced metabolism and competitive interactions in reduction of 
thyroxine levels, 3) the consequences of exposure to HCB for thyroxine 
transport to the brain, 4) the question whether transport of thyroxine and 
pentachlorophenol (PCP), i.e. the major hydroxylated metabolite of HCB, into 
cerebrospinal fluid is mediated by a transport mechanism based on 
transthyretin. These four aspects comprehend the aim of the study. 
The major reasons to chose HCB were: HCB has a the most simple 
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structure in the class of the AHHs and shows comparable physical-chemical 
properties with PCBs. Furthermore, HCB exhibits a large similarity with other 
AHHs concerning toxic effects, including neuro-and thyroid toxicity obseNed 
in humans and several animal species (see previous sections of part B). 
The first experiments (Chapter II) focused on the question whether 
repeated exposure of rats to HCB lead to reductions of serum thyroid 
hormone levels, or morphologic changes of thyroid glands. In addition, the 
activity of hepatic microsomal mixed function oxidases and serum HCB and 
PCP concentrations were determined, since hydroxylated metabolites of 
AHHs are possibly causal factors for induced alterations of thyroid hormone 
levels in blood. 
In Chapter III, it is described whether HCB as parent compound, or rather 
its major metabolites, such as PCP and tetrachlorohydroquinone are able to 
affect rat serum thyroid hormone levels after a single equimolar i.p dose. 
Interactions of PCP or HCB with thyroxine binding sites of serum 
proteins, and their involvement in altered serum thyroxine levels induced by 
HCB or PCP are described in Chapter IV. For these experiments, sera or 
serum extracts were obtained from HCB-or PCP-treated rats to investigate 
occupation of thyroxine binding sites. 
The interaction with serum proteins, in particular transthyretin , is 
possibly a characteristic of several groups of industrial halogenated 
compounds, particularly solvents and pesticides. A binding assay was used 
to estimate the degree of interference of chemical compounds with the 
thyroxine binding sites of serum proteins (Chapter V). 
In Chapter VI, effects of HCB on the activity of hepatic thyroid hormone 
metabolizing enzymes, such as thyroxine and triiodothyronine UDP-
glucuronyltransferases, are described. Furthermore, it was investigated 
whether biliary excretion of thyroxine and/or bile flow were altered by HCB. 
Experiments were performed (Chapter VII) to investigate the significance 
of competitive interactions of PCP with thyroid hormone binding proteins in 
HCB-induced alterations of total or free thyroxine levels in serum. Therefore, 
rats were repeatedly exposed to high doses of HCB followed by 
determination of PCP and thyroxine levels in serum. 
Interactions of AHHs with transthyretin may have consequences for the 
supply of thyroxine from blood to the brain, since an active role for 
transthyretin in thyroxine transport from blood to the brain has recently been 
proposed (Schreiber et ai, 1990). When this assumption is valid, it may also 
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implicate that AHHs with high affinity for the thyroxine binding site of 
transthyretin enter the brain by a manner comparable with thyroxine. In 
Chapter VIII, it was investigated in an experimental rat model whether 
thyroxine transport to cerebrospinal fluid and brain was influenced by HCB 
or PCP. In addition, this was associated with determination of HCB and PCP 
in brain and cerebrospinal fluid. Furthermore, entrance of PCP into 
cerebrospinal fluid was determined in separate experiments. 
Experiments described in Chapter IX concerned the role of transthyretin 
in transport of thyroxine and various AHHs through the blood-cerebrospinal 
fluid barrier. Therefore, various compounds which possess a high affinity for 
the thyroxine binding site of transthyretin were given to rats in the presence 
of [' 25ljthyroxine, whereafter the uptake of label into cerebrospinal fluid was 
determined. Finally, in addition to experiments concerning the blood-
cerebrospinal fluid barrier, it was investigated whether transthyretin (and also 
other thyroid hormone binding proteins) played a role in transport of 
thyroxine through the capillary blood brain barrier during a single pass 
(Bradbury et ai, 1975, Oldendorf et ai, 1976). 
The conclusions of this thesis and an evaluation of its toxicological 
significance to man are presented. 
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CHAPTER II 
EFFECTS OF HEXACHLOROBENZENE ON THYROID HOMEOSTASIS 
IN RATS 
ABSTRACT 
JAG.M. van Raaij'-2, and KJ. van den Berg2 
1) Institute of Public Health and Social Medicine, 
Erasmus University Rotterdam, The Netherlands 
2) TNO Medical Biological Laboratory, Rijswijk, The Netherlands 
In order to characterize the effects of hexachlorobenzene (HCB) on thyroid 
homeostasis, rats were orally dosed with 3.5 mmol HCB/kg three times a week, for four 
weeks. W~h this dosing regimen, few signs of general toxicity, e.g body temperature 
and body weight were noted. Serum levels of total thyroxine (IT4) were reduced by 46 
% after 15 days and remained permanently decreased. Total triiodothyronine (IT3) 
levels were temporarily decreased in the second and third week of dosing (45% 
reduction at day 15). The thyroid gland showed signs of increased activ~ as was 
evident from increased weight, altered morphology and an increased uptake of 131r. 
HCB gradually accumulated in serum to 0.049 mmol/I and pentachlorophenol (PCP), 
the major oxidative metabol~e of HCB to 0.011 mmol/I at the end of the dosing period. 
Induction of hepatic mixed function oxygenases was apparent from a 13-fold increased 
activ~ ethoxyresorufin-O-deethylase (EROD) activ~. 
It is concluded that a repeated dose of HCB to rats results in a hyperactive thyroid, 
and in decreased thyroid hormone levels. The gradual build up of PCP in serum may 
playa role in HCB-induced reductions of thyroid hormone levels. 
INTRODUCTION 
From a vast amount of data in literature, it has become apparent that 
aromatic halogenated hydrocarbons (AHHs), such as hexachlorobenzene 
(HCB), polychlorinated biphenyls (PCBs), and polychlorinated-dibenzo-p-
dioxins (PCDDs) may pose a threat to the health of humans. Many of these 
compounds may be formed during incineration processes, or production of 
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organic solvents and are released into the environment (OIie et ai, 1977, 
Blackwood et ai, 1979, Carpenter et ai, 1986, Safe et ai, 1990). 
From a few human studies, and a number of animal studies, the major 
signs of toxicity of AHHs include dermal lesions, thymic atrophy, and hepato-
toxicity (see chapter I). The thyroid may be a target organ for AHHs since 
this class of chemicals was found ·to induce disturbances of thyroid 
homeostasis in laboratory animals and wildlife species. In particular, 
reductions of plasma thyroxine (T 4) levels were demonstrated in rodents or 
monkeys that were exposed to PCBs and PCDDs (see Chapter I). In contrast 
to a large amount of data on thyroid effects of PCBs and PCDDs, less 
information is available on toxic effects of HCB on thyroid homeostasis in 
mammals, including humans. There is one episode. known about humans in 
Turkey, who became poisoned with HCB via contaminated food, which 
resulted in reductions of T 4 levels in blood and enlarged thyroids (Peters et 
ai, 1982). Some animal studies demonstrated comparable effects with HCB 
(Rozman et ai, 1986, Den Tonkelaar et ai, 1978, Smith et ai, 1987). 
The aim of the present study was to characterize effects on thyroid 
homeostasis of WAG rats repeatedly dosed with HCB for a period of four 
weeks. The functional status of the thyroid was assessed on the basis of 
weight, morphology, and iodine uptake. Furthermore, the activity of hepatic 
microsomal mixed function oxidases, including serum HCB and PCP levels 
of the experimental and control animals were determined, since major 
hydroxylated metabolites of aromatical halogenated hydrocarbons, 
particularly PCBs, may be causally involved in affecting thyroid hormone 
levels in blood (Brouwer et ai, 1986, Brouwer, 1987). 
MATERIALS AND METHODS 
Chemicals 
HCB was purchased from Aldrich, Brussels, Belgium. 131 r (specific activity 
40 mCi/ml respectively) including T 4 and T3 RIA kits (Amerlex-M) were 
acquired from Amersham, U.K. NADPH and (ethoxy)resorufin were obtained 
from Sigma, St Louis, MO, U.S.A. BCA protein kits were obtained from Pierce, 
Illinois, U.S.A. Tween-20 was obtained from Bio Rad Laboratories, Richmond, 
California. 
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Animals and Treatments 
Male WAG/MBL rats (250-300 g) of about 12 weeks of age, were used. 
The animals, which had free access to water and food, were housed in a 
room with a 12 h light/dark cycle and an ambient temperature of 24'C. 
Control animals were dosed by gavage with 2x3 ml vehicle, while 
experimental animals received 2x3 ml of 3,5 mmol HCB/kg (i.e 1 g/kg), three 
days per week for 4 weeks. HCB was used as an emulsion of 0.14 mmol/ml 
in water containing 0.5% Tween-20. Blood was collected by tail bleeding at 
preselected times. During the period of treatment, the general health of the 
animals was monitored three times a week by measuring rectal body 
temperature and body weight. One week after the last dose, animals were 
killed by an overdose of CO2 , whereafter the thyroid glands, livers and sera 
were collected for further histological and biochemical studies. 
Histopathology 
The thyroid glands were weighed, and fixed in 3.5% formalin solution 
until use for microscopical examination. Histological slides were prepared 
and stained with hematoxylin-phloxine-saffron (HPS). 
Thyroid function 
Rats received 50,uCi 1311' in 1 ml of saline Lp (day 46). Approximately 6 
h later, the animals were killed by decapitation. Uptake of 1311' in the thyroid 
glands was determined after gamma counting. 
Thyroid hormones, HCB and PCP in sera 
Total T4 (IT4) and T3 (IT3) levels were determined in sera of control and 
HCB-treated rats with a radioimmunoassay. HCB and PCP concentrations in 
the same sera were analyzed using HPLC as described earlier (van Raaij et 
ai, 1991). The detection limit for PCP in serum was 0.14 ,umol/I and for HCB 
0.35 ,umol/I. The extraction efficiencies for both PCP and HCB were more 
than 95%. 
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Microsomal enzymes 
The frontal portion of the liver was homogenised in 3 weight volumes of 
100 mM KH2P04/K,HP04 , pH 7,4 (buffer A). Liver microsomes were isolated 
by ultracentrifugation (9000 x g, for 30 min) of the homogenates. The 
supernatant was centrifuged once again (100000 x g, for 90 min) whereafter 
the pellet was resuspended in one volume of buffer A. Aliquots of 
microsomes were frozen at -70'C until use. The measurement of 
ethoxyresorufin-deethylase (EROD) activity was used as an indicator of 
microsomal mixed function oxidative (MFO) activity. EROD was measured 
according to published procedures using ethoxyresorufine as a specific 
substrate (Burke et al,1974). Protein concentrations were determined using 
the BCA method (Smith et ai, 1985). 
Statistics 
Student's t-test was utilised for statistical evaluation of mean values of 
various parameters between experimental and control animals. Results are 
presented as means:±: SEM. 
RESULTS AND DISCUSSION 
Body temperatures of rats treated with HCB were slightly decreased by 
about 0.5'C, when compared with control rats during the experimental 
dosing period, although at termination, the difference was not significant 
(Fig.1). Body weights in animals receiving HCB were somewhat increased 
during the first days of dosing and then recovered to follow a normal growth 
curve (Fig.2). These observations indicate low systemic toxicity of HCB and 
possibly indicate that effects of HCB on thyroid homeostasis are not a result 
of altered efficiency of energy utilization. 
Serum TT 4 levels (Fig. 3) significantly decreased beginning after three 
days of exposure. A maximum decrease was found after 15 days as 
compared with control animals (33.9 nmol/I). TT4 levels were declined in 
animals treated with HCB to 18.2 nmol/I (i.e 46 % decrease). Thereafter, TT4 
levels remained at a steady decreased level throughout the rest of the 
dosing period. 
There appeared to be some change in course of control values of serum 
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Fig.1. Effect of HCB on body· temperature 
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Rats were repeatedly exposed to HCB for 4 weeks. At preselected times, rectal body temperature 
of the animals was determined. Significance: * ,p< 0.05, "",p< 0.01. HCB: O~O, CON; ... ~ ... 
Fig.2. Effect of HCB on body- weight 
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Rats were repeatedly exposed to HCB for 4 weeks. At preselected times, the animals were 
weighed. Significance: *,p< 0.05. HCB: 0-0, CON; ..t.-... 
TT 4 levels during the whole exposure period with a minimum at about 2 
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weeks. The time course of TI 4 values as a result of exposure to HCB shows 
a similar effect superimposed on the decrease of TI 4 levels. This is 
maintained by HCB during the whole dosing period. An explanation may be 
that the combination of preventive measures for HCB handling (e.g. cages 
with special filter caps, less frequent cleaning of cages, forced oral dosing 
by stomach tube) induce in the animals in the beginning some stress to 
which they adapt later on. It is known that thyroid hormones are stress 
sensitive (De Groot, 1979). 
Fig.3. Time course of TI4 levels 
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Rats were dosed with HCB for 4 weeks. At the indicated times TT4 levels were determined by 
radioimmunoassay in the same sera as used for the determination of HCB and PCP levels. 
Significance: ** .P< 0.01. HCB: 0-0; CON: ... · ... 
TI3 levels in serum were also found to decrease as an effect of HCB-
treatment (Fig.4). The decrease (44.9%) appeared to be at a maximum after 
15 days. Thereafter, TI3 levels gradually returned to baseline levels. The 
observations confirm and extend observations of Kleinman de Pisarev (1989, 
1990) who found decreased TI 4 levels but no significant alterations in TI3 
serum levels of female Wistar rats, when measured one, and eight weeks 
after the start of HCB dosing. The transient decrease in TI3 levels is a novel 
finding. Den Besten and coworkers (1993) demonstrated significant 
reductions of TI 4, but also of TI3 in serum of female Wistar rats that were 
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exposed to HCB by diet over a 13 weeks period of exposure. In this study, 
serum TI3 levels did not return to normal values in rats exposed to HCB, but 
remained decreased over almost the whole period of exposure. 
Differences in effects on serum TI3 levels after HCB treatment may be 
explained by possible differences in sex, dosing procedure, and animal 
strains. There are indications for strain specific differences in potential of 
glucuronidation of T3. For instance, WAG rats, Wistar LA rats and Fisher rats 
as well show an impaired T3 conjugation with glucuronic acid. This 
phenomenon may be due to a defect in androsterone-UDP-
glucuronyltransferase, e.g an enzyme involved in conjugation ofT3 (Beetstra 
et ai, 1991, Visser et ai, 1991, Van Raaij et ai, 1993). Therefore, the 
Fig 4. Time course of TI3 levels 
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Rats were dosed with HCB for 4 weeks, At the indicated times TT3 levels were determined by 
radioimmunoassay in the same sera as used for the determination of HeB, PCP and TT4levels. 
Significance:*,p<O.05, "'*, p< 0.01. HCB: 0-0; CON: .... -.... 
temporary reduction of serum TI3 levels by HCB in WAG rats is probably not 
based on enhanced hepatic metabolism of T3. Another explanation may be 
a non permanently altered binding of T3 to serum proteins since PCP is 
capable of binding to thyroid hormone binding proteins (Van den Berg, 1990, 
Van den Berg et ai, 1991). The return to baseline levels may also be 
attributed to an increased production of T3 by the thyroid gland as a classic 
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thyromimetic response (Th. Visser, personal communication), or to an 
enhanced activity of hepatic deiodinases. 
Free T4 (FT4) levels in sera of the experimental animals were decreased 
by more than 70 % compared with controls (see Chapter VII). As a reaction 
of the pituitary upon this phenomenon, serum TSH levels were increased 
(56.6 %, Chapter VII). Thyroid glands of the animals dosed with HCB were 
significantly enlarged by 27.3 % (Table 1) compared with control animals. 
Histological examination of slides from thyroids of animals dosed with HCB 
revealed hypertrophy and hyperplasia (Fig. 5). Uptake of 1311' by the thyroid 
gland of the HCB-treated animals was greatly increased (5.5-fold). These 
results suggest that the pituitary-thyroid axis is not impaired by HCB. 
Although the present findings do not imply an impaired function of the 
thyroid gland, a direct effect of HCB on the thyroid may not be excluded. 
The liver/body weight ratio was 1.7-fold increased by HCB (Table 2). In 
addition, hepatic EROD activity (associated with cytochrome P450-1A 1) was 
substantially increased (13-fold), (Table 2). These findings indicate 
stimulation of mixed function oxygenase (MFO) activity as a result of HCB 
administration. Induction of microsomal cytochrome P4S0-1A1 (and also of 
P450-1A2) associated enzymes after HCB exposure in rats had also been 
demonstrated by other investigators (Mehendale et ai, 1975, Linko et ai, 
1986, Smith et ai, 1990). Rozman and coworkers (1986) demonstrated that 
Table 1. Effects on thyroid function 
Parameter HCB 
Thyroid gland (mg) 19.1 :!: 0.9" 
1311' uptake 1366 :!: 213-
N Control 
5 15.0:!:1.2 
5 249:!: 72 
N 
5 
4 
Treatment of animals with HCB is described in thE' Material and Methods section. Rats received 
50 .uCi 13'1' in 1 ml saline Lp. Uptake of 131r in the thyroid is expressed as cpm.103jmg wet 
weight. Significance: * p<O.05, *'" p<O.001. 
the hepatic EROD activity of rats chronically exposed to HCB was 10-fold 
increased at the end of a fourteen week period of exposure. 
There was a progressive accumulation of HCB in serum up to the fourth 
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Fig 5. Effect of HCB (A) or vehicle (B) on thyroid morphology 
Rats were dosed with HCB for 4 weeks and the thyroid glands were isolated, fixed in formalin 
solution 3.5 % and stained with hematoxylinMphloxin·saffron (HPS). After treatment (A), follicles 
are smaller and the lining follicular cells are more cylindrical than in the untreated controls (B). 
Furthermore, colloid is fine granular and faintly eosinophilic in A compared with the hyaline and 
more intense eosinophilic staining observed in B. (HPS), X 210; inset, X 500. 
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Rats were dosed with vehicle for 4 weeks and the thyroid glands were isolated, fixed in formalin 
solution 3.5 % and stained with hematoxylinMphloxin-saffron (HPS). The follicles are relatively 
large and the lining follicular cells are much less cylindrical than in the experimental animals. 
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Fig.S. Time course of HCB and PCP levels 
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Rats were dosed with HCB for 4 weeks. Dosing started at day O. Blood samples were taken at 
the indicated times. Concentrations of HCB and PCP in sera were determined with HPLC 
analysis. HCB: 0-0; PCP: A-A 
week after repeated administration of HCB (Fig.6). A maximum concentration 
of 0.049 mmol HCBjl in serum was reached at day 28. After cessation of 
treatment, the serum levels of HCB declined to 0.039 mmol HCBjl over the 
two-week post-exposure period. 
As a consequence of enhanced MFa activity, there was a gradual build-
up in serum of PCP, the major metabolite of HCB (Koss et ai, 1976, Van 
Ommen et ai, 1985, 1986). PCP levels in serum increased with dosing of 
HCB and achieved maximum values of 0.011 mmol/I (day 24) and then 
remained at a fairly constant level. Control animals had no detectable levels 
of HCB or PCP. 
PCP may possibly be responsible for the decrease of serum TT 4 levels 
after administration of HCB since hydroxylated metabolites of halogenated 
aromatic compounds, such as PCBs, are able to interfere with thyroid 
hormone binding proteins (Van den Berg 1990). This aspect is described in 
following chapters (III-VII) of the thesis. 
In conclusion, the results of the present study indicate that repeated 
dosing of rats to HCB results in 1) time-dependent reduction in both TT4 and 
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TT3 levels in serum, 2) an activated thyroid gland, 3) enhanced activity of 
hepatic microsomal enzymes and 4) accumulation of PCP in serum. 
Table 2. Induction of hepatic microsomal enzymes 
Parameter HCB N Control N 
liver/body weight (x 1 O·~ 5.9 ± O. f' 5 10.0 ± 0.4 5 
EROD (nmol/min/mg) 257.3 ± 15.1- 5 20.1::!: 2.5 4 
Dosing of animals, isolation of livers and preparation of hepatic microsomes was carried out as 
described in the Material and Methods section. Significance: ** p<O.001 
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CHAPTER III 
EFFECTS OF HEXACHLOROBENZENE AND ITS METABOLITES 
PENTACHLOROPHENOL AND TETRACHLOROHYDROQUINONE ON 
SERUM THYROID HORMONE LEVELS IN RATS 
J.A.G.M van Raaij'-2. K.J. van den Berg', R. Engel" 
P.C. Bragt' and W.R.F. Notten '.2 
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(Keywords:Thyrox;ne, triiodothyronine, hexachlorobenzene, pentachlorophenol, tetrachloro-p-
hydro quinone, serum levels) 
ABSTRACT 
Effects of administration of equimolar doses of hexachlorobenzene (HCB) and ~s 
metabol~es pentachlorophenol (PCP) and tetrachlorohydroquinone (TCHQ) serum 
thyroxine (IT4) and triiodothyronine (IT3) levels in rats were studied. Furthermore ~ 
was investigated whether the observed effects were related to the serum levels of HCB 
or PCP. Rats received e~her corn oil (controls) or HCB, PCP or TCHQ in a single 
equimolar intraper~oneal dose of 0.056 mmol/kg. Results indicated that HCB did not 
a~er serum TI4 and TI3 levels for a period up to 96 h after dosing. In contrast, PCP 
and TCHQ were both capable of reducing serum TI4 levels w~h a maximum effect 
between 6 and 24 h after exposure. TCHQ was more effective in repressing TI3 than 
TI4 blood levels. Dose-response experiments were carried out in order to obtain 
insight in the sens~ivity of the observed effects. Rats received different doses of PCP 
or TCHO intraper~oneally. The reductions of TI41eveis by PCP were inversely related 
to serum PCP levels in exposed animals, based on the toxicokinetics and dose-
response profiles. Furthermore, PCP serum levels after HCB administration appeared 
too low to cause an effect. The results of this study indicate that not HCB ~self, but 
rather ~s metabol~es PCP and TCHO may be involved in reduced serum thyroid 
hormone levels after HCB administration. 
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INTRODUCTION 
Hexachlorobenzene (HCB) has been used in industrial applications 
mainly as an antimicrobial agent (fungicide) for wood preservation [1]. 
Symptoms of HCB-induced toxicity includes disturbances of thyroid hormone 
homeostasis. In one human pOisoning episode in Turkey, for example, 
persons poisoned via consumed grain contaminated with HCB, exhibited a 
number of toxic signs including decreased thyroxine levels and an enlarged 
thyroid [2]. Similar phenomena have also been observed in rodents following 
HCB exposure [3,4]. Recently reported effects of HCB in rats deal with an 
increase of hepatic thyroxine metabolism and thyroxine dehalogenation 
accompanied with decreased thyroxine levels in blood and an elevated 
excretion of porphyrinogen in urine [5]. 
Other chlorinated aromatic hydrocarbons have also been found to 
interfere with thyroid homeostasis: Exposure of primates and rodents to 
polychlorinated (PCB) or to polybrominated biphenyls (PBBs) resulted in 
decreased plasma thyroxine levels and altered thyroid morphology [6-10]. 
Organochlorine insecticides were found to decrease protein bound iodine 
levels in workers [11]. Dioxin (2,3,7,8-tetrachlorodibenzo-p-dioxin) appeared 
to reduce serum T 4 levels and was capable of inducing thyroid tumours in 
rodents [12,13J. 
Evidence is accumulating that metabolites of halogenated aromatics such 
as PCBs may playa role in disturbed thyroid hormone plasma levels [14,15]. 
Whether metabolites also are involved in HCB-induced decrease of thyroid 
hormone levels is essentially unknown. The in vitro and in vivo metabolism 
of HCB and PCP is well established [16-20J: In the liver, HCB is first 
metabolized to the main metabolite pentachlorophenol (PCP) and in a 
second step partly to tetrachloro-p-hydroquinone (TCHQ) which is further 
converted to trichlorohydroquinone. Experiments of Koss et al. with labelled 
HCB revealed that in rats almost ha~ of the amount of HCB is eliminated as 
metabolites [19]. Part of the metabolites appears in the urine in the form of 
PCP-glucuronide or tetra/trichloro-p-hydroquinone glucuronide [16,17,21 J. 
Recently, Van den Berg demonstrated interference of PCP with thyroid 
hormone carriers in vitro [22J. 
In this paper we investigated the influence of HCB and its metabolites 
PCP and TCHQ on serum thyroid hormone levels in rats after single i.p 
dosing. Additionally, HCB or PCP serum concentrations were measured and 
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correlated with serum concentrations of thyroid hormones. 
MATERIALS AND METHODS 
Materials 
HCB was obtained from Serva, Heidelberg, Germany, PCP from Aldrich 
Chemical Company, Brussels, Belgium and TCHO from Sigma, St Louis, MO 
U.S.A. These chemicals were dissolved in pure corn oil. T4 and T3 RIA kits, 
(Amerlex-M), were acquired from Amersham, England. 
Methods 
Twelve-week old male WAG/MBL rats, weighing 250-300 gram, were 
used. The animals were housed in a 12 h lighted room maintained at a 
temperature of 24°C and a humidity of 50-70 %. Water and food were 
available ad libitum. In the toxico-kinetic experiments, the animals were 
injected intraperitoneally with 1 ml of a single equimolar dose of 0.056 
mmol/kg HCB, PCP or TCHO (i.e. 16, 15, or 14 mg/kg respectively). Control 
rats received a single 1 ml injection of com oil. Blood samples were taken 
under ether anaesthesia from the tail just before exposure (t=O) and at 
2,4,6,24,48 and 96 h after dosing. Each chemical was administered to a 
group of 4-5 animals. 
In the dose response experiments, PCP and TCHO were tested using 6 
and 4 different doses respectively. The highest dose of PCP administered 
was 0.105 mmol/kg (28 mg/kg) and that of TCHO, 0.052 mmol/kg (13 mg/kg) 
both in a volume of 2.5 ml. Higher doses of TCHO were not possible 
because of the appearance of toxic signs, such as hypothermia and 
diarrhoea. Each dose was tested in groups consisting of 4 animals. Control 
rats (300 g) received 2.5 ml corn oil. In these dose-response-experiments 
blood was collected 6 h after exposure, when effects appeared to be at a 
maximum. 
Total T4 (IT4) and total T3 (IT3) levels in sera were analyzed by 
radioimmunoassay according to the manufacturer's instruction. Pilot studies 
indicated that neither HCB, PCP, orTCHO disturbed the RIA assay methods, 
nor was there an effect of corn oil on TI 4 or TI3 levels compared to saline 
injected rats. 
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Total HCB and PCP levels in rat sera (i.e. free + protein-bound fractions) 
were determined by HPLC analysis: a 1001'1 sample of 1 molll hydrochloric 
acid was added to 1001'1 of serum. The sample was further diluted to 1 ml 
with water and subsequently extracted with 4 ml of n-hexane. An aliquot of 
the n-hexane phase (3.5 mQ was evaporated under a gentle nitrogen flow at 
room temperature, in the presence of propanediol, to prevent evaporation of 
HCB and PCP. The residue was taken up in methanol and a 201'1 sample 
was injected into the HPLC system. Chromatography was carried out with a 
Waters RCM 8x1 a cartridge holder containing a 8NVC18-4,u cartridge. Elution 
was performed with methanol, containing 10 ml of water, 4 ml of acetic acid 
and 2 g of sodium perchlorate per litre at a flow rate of 1.5 ml/min. 
Fig.1. Time course of TT4 levels 
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Rats were injected Lp with 1 ml of corn oil, HCB (hexachlorobenzene), PCP 
(pentachlorophenoQ or TCHQ (tetrachlorohydroquinone) in doses of 0.056 mmol/kg. Blood 
samples were taken at the indicated times after exposure. 
Statistical significance:*, p<O.05, **, p<O.005, ***, p<O.OO1. CON +-+; HCB 0-0; PCP .. - ... ; 
TCHQ;o·O 
Detection was carried out by means of two detectors in series. The use 
of two detectors, consisting of a coulometric detector (ESA model 5100 A; 
set to + 0.63 V) for the detection of PCP and a UV detector (Perkin-Elmer 
model LC-95, set to 254 nm) for the detection of HC B allowed for the 
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determination of HCB and PCP in one run. Extraction efficiencies for HCB 
and PCP were 100%. No interfering peaks were detected when serum 
samples from animals not treated with HCB or PCP were analyzed. Detection 
limits were 0.15 ,umolll and 0.35 ,umolll for PCP and HCB respectively. TCHO 
could not be detected with the procedures described above. On addition of 
TCHO to control serum, TCHO levels were undetectable, which made further 
extraction and recovery impossible. 
Statistical analysis of effects was performed using Student's t tests. The 
variation in the concentrations of thyroid hormones, HCB or PCP is 
represented by the standard error of the mean. 
Fig.2. Time course of TT3 levels. 
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The same chemicals as described in the legends of Fig. 1 were i.p injected in rats and serum TT3 
levels were determined. 
RESULTS 
The time course of changes in serum TT 4 after exposure to an equimolar 
dose of HCB, PCP or TCHO is presented in Fig. 1. After HCB administration 
no significant changes in serum TT 4 levels were detected over a 96 h period. 
In contrast, PCP caused a marked decrease in TT4 levels compared with the 
control values. This effect was strongest between 6 and 24 h after exposure. 
The average serum TT 4 level after PCP injection dropped from 34.3 ± 1.8 to 
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12.2:!: 0.8 nmol/I (i.e. 64.4 % decrease) at the time of peak effect. Thereafter, 
serum TI 4 levels slowly returned to control levels, TCHO also caused 
significant reductions of serum TI 4 levels after 6 and 24 h, although the peak 
magnitude of the effect was less compared with PCP (i.e. 25.9% decrease). 
After 48 h, serum TI4 levels following TCHO were back to normal values. 
Serum TI3 levels, as shown in Fig. 2, did not change after HCB 
administration. However, PCP treatment resulted in a slight but significant 
decrease of 28% after 2 h. TCHO caused greater reductions in TI3 levels 
between 6 and 24 h than did PCP. After 24 h, TI3 concentrations appeared 
to be at a minimum (i.e. 85.4 % decrease). Thereafter TI3 levels slowly 
increased, but still were significantly lower than control values up to 96 h. 
To obtain more insight into the sensitivity of TI4 and TI3 responses to 
these chemicals, dose-response experiments were done. Because effects 
appeared at their maximum at 6 h after exposure, this time point was 
selected. The effects of different doses of PCP and TCHO on TI 4 and TI3 
levels are presented in Table 1. A significant decrease in serum TI4 level 
was demonstrated at 0.007 mmol PCP/kg (1.75 mg/kg). Effects on TI4 levels 
after administration of TCHO were less as compared to PCP, with a dose of 
0.034 mmol TCHO/kg (8.4 mg/kg) being the lowest effective dose. In 
addition, the no-effect level was 5-10 times higher for TCHO than PCP (i.e. 
0.026 mmol TCHO/kg vs 0.002 mmol PCP/kg). 
With respect to TI3 levels, the chosen range of PCP dOSing had no 
obvious effects except at doses higher than 0.052 mmol/kg. TCHO appeared 
to have an effect on TI3 (and TI4 levels) if a minimum dose of 0.034 
mmol/kg (8.4 mg/kg) was used. 
The time course of the HCB levels and the levels of its metabolite PCP 
after exposure of 0.056 mmol HCB/kg is represented in Fig. 3. Up to 4 h after 
HCB dosing, HCB levels were hardly detectable. From 6 h on, however, HCB 
was detectable (0.63 ,amol/I), reaching to a steady-state level of about 1.58 
,amol/I HCB at 24 h. The PCP levels after HCB administration reached a final 
mean level of 0.20 ,amolll after 96 h. 
Figure 4 represents the PCP concentrations in serum after a single dose 
of 0.056 mmol PCP/kg. Maximum PCP concentrations (varying from 0.19 to 
0.16 mmollQ were found at 2, 4 and 6 h after administration. At 24, 48 and 
96 h after exposure the level decreased to less than 0.0002 mmol/I. 
Figure 5 shows the relationship between serum PCP levels and the dose 
of PCP administered. 
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Table 1. Effects of the dose of PCP and TCHO on serum TT 4 and TT3 levels. 
Dose of TT4 (nmol/I) TT3 (nmol/I) 
chemical 
(mmol/kg) 
PCP 
0 31.2 :t 0.92 0.68:t 0.04 
0.002 32.0 :t 0.48 0.53 :t 0.01 
0.007 20.0 :t 1.60""" 0.61 :t 0.02 
0.013 17.3 :t 0.70-" 0.69:t 0.02 
0.026 17.1 :t 1.55""" 0.69:t 0.10 
0.052 13.6 :t 0.46""" 0.62:t 0.02 
0.105 9.4 :t 0.70""" NO 
TCHQ 
0 31.2:t 0.92 0.68 ± 0.04 
0.026 32.0 ± 2.70 0.67 ± 0.04 
0.034 26.1 ± 1.40" 0.55 ± 0.02 
0.042 21.4 ± 1.10- 0.34 ± 0.04""" 
0.052 26.2 :t 1.75" 0.41 ± 0.02"" 
Serum TI4 and TI3 levels of rats Lp. injected with 2.5 ml of PCP or TCHQ in 6 or 4 different 
doses, respectively. Blood samples were taken at 6 h after exposure. Control animals received 
corn oil only. Data are expressed as mean ± S.E.M. ND= not done. Statistical significance is 
indicated as in Fig.1. 
DISCUSSION 
The results presented in this study show that HCB administered 
intraperitoneally (i.p) is rather inefficient in decreasing thyroid hormone levels 
in rats as compared with the i.p administration of its metabolites PCP and 
TCHO after a single equimolar dose of 0.056 mmol/kg. Whereas PCP caused 
an almost 65% reduction of TT4 levels between 6 and 24 h, and TCHO a 
reduction of TT3 levels of about 85% after 24 h, a similar dose of HCB had 
neither effect on TT 4 or TT3 levels. Other HCB studies, where HCB was daily 
administered to rats in much higher concentrations (60x) compared to the 
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Fig. 3. Serum HCB and PCP levels after a single dose of 0.056 mmol HCBlkg 
(16 mglkg), determined with HPLC analysis. 
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Fig. 4. Time course levels of serum PCP levels. 
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Concentrations were analyzed by HPLC as reported in Materials & Methods. The mean PCP 
concentrations are represented by a black line. Mean serum TT4 levels from Fig. 1 are 
superimposed (dotted line). 
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present study, showed a decrease in TT4 levels in blood [5]. Studies with 
rats which were fed with a HCB enriched diet for 55 days, exhibited 
significant decreases in thyroxine and triiodothyronine levels [4]. 
The difference in toxicokinetics of the compounds is probably a 
determining factor in affecting thyroid hormone levels. After i.p injection of 
HCB, dissolved in corn oil, it will be released more slowly into the circulation 
than PCP, because of the higher oil-water partition coefficient of HCB. 
Furthermore, HCB is··easily trapped by fatty tissue and the liver where it 
accumulates. It is known that adipose tissue HCB levels rise rapidly after 
exposure, being 200-500 fold higher than serum levels [23]. Measurements 
of serum HCB levels indicated comparatively low levels (Fig. 3). PCP dosing, 
however, resulted in substantial concentrations in the circulation as 
demonstrated in this study (Fig. 4). The toxicokinetic profile of PCP was 
essentially similar as reported by Braun [21] who determined the elimination 
rate of a single 10 mg/kg dose of radiolabelled PCP (half-life value being 20 
h) to rats and found also plasma peak of PCP at 4 to 6 h after exposure. 
During this time the availability of PCP and protein binding appeared at a 
maximum. Plasma protein binding and retention by the liver slowed the 
removal of PCP from the body by urinary excretion. Ninety percent of the 
administered PCP was eliminated within 3 days while the remaining part was 
eliminated more slowly [21]. 
TCHQ is one of the metabolites of PCP, and was found decrease TT3 
serum levels to a much higher degree than TT 4 levels. This was an 
unexpected finding since most halogenated aromatics studied thus far with 
respect to thyroid hormone levels, e.g. PCBs, PBBs, phenoxy-acids, TCDD, 
HCB, have their main effect on TT 4 levels, usually the TT3 levels being less 
affected [4,8,10,12,24,25]. Attempts to relate serum TCHQ levels to decrease 
of serum TT4 and TT4 levels were unsuccessful. HPLC methods for TCHQ 
analysis failed, possibly because of covalent binding to serum proteins 
[20,26]; alternatively, TCHQ and TCHQ glucuronide may be rapidly excreted 
via the urine and therefore do not persist in the circulation [21]. 
One interpretation of the present findings is that actually PCP, the major 
metabolite of HCB, is the cause of the decreased serum TT4 levels in 
chronically HCB-fed or poisoned individuals. There is an inverse correlation 
between serum concentrations of PCP, and decrease of serum TT41eveis as 
is obvious when Table 1 and Fig. 5 are compared. Upon inspection of the 
time course of TT4 level and the toxicokinetics of PCP (Fig. 4) these two 
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curves are near mirror images; serum PCP levels peak when serum TT 4 
levels are at a minimum. After a single dose of HCB, circulatory PCP reached 
rather low levels (Fig. 3) (less than 0.00014 mmol/I), while a serum level of 
about 0.0188 mmol/I was at least required for a decreased serum TT 4 6 h 
after dosing (Table 1). Multiple dosing and chronic feeding however may lead 
to a considerable liver storage of HCB. The induction of hepatic P-450 
microsomal enzymes by HCB [1,27] may result in PCP levels high enough 
to affect thyroid hormone homeostasis. 
The decreased thyroid hormone levels by PCP and TCHQ may be 
caused by a disturbed synthesis, a diminished release of thyroid hormones 
by the thyroid, and an accelerated uptake by other organs. In addition, 
Fig. 5. Dependency of serum PCP levels on administered dose. 
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Doses of 0.0005, 0.001, 0.002, 0.007, 0.013, 0.026, 0.052 and 0.105 mmol PCP/kg were injected 
i.p. Sera were taken after 6 h. and analyzed by HPLC. 
several specific mechanisms have been advanced in connection with 
halogenated aromatics such as: (1) accelerated metabolism of the thyroid 
hormones via a rapid conjugation followed by excretion into the bile 
[7,12,28,29]; (2) accelerated deiodination of thyroxine [5]; and (3) 
interference with thyroid hormone binding proteins. With respect to the last 
possibility, recent studies indicate that a number of xenobiotics possess the 
property to bind to thyrOid hormone transport proteins leading to decreased 
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thyroid hormone levels [15,22,30]. Whether such a phenomenon exists in 
HCB or PCP treated animals is under investigation. 
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CHAPTER IV 
HEXACHLOROBENZENE AND ITS METABOLITES 
PENTACHLOROPHENOL AND TETRACHLOROHYDROQUINONE: 
INTERACTION WITH THYROXINE BINDING SITES OF RAT THYROID 
HORMONE CARRIERS EX VIVO AND IN VITRO 
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ABSTRACT 
Previous results have indicated that hexachlorobenzene (HCB)-induced 
hypothyroidism may be caused by its main metabol~e pentachlorophenol (PCP), and 
by tetrachlorohydroquinone (TCHQ), rather than by the parent compound. In the 
present experiments it was investigated whether hormone displacement from serum 
carriers could be a factor in the development of this hypothyroidism. 
In an in vitro competition assay PCP was an effective competitor for the thyroxine 
(T4)-binding sites of serum carriers, whereas HCB was ineffective. Ex viVo experimental 
results demonstrated occupation ofT4-binding s~es in sera from PCP-exposed animals 
but not in sera from HCB- or TCHQ-treated animals. Competing ability for T4-binding 
s~es was still present in sera of PCP-exposed animals but was absent in HCB or 
TCHQ-exposed animals. The results suggest that thyroid hormone displacement by the 
major metabolITe PCP may playa role in HCB-induced hypothyroidism. 
INTRODUCTION 
It is well known that exposure to a number of halogenated aromatic 
compounds such as polychlorinated biphenyls (PCBs), polybrominated 
biphenyls (PBBs), and hexachlorobenzene (HCB) may induce alterations of 
the thyroid function in several species. Hyperplasia and hypertrophy, as well 
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as decreases in thyroxine levels in the circulation, have been reported [1-8]. 
Evidence is accumulating that interaction of hydroxylated metabolites of 
these compounds with thyroid hormone transport carriers may play an 
important role in the reduction of thyroxine levels. It was found in vivo that 
the hydroxylated metabolite of3,4,3',4'-tetrachlorobiphenyl specifically binds 
to transthyretin (TTR), a transport carrier of thyroid hormones and vitamin A 
[9]. Furthermore, in vitro, various hydroxylated PCBs have been shown to 
compete with the thyroxine (T4)-binding site of TTR [10,11]. Hydroxylated 
PCBs with a linear, and symmetrical molecular shape (i.e. a rigid planar 
structure), and a lateral halogenation of the molecule appear to have a 
favourable configuration for high-affinity interaction with the T 4-binding site 
of TTR [10]. 
Several derivatives of tetrachloro-dibenzo-p-dioxins, tetrachloro-dibenzo-
furans also strongly interact in a competitive manner with the T 4-binding site 
[10,12,13J. In addition, a number of other halogenated aromatic industrial 
chemicals, i.e. chlorophenols, chlorinated phenoxy acids, brominated and 
iodinated benzonitrils, have been found to compete with the T 4-binding site 
of TTR and were able to reduce serum T41evels in vivo [8,14,15]. Recently, 
it was demonstrated that pentachlorophenol (PCP), the major metabolite of 
HCB, as well as tetrachlorohydroquinone (TCHO), the minor metabolite, were 
much more efficient in the reduction of serum T 4 levels than the parent 
compound, HCB [8], an effect that may be similar to that of 3,4,3',4'-
tetrachlorobiphenyl and its metabolites [11]. 
In the present study experiments were carried out to determine the extent 
of thyroid hormone displacement from its carriers by HCB or its metabolites. 
Firstly, the interaction of HCB, PCP and TCHO with the T4-binding sites of 
serum carriers was studied in vitro. Secondly, the occupation of carrier-sites 
and T 4-displacement ability in serum extracts from animals dosed with HCB, 
PCP or TCHO was investigated in ex vivo experiments. 
MATERIALS AND METHODS 
Materials 
HCB was obtained from Serva (Heidelberg, F.R.G.), PCP from Aldrich 
Chemical Company (Brussels, Belgium), TCHO and L-thyroxine from Sigma 
(St Louis, MO, U.S.A.) and L-[3',5'-12'I]thyroxine (spec act 1500 I'Ci/l'g, 55 
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MBq/,ug) from Amersham (Buckinghamshire, U.K). 
Methods 
To examine the ability of HCB, PCP and TCHO to displace T4 from the 
T4-binding sites of thyroid hormone serum carriers, sera of WAG/-MBL rats 
(250-300 g) were taken for in vitro competitive binding studies, as described 
earlier [8]. Different concentrations of HCB, PCP or TCHO (range 1 nM - 0.1 
mM), all dissolved in ethanol 100%, were incubated with 12'1-labelled 
thyroxine, in phosphate buffered saline (PBS:O.Ol M phosphate, pH 7.3, 
0.154 M NaCO, and diluted serum (1/50 in PBS) for 50 minutes at room 
temperature to obtain maximum T 4-binding. As a reference, different 
concentrations of unlabelled thyroxine were incubated instead of the 
chemicals. After incubation, bound T 4 was determined with gamma counting 
after separation the free T 4 from bound T 4, using G-25 Sephadex column 
chromatography [16]. In every competition assay an excess of T4 (i.e 10 
I'M) or ethanol 100% was added instead of the chemicals to determine the 
non-specific bound T4, or the maximum T4-binding to serum respectively. 
Non-specific binding was always lower than 6%. 
To study the competitive effects ex vivo, groups of 3-4 rats were 
intraperitoneally injected with 1 ml of an equimolar dose (0.052 mmol/kg) of 
HCB (16mg/kg), PCP (15 mg/kg) or TCHO (14 mg/kg), dissolved in corn oil. 
Control rats received 1 ml corn oil. Several times after injection blood 
samples were taken by tail bleeding where after the sera were stored at -
20·C. 
Occupation of binding sites was determined in separate serum samples, 
diluted 1/30 in PBS. To obtain evidence that compounds from sera of 
animals treated with aromatic compounds were capable of competing with 
T 4 for binding sites of carrier proteins, an organic acid extraction was 
performed from pooled sera from animals treated with corn oil, HCB or PCP 
(0.052 mmol/kg) as described by Van Raaij et al [8]. The extraction efficiency 
was 100 % for HCB and PCP. Concentration of the serum HCB extracts was 
done using propanediol/methanol 2:8 as described previously (extraction 
procedure A) [8]. To correct for a competitive effect of propanediol, the latter 
was also added to serum of corn oil-treated rats, whereafter the extraction 
procedure was performed (extraction procedure B). The specific competition 
caused by HCB was determined by subtraction of the competition 
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determined by extraction procedure B from that determined by extraction 
procedure A. Different dilutions of the extracted material were tested in the 
standard competition assay. To compare competing effects in propanediol 
containing extracts of sera of corn oil-treated animals with those in extracts 
of corn oil-treated-animals, the sera of corn oil-treated animals were extracted 
without propanediol. 
RESULTS AND DISCUSSION 
Results from the in vitro studies indicated that HCB was hardly able to 
compete with thyroxine for binding sites of serum carriers, i.e. less than 15% 
competition at 10.5 M (Fig. 1). PCP however, had a high potency to displace 
Fig.1. Competition of HCB. PCP, and T4 with T4-binding sites of serum 
carriers. 
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Different concentrations of HCB (0-0), PCP (0.0) or T4 (.I._A), as indicated on the x-axis, were 
incubated with [1251]T4 and diluted rat serum under standard conditions. Competition was 
determined as described in Materials and Methods. 
thyroxine from carriers (lCso about 10" M). T4 competed more efficiently (lC50 
about 10" M) than PCP. Competition experiments with TCHQ gave evidence 
of interterence as described previously [15J, but the results which were 
obtained did not allow the construction of a proper displacement curve. 
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While at concentrations of TCHO from 10.2 to 3.3.10'" M there was a dose 
dependent inhibition of T4-binding, at concentrations above 10'" M more 
radioactivity (up to 50 % more) was eluted in the void volume than in the 
control incubation without anything added. 
Due to the reactivity of hydroquinones, these compounds may have 
reacted with components of the assay system, TTR, T 4 or the column 
material. The strong competitive interaction of PCP with the pool of serum 
thyroxine carriers confirms previous work that showed strong separate 
interactions with 3 major human carriers, namely TTR, thyroxine binding 
globulin and albumin [17]. In this study little interaction of HCB with the pool 
of T4 carriers, in rats predominantly albumin and TTR [18]. could be 
detected, but some affinity of HCB for the T 4 site of human TTR has been 
reported by us in previous studies [15]. 
In the ex vivo experiments, where animals were treated with a single dose 
of HCB, little evidence of reduced thyroid hormone levels (Table 1) could be 
detected. However, an equimolar dose of PCP caused a drastic fali in total 
thyroxine (TT4) levels (Table 1). Previous studies indicated that an equimolar 
dose of TCHO did not have an early effect on TT 4 levels, but at later time 
Table 1. TT4 levels and relative availability of T4-binding sites in sera from 
rats treated with corn oil. HCB, PCP or TCHO. 
Treatment N [TT4] nmol/I % Binding 
Corn oil 5 32.0 :t 3.9 100.0 
HCB 4 29.9 :t 3.2 112.3 :t 6.4 
PCP 4 13.4 :t 1.2- 18.2 :t 2.4 -
TCHO 4 27.0 :t 3.6 115.7:t 9.3 
Rats were injected Lp with 2.5 ml of corn oil (control animals), HeB, PCP or TCHQ (0.052 
mmol/kg). Blood samples were taken by tail bleeding at 6 h after exposure. Occupation of T4 
sites in serum carriers was determined as described in Materials and Methods. Results are 
expressed as mean ± standard-deviation. Statistical analysis of effects was done with Student's 
t-tests. Significance:*, p<O.05, **, p<O.005. ***, p<O.OO1 
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points especially TT3 but also TT4 levels were lowered [8]. In the ex vivo 
experiments presented in Table 1, the occupancy ofT4 carrier sites in sera 
of these treatment groups was examined. Sera were taken at the time of the 
lowest observed levels of thyroid hormone. The results showed that 
occupation of T 4 carrier sites, as determined by the binding of radiolabelled 
T4 to sera of HCB- or TCHQ- treated animals, was similar to that of control 
sera (Table 1). In contrast, in sera of animals treated with an equimolar dose 
of PCP, significantly less radiolabelled thyroxine was able to bind to serum 
carriers (18.2 % of control values, p<O.001). These results suggest that in 
animals treated with PCP, circulating T4 sites on serum carriers may be 
available only in very limited numbers while at the same time serum TT 4 
levels are strongly decreased. An alternative explanation is a drastic 
reduction in the number of carrier protein molecules. Data from experiments 
with 3,4,3' ,4' -tetrachlorobiphenyl, which induces a similar hypothyroidism and 
interaction with T4 carriers, however, did not show alterations in serum TTR 
levels [19]. 
In a second series of ex vivo experiments it was studied whether sera of 
animals exposed to HCB, PCP or TCHQ contained compounds that were 
able to compete for T 4 carrier sites. Sera were extracted according to 
procedures that allowed maximal recovery of HCB and PCP as described 
previously [8]. Current procedures, however, have failed to recover TCHQ 
from sera of treated animals as well as from spiked control serum, possibly 
due to covalent protein binding of TCHQ [20]. 
Extracts were tested in the competition assay with the T4 site of serum 
carriers. The results presented in Figure 2 show that extracts from sera of 
HCB-treated animals had about the same low competing activity as extracts 
from control sera. No competitive ability of the serum extracts at 2, 6, or 
24 h after HCB administration, as compared with the control sera, was found. 
Extracts of sera early (2 and 6 h) after administration of PCP were highly 
efficient competitors while extracts obtained after 24 h were less competitive. 
These results indicate the presence of components able to occupy the T 4-
binding sites of serum carriers in animals dosed with PCP and which are 
present only in very low amounts or are absent in animals given an 
equimolar dose of HCB. Previously, HPLC analysis of sera from the HCB-
groups revealed low levels of HCB and PCP (0.63 ,umolll and <0.14,umol/l, 
respectively) while relatively high levels of PCP (190 ,umol/Q were present in 
animals treated with an equimolar dose of PCP. The 24 h serum levels of 
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PCP were also found to be much lower than the 2 and 6 h levels [8]. These 
results are indicative of a close relationship between competing ability in vivo 
and serum levels of PCP in animals treated with a single equimolar dose of 
PCP or HCB. 
In conclusion, the present results demonstrate that: (1) PCP is a much 
more potent competitor for the T4-binding sites of serum carriers than HCB; 
(2) T 4-binding sites of thyroid hormone carriers are occupied in sera of PCP-
dosed but not in HCB- or TCHQ-dosed animals; (3) serum levels of PCP in 
PCP- or HCB-dosed animals are correlated with competing ability of extracts 
Fig.2. Competing ability of extracts from serum of rats treated with HCB, PCP 
or corn oil. 
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Rats were given Lp a single equimo[ar dose of 0.052 mmol/kg of HeB, or PCP, or corn oil only 
(controls). Blood samples were taken after 2,6, and 24 h. Sera from animals were pooled and 
extracted as described in Methods and Materials. Competition was determined in different 
dilutions of extracts, which were incubated in the presence of [125[]T4 and diluted rat serum 
under standard conditions. Atdifferenttimes after exposure, blood was taken from animals, where 
after the sera were pooled, and extracted. +-+ = control extract, 6 h after exposure. GO = HCB 
extract 24 h after exposure. V-V, "'-.&. and t:.-t:., PCP extracts 2,6 and 24 h after exposure. 
from those sera; (4) at present, the effect of the minor HCB-metabolite TCHQ 
on serum TI 4 and TI3 levels cannot be explained on the basis of 
competition withthyroid-hormone-binding-sites. Taken together, these results 
suggest the displacement of thyroid hormone carriers by the major 
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metabolite PCP as a possible factor in hypothyroidism due to chronic HCB 
administration. Experiments are in progress specifically aimed at testing this 
hypothesis. 
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ABSTRACT 
Previous resutts in experimental systems have suggested that hydroxylated PCBs 
may decrease thyroid hormone levelS through associative interaction with transthyretin. 
In the present paper it was investigated whether this property was also shared by 
various industrial chemicals, mainly pesticides. In total, 65 compounds from 12 
chemical groups were analyzed for direct interference with the T4-binding site of 
transthyretin using a competitive binding assay. Sixty per cent of the compounds were 
competitive at a concentration level of 100 I'M. Relatively strong interactions were 
observed by several chlorophenols, chlorophenoxy acids and nitrophenols, as well as 
by individual compounds such as hexachlorobenzene, dicofol, bromoxynil and 
tetrachlorohydroquinone. Examples from these chemical groups, e.g. 
pentachlorophenol, 2,4-dichlorophenoxybutyric acid, dinoseb and bromoxynil, also 
reduced plasma TI4 levels in rats. In addition, bromoxynil decreased plasma TI3 
levels. 
The resutts suggest the existence of a number of halogenated industrial chemicals 
with a potential for lowering plasma thyroid hormone levels through interference with 
hormone transport carriers. 
INTRODUCTION 
Exposure of man and experiment animals to a number of xenobiotics, 
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including halogenated organic chemicals, may lead to changes in thyroid 
hormone homeostasis. This is generally characterised by reduced plasma 
hormone levels and increased levels of TSH through feedback regulating 
mechanisms of the pituitary-thyroid axis. The normal morphology of the 
thyroid is altered towards hyperplasia and hypertrophy. The toxicological 
consequences of an induced long term stimulatory pressure on the thyroid 
and the pituitary have been reviewed recently (Zbinden 1987; Hill et al. 
1989). 
Only a few cases of occupational exposure to halogenated chemicals 
concerning effects on the thyroid are known. Workers handling 
organochlorine insecticides had lower protein-bound iodine levels than non-
exposed workers (Wassermann et al. 1971). Among workers in a plant 
manufacturing polybrominated biphenyls (PBBs), a high prevalence of 
primary hypothyroidism was encountered (Bahn et al. 1980). Although non-
occupational treatment of patients with the organochlorine pesticide o,p'-DDD 
decreased serum protein-bound iodine (Danowski et al. 1964). Long term 
toxic effects of consumed grain treated with hexachlorobenzene included 
reduced plasma thyroid hormone levels accompanied bythyromegaly (Peters 
et al. 1982). 
In experimental animal systems, rodents as well as primates, interference 
in thyroid homeostasis by polychlorinated biphenyls (PCBs), polybrominated 
biphenylS (PBBs), 2,3,7,8-tetrachloro-p-dioxin (TCDD), HCB and DDT is well 
documented (Wassermann et al. 1973; Hurst et al. 1974; Bastomsky 1977; 
Gupta et al. 1983; Rozman et al. 1986; Van den Berg et al. 1988). 
The mechanism of decreased plasma thyroid hormone levels by these 
chemicals is not clear. Enhanced hepatic thyroxine metabolism may in part 
be responsible for reductions of T 4 levels by TCDD (Bastomsky 1977; Henry 
and Gasiewicz 1987). With respect to PCBs, we have recently obtained 
evidence that in vivo a metabolite was associated specifically with 
transthyretin (TTR), a carrier of both vitamin A and thyroid hormones 
(Brouwer and Van den Berg 1986). This has led to the suggestion that PCBs 
may cause a decrease in plasma vitamin A and thyrOid hormone levels 
through displacement of the physiological compounds from their binding 
sites by hydroxylated metabolites (Brouwer and Van den Berg 1986; Brouwer 
1989). Direct evidence for competition of hydroxylated PCBs for the T4-
binding site of TTR in vitro has recently been provided (Rickenbacher et al. 
1986). 
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In an attempt to determine whether this was a unique property of PCB 
metabolites or a more general phenomenon among industrial chemicals, a 
number of compounds from various chemical origins were investigated for 
the ability to occupy the T 4-binding site of TIR. In addition, the effect of a 
few of these industrial chemicals on plasma thyroid hormone levels in vivo 
was studied. 
MATERIALS AND METHODS 
Materials 
Chemicals were of the highest purity commercially available and were 
obtained from Aldrich, Brussels, Belgium; from Sigma, St. Louis, Mi USA and 
from Serva, Heidelberg, Germany. Stock solutions (0.023 M) of the 
compounds were made in ethanol, except for 3,4,3',4' -tetrachlorobiphenyl 
(ethanoI/DMSO,1:1). Human transthyretinwas obtained from Sigma, St Louis, 
Mi USA. L-[3"5,-'25Ijthyroxine (specific activity about 1500 ,uCi/,ug, 55 Mbq/,ug) 
was purchased from Amersham, England. All other chemicals used were of 
analytical grade. 
Methods 
Competition assay. The capacity of various compounds to compete with 
T 4-binding sites was studied essentially as described by Somack et al. 
(1982) with modifications as described in detail elsewhere (Van den Berg, 
1990). Briefly, an aliquot of the compound was added to a reaction mixture 
consisting of phosphate buffered saline (PBS, 0.01 M phosphate pH = 7.3 
+ 0.154 M NaCI), radiolabelled thyroxine (about 0.2 ,uCi/7,4 kBq) and 
transthyretin (TTR 1.1 ,ug/ml, final concn) in total volume of 460 ,ul. The 
reaction mixture was allowed to reach equilibrium for 30 min at room 
temperature. A 200,u1 aliquot of the reaction mixture was placed on a 1 ml 
Sephadex G-25 column kept at DoC. TIR-bound radioactivity was eluted with 
300,u1 ice-cold PBS using slight overpressure. The column was subsequently 
eluted with 1.0 ml PCS to assess the amount of free iodide (about 10%). 
Replicate 200,u1 samples were processed on separate columns. Radioactivity 
in eluate fractions was determined in a gamma counter. For determination 
of maximum binding ethanol was added instead of the test compound. 
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Protein-bound radioactivity amounted to 15% of the total amount of label in 
the reaction mixture. Non-specific binding was also determined in each series 
of experiments, by addition of cold T4 to 10,uM final concentration and was 
less than 10%. 
Animal studies. Chemicals were dissolved in corn oil and administered 
i.p. to WAG/MBL rats (male, 12 weeks old, 250-300 g, 4-6 animals/dose 
group) in a single dose. Control animals received 1 ml corn oil i.p. After 6 h 
blood was taken from the tail vein under ether anaesthesia. Plasma samples 
were prepared and stored at -20°C for analysis of thyroid hormones. 
Determination of plasma TT 4 and TT3 levels was done using commercial RIA 
kits (Amerlex-M, England). It was ascertained that the chemicals did not 
interfere in the thyroid hormone assays. 
Statistics. Statistical difference between the means of the groups dosed 
with chemicals and the control group was determined using Student's I-test. 
RESULTS AND DISCUSSION 
A total of 65 industrial compounds from 12 different chemical groups 
were analyzed with respect to a possible interference with the thyroxine 
binding site of TTR. The results, presented in Table 1, show that 39 
compounds (60%) were competitors for T4 binding at a concentration level 
of 100 ,uM. A global differentiation in potency of the compounds was made 
over three ranges of competition. It reveals that 21 compounds (32%) are 
moderate to potent competitors, 10 (15%) weak and 8 (12%) very weak 
competitors. 
The competition assay used is very sensitive owing to the high specific 
radioactivity of T4, since a 50% competition level (ICsol could be attained by 
4 X 10" M cold T4 under standard assay conditions. Additional studies with 
chlorophenols (Van den Berg 1990) indicate that relative affinities [defined 
as IC50(f4)/ICso(Chemical)] of 0.001-1 are in the highest (+++) group, while 
the middle (+ +) group harbours compounds with a relative affinity of about 
0.0001. In the scale of competition used in the table very weak interactions 
«0.0001 relative affinity) are apparent in the + group. The classification of 
competition levels in the table may therefore be somewhat over-representing 
low affinity interactions. 
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The compounds with the highest level of competition were found among 
the chlorophenols. This group of chemicals has recently been studied in 
more detail (Van den Berg 1990). The results indicate that 0 interaction with 
the T 4 site is dependent on the degree of chlorination, iO the combination of 
hydroxyl and chlorine groups is more competitive than either group 
separately, iiO displacement of T4 from the binding site is by a competitive 
type of interaction. In order to investigate in vivo effects with respect to 
thyroid hormone levels, rats were dosed with pentachlorophenol (PCP, 0.06 
mmol/kg i.p.). The results (Fig. 1) show a reduction of plasma TT4 level by 
PCP of 72% as compared with the control values. Plasma TT3 concentrations 
were not significantly changed by PCP (Fig. 2). 
Fig.1. Effect of industrial chemicals on plasma TT4 levels. 
50 
40 ~ 
3 
0 
E 30 
.s 
•• 
~ • 
~ 
>- ~ 
>-
••• • 20 E 
• 
• 
~ 
... 
a: 
~ 
10 
, 
.' 
..... 
'. 
-; 
0 
CON 2,4-0B DIN SAX PCP 
The chemicals were administered to rats and plasma samples were obtained for determination 
of TT4 levels as described in the Materials and Methods section. CON (controQ, 2,4-D8 (2,4-
dichlorophenoxybutyric acid, 0.06 mmol/kg), DIN (dinoseb, 0.03 mmol/kg), SAX (bromoxynil, 0.06 
mmol/kg). PCP (pentachlorophenol, 0.06 mmol/kg). Values are expressed as means ± SEM. 
Statistical significance: .p < 0.01, **p < 0.005, ...... p < 0.0001 
Additional industrial chemicals such as chlorophenoxy acids (Table 1, 
group 2) and nitrophenols (Table 1, group 3) were also effective competitors 
for the T 4-binding site. Theoretical modelling studies by Cody (1985) have 
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Table 1. Competition of industrial chemicals for the T4-binding site of 
transthyretin QTRl 
Number of 
Chemical group Compounds 
-" +aJ ++a) +++a) 
tested 
1. Chlorophenols 10 l' 2' -r 
2. Phenoxy acids 8 14 7' 
3. Nitrophenols 3 3' 
4. Chlorobenzenes 3 17 16 1" 
5. DDTs 4 1'0 2" 1'2 
6. Organophosphates 5 2 13 114 2 15 
7. Biphenyls 3 2" 117 
8. Chloroalkanes 9 7'6 1 '9 120 
9. Phenyldimethylurea 5 321 122 123 
10. Phenols 8 724 12' 
11. Organotin 2 2'6 
12. Others 5 2" 128 22fJ 
Totals 65 26 8 10 21 
a: Competition; - = <10 %, + = 11-40 %, ++ = 41-70 %, +++ = 71-100 %. 
All compounds were tested at 100.uM in the standard assay as described in Materials and 
Methods. Compounds are specified below by superscripts 1-29. 
1 4-chlorophenoJ 
2 2-chlorophenol, 3-chlorophenol 
3 Pentachlorophenol, hexachlorophene, 2,4,6-trichlorophenol, 2,4,S-trichlorophenol, 2,3 
dichlorophenol, 2,4-dichlorophenol, 2,6-dichlorophenol 
4 2,4,S-trichlorophenoxyacetic acid methyl ester 
5 2,4,5-trichlorophenoxyacetic acid (2,4,5-1), 2,4-dichlorophenoxyacetic acid (2,4-0). 2,4-
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dichlorophenoxybutyric acid (2,4-D8), 2-(2,4-dichlorophenoxy) propionic acid (Dichlorprop), 
4-(chloro-O-tolyoxy) acetic acid (MCPA), 4-(4-chloro-2-methylphenoxy) butyric acid (MCPB), 
2-(2,4,5-trichlorophenoxy) propionic acid (Fenoprop) 
6 2,4-dinitrophenol, 2,4-dinitro-6-methylphenol (ONOC) , 2,4-dinitr0-6-sec-butylphenol 
(Oinoseb) 
7 dichlorobenzene 
8 trichlorobenzene 
9 hexachlorobenzene 
10 methoxychlor 
p,p'-DDD, D,p'-DDD 11 
12 1,1, 1-trichloro-2,2-bis(chlorophenyQethano! (DicofoQ 
13 paraxon, ethyl-azinphos 
14 malathion 
15 ethyl-parathion, ethyl-bromophos 
16 3,4,3',4 '·tetrachlorobiphenyJ, 4-hydroxybiphenyl 
17 2-hydroxybiphenyl 
18 trichloroethylene, perchloroethylene, tetrachloroethane, chloroform, chloral hydrate, 
hexachloroethane, tetrachloromethane 
19 trichloroacetic acid 
20 hexachlorocyclohexane ( -lindane) 
21 monuron, diuron, neburon 
22 linuron 
23 chloroxuron 
24 phenol, catechol, resorcinol, o-cresol, 3-aminophenol, 4-tert-butylphenol, 2,6-di-tert-butyl-4-
methylphenDI (BHT) 
25 pyrogallol 
26 trimethyltin, triethyltin 
27 benzene, endosulfan 
28 dioctylphtalate 
29 3,5-bibromo-4-hydroxybenzonitril (Bromoxynil), tetrachlorohydroquinone 
suggested potential fItting of chlorophenoxy acids in the binding pocket of 
transthyretin. Little is known about in vivo effects of chlorophenoxy acids and 
nitrophenols with respect to thyroid hormone levels in man or experimental 
animals. Therefore, rats were dosed with 2,4-dichlorophenoxybutyric acid 
(2,4-DB, 0.06 mmol/kg) or 2,4-dinitro-6-sec-butylphenol (dinoseb, 0.03 
mmol/kg). The results show that plasma TT4 levels were significantly 
decreased by 2,4-DB (by 32%) or dinoseb (by 40 %, Fig. 1). No significant 
changes of plasma TT3 levels were obselVed by 2,4-DB or dinoseb (Fig. 2). 
With respect to the group of chlorobenzenes (Table 1, group 4) a clear 
increase in binding ability was obselVed from dichlorobenzene (compound 
7), via trichlorobenzene (compound 8) to hexachlorobenzene (compound 9). 
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Fig.2. Effect of industrial chemicals on plasma TT3 levels. 
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Plasma TT31eveis were determined as described in Materials and Methods. Other details are the 
same as in the legends of Fig.1 
Hexachlorobenzene (HCB) poisoning in man has led to a number of toxic 
symptoms including thyromegaly along with lowered thyroid hormone levels, 
especially in women (Peters et al. 1982). Furthermore, chronic HCB treatment 
of experimental animals has been shown to result in significant reductions 
in plasma thyroid hormone levels (Rozman et al. 1986). Experiments are 
currently in progress to determine the respective contributions of HCB and 
its metabolites pentachlorophenol and tetrachlorohydroquinone (Ahlborg et 
al. 1978; Van Ommen et al. 1986) in lowering thyroid hormone levels in vivo. 
A few DDT-like chemicals such as p,p'-DDD, o,p'-DDD and dicofol, in 
particular, were found to interact with thyroid hormone carrier (group 5, 
compounds 11/12). In man, o,p'-DDD has been found to lower serum protein 
bound iodine by intervening with thyroid hormone carrier (Marshall and 
Tompkins 1968). Modelling studies also indicate a frr of DDT in the T4-
binding pocket of transthyretin (Cody 1985). The thyroid hormone-lowering 
effect of DDT, the parent compound, in a few experimental animals systems 
is well known (Bastomsky 1974; Hurst et al. 1974). To date, very limited data 
is available on effects of dicofol with respect to plasma thyroid hormone 
levels. Bromoxynil, a brominated benzonitril herbicide, was found to be an 
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efficient competitor for the T4-binding site of TTR (Table 1, group 12, 
compound 29). In rats dosed with bromoxynil (0.06 mmol/kg) a significant 
56% reduction of plasma TT4 levels was found (Fig. 1). In addition, plasma 
TT3 levels (Fig. 2) were significantly decreased by bromoxynil (by 41 %). 
Recently, a related compound, ioxynil (an iodinated benzonitriQ, showed 
binding specifically to the T 4 site of transthyretin and may affect the thyroid 
of experimental animals (Ogilvie and Ramsden 1988). 
A number of compounds among organophosphates, (halogenated) 
biphenyls, chloroalkanes, and phenyldimethylurea showed definite ability for 
specific competition with thyroid hormone Carrier albeit with low affinity (Table 
1, groups 6-9). There are indications that malathion may decrease serum 
protein-bound iodine in experimental animals (Balasubramanian et al. 1986). 
The effect of halogenated biphenyls on the thyroid is supported by a vast 
amount of data mainly in experimental animal systems both in rodents and 
in primates (Wassermann et al. 1973; Hurst et al. 1974; COllins et al. 1977; 
Sleight et al. 1978; Gupta et al. 1983; Byrne et al. 1987; Van den Berg et al. 
1988). In man, occupational exposure to polybrominated biphenyls (PBBs) 
may result in reduced plasma thyroid hormone and increased thyrotropin 
levels (Bahn et al. 1980). Metabolites of PCBs have been found as a complex 
with transthyretin and are thought to be involved in reduced serum thyroid 
hormone and vitamin A levels in experimental animals (Brouwer and Van den 
Berg 1986; Brouwer 1989). Using similar in vitro binding assays as in the 
current work, Rickenbacher et al. (1986) demonstrated binding of 
hydroxylated PCBs to the thyroxine site of transthyretin as well as to the 
nuclear receptor. Besides the interaction of PCBs with thyroid hormone 
carriers, these compounds may induce hepatic thyroxine metabolism, e.g. 
glucuronidation. This may also contribute to decreased plasma hormone 
levels (Bastomsky 1977; Henry and Gasiewicz 1987). 
Most compounds tested in the group of chloroalkanes were not 
competitors at 100 I'M, except for trichloroacetic acid and T-
hexachlorocyclohexane (r-lindane) (Table 1, group 8, compounds 19/20) that 
exhibited a low to moderate level of interaction. In vivo data concerning 
thyroid effects of these compounds is not at hand. Of the phenyldimethylurea 
pesticides investigated, linuron and chloroxuron were weak to moderate 
competitors (Table 1, group 9, compounds 22/23). Effects of urea pesticides 
on the thyroid in experimental studies have been reported [cited in Bainova 
(1982)]. 
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The present results show that examples from a variety of halogenated 
pesticides with different chemical backbones are able to interact with the T 4-
binding site of transthyretin, one of the carriers of thyroid hormones in the 
circulation. It should be noted, however, that in man TBG is the major carrier 
of thyroid hormones but recent studies have also provided evidence for 
interaction of chlorophenols with the T 4-binding site of TBG and albumin in 
addition to transthyretin (Van den Berg 1990). 
The interaction of number of industrial chemicals with circulatory carriers 
may have several consequences. Firstly, total plasma thyroid hormone levels 
may be altered. A~hough it is too early to make final conclusions, there 
appears to be an indication of a relationship between interference of 
chemicals at the carrier level and a concomitant reduction of plasma 
thyroxine levels in vivo. More combined in vitro! in vivo studies are required 
to establish a firm relationship that may lead to a relatively simple in vitro tool 
to predict thyroid effects of industrial/occupational chemicals. In occupational 
settings with possible exposure to halogenated organic chemicals of various 
sorts it may be valuable to determine thyroid parameters. 
Secondly, interaction of chemicals with transthyretin may also have 
implications for neurobiological/toxicological processes in exposed 
individuals. Transthyretin is one of the few proteins identified in the 
cerebrospinal fluid (CSF), that is synthesized in the choroid plexus (Kato et 
al. 1986) and may have a function in the transport of thyroxine through the 
blood-CSF barrier (Dickson et al. 1987). It is possible that chemicals 
interacting with transthyretin may affect the transport function of the choroid 
plexus with possible consequences for brain functions. A large proportion of 
the chemicals with affinity for thyroid hormone carrier (Table 1) appear to 
have neurotoxic properties (Bainova 1982). In fact, recent evidence indicates 
that neurotoxic chemicals such as 2,4,5-T and 2,4-0 (Table 1, group 8, 
compound 5) affect choroid plexus transport (Pritchard 1980; Kim et al. 1983, 
1987). 
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CHAPTER VI 
INCREASED GLUCURONIDATION OF THYROID HORMONE IN 
HEXACHLOROBENZENE·TREATED RATS 
J.A.G.M van Raaij'·2, E.Kaptein3, T.J. Visser and KJ van den Berg2 
ABSTRACT 
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Metabolism of thyroid hormones was investigated in WAG/MBl rats that had been 
exposed to hexachlorobenzene (HCB). Serum thyroxine (T4) levels were lowered by 
35.5 %, whereas triiodothyronine (T3) levels were not changed. Bile flow, as well as T4 
excretion in bile were increased by HCB·treatment. Analysis of bile by HPlC revealed 
a more than 3·fold increase of T4-glucuronide (T4G) and a concomitant reduction of 
non-conjugated T4. T4·UDP·glucuronyttransferase activity (T4 UDPGT) activity in 
hepatic microsomes was increased more than 4.5·fold in animals exposed to HCB. p-
nitrophenol (PNP) UDPGT showed a comparable increase by HCB. Both T3 and 
androsterone UDPGT activities were low in WAG/MBl rats compared with normal 
Wistar rats. T3 UDPGT activity was increased 2.5·fold by HCB, but androsterone 
UDPGT activity was unchanged. These resutts suggest that T4 is a substrate for HCB· 
inducible PNP UDPGT and T3 for androsterone UDPGT. In the absence of the latter, 
T3 is also glucuronidated to some extent by PNP UDPGT. Type 1 iodothyronine 
deiodinase activity was decreased by HCB treatment. 
It is concluded that decreased T4 levels in serum of animals after exposure to 
HCB may be due to a combined effect of displacement of T4 from carriers, an 
increased glucuronidation of T4 and enhanced bile flow. 
INTRODUCTION 
It is well known that the fungicide hexachlorobenzene (HCB) affects the 
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thyroid system. Chronic exposure of different species of animals but also of 
humans leads to a decrease of thyroid hormone levels in the circulation (1-7). 
Several chlorinated aromatic compounds, such as polychlorinated biphenyls 
(PCBs) and dioxins have also been found to cause hypothyroidism (8-11). 
The mechanisms responsible for reduced thyroid hormone levels after 
chronic exposure of rats to HCB are not completely understood. There are 
indications that the major metabolite of HCB, i.e. pentachlorophenol (PCP), 
may playa role because PCP is more potent in decreasing serum thyroid 
hormone levels in rats than an equimolar dose of HCB (3). In addition, in vitro 
and ex vivo observations suggest that PCP interacts strongly with serum 
thyroxine (T4) carrier proteins as compared to HCB (4,12,13). PCP was found 
to interact competitively with the T 4-binding site of transthyretin, while the 
affinity of PCP is about 2-fold higher than that of T4 (12). This competition 
with thyroid hormone carriers may contribute to the lowered blood T 4 levels 
(4,12,13). 
Enhanced hepatic metabolism of T4 in HCB-treated rats might be an 
additional mechanism for reducing serum T4 levels (5,6,14,15). The most 
prominent metabolic routes for T4 are the deiodination pathways and hepatic 
conjugation of the phenolic hydroxyl group with glucuronic acid or sulfate. 
Recent studies reported that multiple UDP-glucuronyltransferase (UDPG1) 
isozymes are involved in the glucuronidation of thyroid hormones, and 
suggested that T4 is glucuronidated by p-nitrophenol (PNP) and bilirubin 
UDPGTs, and triiodothyronine (T3) specifically by androsterone UDPGT 
(16,17). 
In the present study, the role and identity of enzymes involved in the 
metabolic clearance of thyroid hormones in HCB- or vehicle exposed rats 
were investigated by determining (1) bile flow and biliary excretion of thyroid 
hormone glucuronides (2) T4 and T3 UDPGT and type 1 deiodinase activities 
in liver microsomes in parallel with PNP and androsterone UDPGT activities. 
MATERIALS AND METHODS 
Chemicals 
HCB was obtained from Aldrich (Brussels, Belgium); ['25I]T 4 (SA> 1200 
ftCi/ftg), [, 251]T3 (SA 2800 ftCi/ftg), ['251]rT3 (SA> 1200 ftCi/ftg), T4 and T3 
radioimmunoassay (RIA) kits (Amerlex-M) from Amersham (Amersham, U.K); 
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androsterone from Steraloids (Wilton, NH, U.S.A); [3H] androsterone (SA 116 
pCi/pg) from New England Nuclear (Boston, MA, U.S.A); UOP glucuronic acid 
(UOPGA) from Boehringer (Mannheim, F.R.G.); bovine serum albumin (BSA), 
3,3-cholamidopropyl-dimethylammonio-1-propanesulfonate (CHAPS), di-
thiothreitol (011), PNP, T4, and T3 from Sigma Chemical Co. (St louis, MO, 
U.S.A); 3,3',5'-triiodothyronine (rT3) from Henning (Berlin, F.R.G.); Sephadex 
lH-20 from Pharmacia (Uppsala, Sweden). Radiolabelled T4 and T3 were 
purified on Sephadex LH-20 before incubation. 
Animals and Treatments 
Male WAG/MBl (WAG) rats, weighing 200-300 g were maintained on 
regular diet and tap water ad libitum. They were housed in a constant 
environment with a 12 h light: 12 h dark cycle, a temperature of 24°C and 
a humidity of 50-70 %. Animals were treated orally three times a week for 4 
weeks with 3 ml of either 1 g HCB/kg (40 mg/ml, 0.5 % Tween-20 in water) 
or water plus 0.5% Tween-20 only. After the last dose, liver and sera were 
collected from animals after killing by decapitation. Livers were frozen at -
70°C until preparation of microsomes. Sera were also stored at -70°C until 
analysis of T 4 and T3 by commercial radioimmunoassay (RIA) kits. 
Bile flow and biliary clearance 
Animals were injected Lp with 25 pCi [,251]T4 in 1 ml saline. After about 
5 h, bile ducts were cannulated under halothane anaesthesia. Bile was 
collected in fractions of 10 min for a 1 h period. After termination of the 
experiment, serum samples were collected. Radioactivity in serum and bile 
samples was determined in a gamma counter. 
HPLC analysis of bile samples 
Representative chromatograms of T 4 glucuronide (T 4G) excretion were 
obtained by injecting 20 pi of pooled bile from HCB- or vehicle-treated rats 
into a reverse phase HPLC C18 system, eluting with linear gradients of 
acetonitrile in ammonium acetate (pH 4), as described earlier (18). This 
procedure results in the separation of iodide, sulfated, glucuronidated and 
non-conjugated iodothyronines (18). Fractions were collected and counted 
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for radioactivity. Recovery of applied radioactivity amounted to SO and 100 
%. 
Microsomal preparations 
Livers from WAG rats were homogenised in 5 volumes of 0.25 M sucrose, 
10 mM Hepes, 1 mM DTT (pH 7.0) at 4°C. Microsomes were obtained by 
centrifugation for 10 min at 25000 x g and subsequent centrifugation of 
supernatants for 60 min at 100000 x g. The microsomal pellets were 
suspended at a protein concentration of 10-20 mg/ml in 0.1 M phosphate 
(pH 7.2), 2 mM EDTA and 1 mM DTT, and frozen in 0.5 ml aliquots at -SO°C. 
Protein contents in microsomes were measured with the bicinchoninic acid 
procedure (is), or with the Bio-Rad assay (Richmond, CA, U.S.A), using BSA 
as the standard. 
Assays 
T 4 and T3 UDPGT activities were assayed essentially as previously 
described (16) in incubations of 1 ,uM labelled T4 or T3 with 1 mg/ml protein 
and 5 mM UDPGA in 75 mM Tris (pH 7.S), 3.75 mM MgCI2 , containing 0.125 
% BSA and 0.025 % CHAPS. PNP UDPGT (20), androsterone UDPGT (21) 
and type I deiodinase activity (22) were also measured according to 
published methods. 
Statistics 
Bile flow and biliary T 4 clearance in control and HCB-treated rats were 
statistically evaluated by analysis of variance and covariance with repeated 
measures. Student's t-tests were used for comparing other effects in control 
and HCB-treated animals. 
RESULTS AND DISCUSSION 
When animals had been exposed to HCB for 4 weeks, serum T4 levels 
were decreased by 35 % compared with control animals (Table 1). Serum 
levels of T3 were not different between both groups (Table 1). In earlier 
studies (5), a transient decrease in serum levels ofT3 during the second and 
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third week of dosing was observed. 
To investigate whether lowered T41evels after dosing with HCB were the 
result of an increased metabolism, biliary T 4 clearance was analysed. It 
appeared that bile flow was significantly increased (p<0.05) by more than 
100 % after HCB treatment compared with control values (Fig. 1). This may 
Table 1. Serum T4 and T3 levels of rats treated with HCB 
Hormone HCB N Control N 
T 4 (nmol/L) 12.9 :!: 0.58' 5 20.0 :!: 2.00 5 
T3 (nmol/L) 0.63 :!: 0.16 5 0.65 :!: 0.15 5 
Rats were exposed to HCB for 4 weeks. After the last dose, serum levels of T4 and T3 were 
determined by radioimmunoassay. Results are given as mean ± SEM. *, p<O.001. 
be explained by enlargement of the liver, which was significantly increased 
in weight by HCB: livers of rats exposed to HCB or vehicle weighed 16.7 :!: 
0.5 g and 10.0 :!: 0.4 g respectively (p< 0.001). Recently, Cuomo et al.(23) 
reported an increased bile acid independent flow (BAIF) by HCB. 
In order to examine excretion of T4 in bile, animals received [' 25I]T4. 
Radioactivity excreted into bile fluid was also significantly increased (more 
than 100%, p<0.01) by HCB (Fig. 2, Table 2). Therefore, it may be 
concluded that HCB increases the elimination of T 4 by an increased bile 
flow. 
The composition of biliary radioactivity was analysed by HPLC. A 
chromatogram of bile from control animals showed the label predominantly 
in association with T 4G and to a minor extent with non-conjugated T 4 
(Fig.3A). Some iodide was present in the void volume fractions. A similar 
chromatogram of bile from animals exposed to HCB revealed a greater 
extent ofT4 glucuronidation (Fig.3B). Excretion ofT 4G was increased 3.7 -fold 
by HCB exposure, whereas non-conjugated T4 was decreased 2.6 fold 
(Table 2). 
HCB stimulation of biliary T4G excretion may be due to an enhanced T4 
UDPGT activity. Indeed, a 4.7-fold increase of T4 UDPGT activity was 
observed (Table 3), which appeared somewhat more substantial than the 
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Fig 1. Bile flow in control and 
HCB-treated rats. 
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Bile ducts were cannulated from rats 
exposed to HCB (N=4) orto vehicle (N=3). 
Bile was collected in 10 min fractions and 
weighed. Results are expressed as the 
cumulative weight of bile collected. 
Fig 2. Cumulative biliart T4 
clearance in control and HCB-
treated rats. 
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Rats exposed to HCB (N=4) or to vehicle 
(N=3) received C250T4 i.p. About 5 h later 
bile collection was started. Bile samples 
were weighed and counted. 
Table 2. Biliart T4 clearance in control and HCB- treated rats 
Parameter HCB N Control N 
(% of dose) (% of dose) 
Bile radioactivity 2.9 ± 0.12' 4 1.3 ± 0.22 3 
T4G 1.5 ± 0.06- 4 0.4 ± 0.08 3 
T4 0.07 ± 0.01 4 0.18 ± 0.05 3 
Rats were exposed for 4 weeks to HCB or vehicle. At the end of the experiment, the animals were 
injected i.p with 25,uCi C2511T4. About 5 h later, bile ducts were cannulated for collection of bile. 
Total bile was analyzed by HPLC as described in Materials and Methods. Results are given as 
means ± SEM. '*, p < 0.01. '*'*, P < 0.001 
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excretion of T4G into bile (Table 2). Increased levels ofT4G in bile were also 
demonstrated after exposure of rats to PCBs, associated with a strong 
induction of T4 UDPGT (16). Thus, HCB induces processes involved in the 
metabolism of T4. 
There are indications that in rats T4 and PNP are substrates for a 
common UDPGT isozyme and that xenobiotics, such as PCBs, 
methylcholantrene, dioxines, and other various hepatic microsomal enzyme 
inducers, are potent inducers of T 4 and PNP glucuronidation (14-16, 24-26). 
PNP UDPGT activity in the WAG rats used in the present study was 
increased 4.5-fold by HCB (Table 3). In view of the broad substrate 
specificity, this enzyme could also be involved in glucuronidation of PCP, the 
major metabolite of HCB. Our findings suggest that also in the WAG rat the 
enzyme responsible for enhanced T 4 glucuronidation by HCB may be 
identical to the HCB-induced PNP UDPGT. 
Table 3. Effects of HCB on UDPGT and type I deiodinase activities 
Enzyme activity HCB N Control N 
T4 UDPGT 1.26 :!: 0.07- 5 0.27 :!: 0.02 5 
(pmol/min/mg) 
PNP UDPGT 278 :!: 8.94" 5 62 :!: 2.68 5 
(nmol/min/mg) 
T3 UDPGT 0.88 :!: 0.04- 5 0.35 :!: 0.01 5 
(pmol/min/mg) 
Androsterone UDPGT 0.52 :!: 0.01' 5 0.47 :!: 0.02 5 
(nmol/min/mg) 
Deiodinase 442 :!: 90' 5 641 :!: 131 5 
(pmol/min/mg) 
Dosing of animals, isolation of livers, preparation of hepatic mlcrosomes and enzyme assays were 
carried out as described in Materials and Methods. *, p < 0.05. *", p < 0.001 
Androsterone UDPGT activity in untreated WAG rats was =10% of that 
measured in livers of normal Wistar (HA) rats and similar to the androsterone 
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UDPGT activity in Wistar LA and Fisher rats, which have a genetic defect in 
the gene coding for this isoenzyme (16,17). Like Wistar LA and Fisher rats, 
T3 UDPGT activity in WAG rats is only about one-third of that in Wistar HA 
rats, suggesting that T3 is a substrate for androsterone UDPGT.while HCB 
has little influence on the (low) androsterone UDPGT activity in WAG rats, it 
increases liver microsomal T3 glucuronidation 2.5-fold (Table 3). This 
suggests that in the absence of androsterone UDPGT, T3 is glucuronidated 
to some extent by the HCB-inducible PNP UDPGT. 
In conclusion, decreased serum T4 levels in animals exposed to HCB 
may be explained by a combination of factors: displacement of T 4 from 
serum proteins and induction of T4 UDPGT activity. The resultant increase 
in thyroid activity apparently does not fully compensate for the increased T 4 
clearance. 
Fig 3. HPLC analysis of bile from control (A) and HCB-treated (B) rats. 
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CHAPTER VII 
HEXACHLOROBENZENE-INDUCED HYPOTHYROIDISM: 
INVOLVEMENT OF DIFFERENT MECHANISMS BY PARENT 
COMPOUND AND METABOLITE 
J.A.G.M. van Raaij'·2, C.M.G. Frijters2, and KJ. van den Berg2 
ABSTRACT 
1) Institute of Public Health and Social Medicine, 
Erasmus University Rotterdam, The Netherlands 
2) TNO Medical Biological Laboratory. Rijswijk, The Netherlands 
Rats received repeated oral treatment with different doses of hexachlorobenzene 
(HCB) (0 - 3.5 mmol/kg) for 2 or 4 weeks. Measurements of thyroid hormone status 
after 2 weeks showed a dose-dependent decrease of total thyroxine (TT4) levels, 
decreased free thyroxine (FT4) levels and little change of total triiodothyronine (T3) 
levels. The effects on thyroid hormone status were more pronounced after 4 weeks and 
also included increased thyroid stimulating hormone (TSH) levels. These conditions 
suggest that HCB had induced hypothyroidism in these animals. Indications for 
occupation of thyroid hormone binding proteins were found in serum of exposed 
animals. The major metabolite pentachlorophenol (PCP) also caused, by competnive 
interactions with thyroid hormone binding proteins in serum, a rapid and dose-
dependent decrease of TT4 and FT4 levels, but not of TT3 levels in serum. The 
decrease of serum TT4 levels by repeated dosing with 3.5 mmol HCB/kg for 4 weeks 
could be attributed to competitive interactions of PCP with hormone serum binding 
protein and to increased metabolism induced by HCB to an equal degree. At lower 
dose levels or with shorter dosing periods, increased metabolism of T4 is the main 
cause of decreased TT4 serum levels. 
This is the first indication that a similar effect is caused at the same time by parent 
compound and metabolite through different and independent mechanisms. 
INTRODUCTION 
Hexachlorobenzene (HCBl, a polyhalogenated aromatic compound, has 
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been used in industry mainly as a fungicide and occurs as a by-product of 
industrial aromatic chlorination processes (1). Accidental poisoning of 
humans to HCB by consumption of HCB-treated grain has been reported 
and toxic effects observed included enlargement of the thyroid gland and 
decreased blood thyroxine (T4) levels (2). 
In experimental animal systems a number of biological and biochemical 
effects of HCB on thyroid homeostasis have been described. Chronic feeding 
of laboratory animals with HCB was found to induce thyroid adenomas (3), 
thyromegaly, and hypothyroidism (4-6). Similar effects concerning the thyroid 
have been observed in rodents and primates chronically exposed to other 
halogenated aromatics such as polychlorinated biphenyls (PCBs) or 
polybrominated biphenyls (PBBs), (7-10). 
The mechanism{s) involved in HCB-induced hypothyroidism is not clear. 
Microsomal enzymes are strongly induced by HCB (4,6,11) and this could 
lead to an increased T4 catabolism. Recently, it was shown that HCB 
strongly enhanced glucuronidation of T 4 through induction of several UDP-
glucuronyltransferases (UDPGTs) (12), resulting in an augmented 
disappearance of T4 from the body (12). In animals exposed to PCBs and 
dioxins, such a mechanism has also been advanced (13-16). 
An additional factor that might contribute to depressed thyroid hormone 
levels in HCB-induced thyroid changes is pentachlorophenol (PCP), the 
major oxidative metabolite of HCB (17-19). PCP has been found more 
effective in reducing thyroid hormone levels than HCB itself in acute in vivo 
experiments (20). Furthermore, in vitro studies have demonstrated 
competitive interactions of PCP and T 4 for binding sites on T4-binding serum 
proteins with a greater specificity for binding to transthyretin (TTR) than 
either thyroid binding globulin (TBG) or albumin (21,22). Comparable results 
have been found in animals exposed to chlorinated benzenes or 3,4,3',4'-
tetrachlorobiphenyl (TCB), suggesting that not only the hydroxylated form of 
chlorinated aromatic compounds might be responsible for lowered T 4 levels 
in serum through competitive interactions with T 4-binding serum proteins (23-
26). 
Other studies showed that hydroxylated PCBs, but also the hydrophylic 
derivates of dioxins and dibenzofurans are capable to interact with the T 4-
binding sites of TTR and nuclear thyroid hormone receptors (27-30). In 
addition, it was demonstrated by molecular modelling that DDT 
(dichlorodiphenyltrichloroethane), an insecticide that also lowers thyroid 
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hormone levels, fitted into the T4-binding sites of TTR (S1). 
The aim of the present study was to determine the relative contributions 
of 1) increased microsomal catabolism of T4 by HCB and 2) interference of 
PCP at the thyroid hormone binding protein level in hypothyroidism induced 
by HCB. For this purpose, animals were repeatedly dosed with HCB to 
induce hypothyroidism as determined from measurements of thyroid 
hormone status. In addition, serum concentrations of HCB and PCP in these 
animals were analyzed. In separate experiments the capacity of PCP to 
decrease thyroid hormone levels by competitive interactions was determined. 
The combined results were used to estimate the relative role of both types 
of mechanisms in hypothyroidism induced by HCB. 
METHODS 
Chemicals 
HCB and PCP were purchased from Aldrich (Brussels, Belgium). 
Commercial TT4 (Amerlex-M), TTS (Amerlex-M) and TSH RIA kits (Amerlex-M, 
code RPA 554) were purchased from Amersham (Amersham, U.K). The FT4 
and FT3 assays (Amerlex-MAB) were obtained from Kodak Clinical 
Diagnostics Ltd, (Cardiff, U.K). Tween-20 was obtained from Bio Rad 
Laboratories, Richmond, California. 
Animals and Treatments 
Male rats of the inbred Wistar strain (WAG-RIJ), weighing 200-300 g and 
approximately 12 weeks of age, were used. They were housed in animal 
quarters with a 12-h light/dark cycle and an ambient-temperature of 24°C and 
a humidity of 50-70%. Water and food were freely accessible. Animals were 
treated with oral doses of either vehicle (control animals) or different doses 
of HCB (3.5, 2.6, 1.7 and 0.9 mmol/kg, 5 animals per dose group), 3 days 
per week over a period of 2 weeks and with a dose of 3.5 mmol/kg for 4 
weeks. These experiments (2 or 4 weeks dosing) were conducted at a 
different time point. HCB was administered as an emulsion of 0.14 mmol/ml 
in water containing 0.5% Tween-20. Approximately 2 days after cessation of 
dosing, blood was collected from the tail vessel, and the prepared serum 
stored at -20°C for further analysis. During the period of HCB dosing, the 
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general health of the animals was monitored three times a week by 
measuring rectal body temperature and body weight. 
In experiments with PCP, the compound was dissolved in corn oil and 
administered Lp on an acute basis at doses between 0 and 100 ,umol/kg. 
Each dose of PCP was tested in groups consisting of four animals. Serum 
was collected 6 h after exposure, when effects on thyroxine levels are at a 
maximum (20). 
Biochemical analysis 
TT4, TT3, free T4 (FT4) , free T3 (FT3) and TSH levels were determined 
in sera of control and experimental rats using appropriate RIAs (Amersham). 
HCB and PCP concentrations in sera were analyzed using HPLC as 
described earlier (20). The detection limit for PCP in serum was 0.075,umol/l 
and for HCB 0.351,umol/l. The extraction efficiencies for both PCP and HCB 
were more than 95%. 
Competitive interactions with T 4-binding proteins 
Occupation of thyroid hormone binding sites by HCB and/or PCP was 
studied by a competitive binding assay as described previously (21,32). Sera 
were obtained from control and experimental animals (day 39) and diluted 
with phosphate-buffered saline (PBS) (1 :30, v/v) before competitive binding 
of radiolabelled T 4 was determined USing mini-Sephadex G-25 columns. 
Radioactivity of eluate fractions was determined in a gamma counter. 
Statistics 
Student's t-test was used for statistical evaluation of mean values of 
various parameters between experimental and control animals. Results are 
presented as means ± SD. 
RESULTS 
Effects of sub-chronic dosing with HCB on general health parameters 
Rectal body temperature of rats treated with repeated doses of HCB (3.5 
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mmol/kg) for a period of 4 weeks was not altered on the last day of the 
dosing period (38.0°C :t 0.41 vs 37.7°C :t 0.49 in control- and experimental 
animals respectively). Body weights of the experimental and control animals 
were not different (285 g :t 11.7 vs 285 g:t 14.7 in control- and experimental 
animals, respectively), and also followed a normal growth curve (results not 
shown). 
Effect of HCB on thyroid hormone status 
Treatment of rats for 2 weeks with 3.5 or 2.6 mmol/kg HCB produced a 
significant reduction (p<O.05) of serum TT4 levels (36.9 % and 24.8 % 
respectively, Table 1). Levels of FT4 in serum were also significantly reduced 
(p<0.05) at a dose of 2.6 mmol/kg HCB (19.3 % decrease, Table 1). After 4 
Table 1. Effect of HCB on thyroid hormone status 
HCB N Expt TT41) FT42) TI3') TSH') 
(mmol/kg) (wks) 
0.0 4-5 2 21.4 ± 2.1 14.7 ± 2.2 0.44 ± 0.06 3.5 ± 0.5 
0.9 3-5 2 23.7 ± 2.6 17.2 ± 2.2 0.44 ± 0.08 4.9 ± 1.1 
1.7 3-5 2 19.2 ± 2.7 13.3 ± 1.9 0.42 ± 0.08 5.1 ± 1.6 
. . 
2.6 5 2 16.1 ± 3.7 11.8±O.7 0.33 ± 0.13 4.6 ± 1.6 
3.5 4-5 2 13.5±1.2* 12.1 ± 1.2 0.38 ± 0.07 4.8 ± 1.8 
0.0 3-5 4 35.3 ± 3.8 9.2 ± 1.3 0.48 ± 0.06 7.6 ± 0.4 
3.5 4-5 4 20.9 ± 3.4* 2.7 ± 0.6 
. 
0.50 ± 0.17 11.6±2.9 
. 
Groups of rats (N=3-5) were orally dosed three times a week with different doses of HCB for a 
period of 2 or 4 weeks. Within 24 h after the last dose, blood was collected from the tail, and 
thyroid hormone parameters were determined. #: The doses of HCB expressed in mgJkg are O. 
250, 500, 750 and 1000, respectively. Statistical significance: ." p<O.05. 1), 2) and 3): 
concentrations in nmol/L, pmol/L and ng/mL respectively. 
weeks of dosing, TT4 and FT4 levels in animals exposed to HCB were even 
more depressed (41 % for TT4, and 70.7 % for FT4). In contrast, no 
significant decrease of TT3 levels in serum were found (Table 1) after a 2 or 
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4 week dosing period with a dose of up to 3.5 mmol HCB/kg. A trend of 
increased TSH levels in serum by HCB was noted after 2 weeks. TSH levels 
were significantly increased by 56.6 % after a dosing period of 4 weeks with 
3.5 mmol HCB/kg. An increasing effect of at least 31 % was found comparing 
control values of TSH (Table 1). 
Effects of administered PCP on serum (free) thyroxine levels 
In separate dosing experiments investigating the competitive interactions 
of PCP with thyroid hormone serum binding proteins, results indicated that 
PCP caused a rapid and substantial reduction in TT 4 concentration in serum 
that was highly dose dependent (Fig.1). When rats were exposed to the 
Fig.1. Effect of the dose of PCP on serum TT 4 levels. 
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Groups of rats (N=4) received a single Lp injection of different doses of PCP (0-0.105 mmol/kg 
in corn oil). Control rats received corn oil only. Blood samples were taken at 6 h after exposure. 
TT4 levels in serum were determined with a RIA. The results represent combined data from 'toNe 
independent animal experiments. 
highest dose of PCP (0.10 mmol/kg), TT4 concentrations in serum were 
reduced by more than 65 % (Fig.1). FT41eveis in serum were also strongly 
reduced (by 60 %) after dosing with PCP compared with control values 
(Fig.2). PCP had neither clear effects on serum levels of (F) T3 nor on TSH 
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levels (data not shown). 
HCB and PCP levels in serum during HCB treatment 
Accumulation of HCB and its major metabolite PCP in serum after 
repeated exposure of animals to different doses of HCB was determined by 
HPLC methods. A clear dose-response relationship was found between the 
serum concentrations of HCB or PCP reached and the administered dose of 
HCB after 2 weeks (Table 2). At a given dose of HCB (3.5 mmol/kg) doubling 
of the exposure period from 2 to 4 weeks generally resulted in higher serum 
concentrations of both HCB and PCP, as also appeared from a separate 
time-course study (results not shown). Control animals had no detectable 
levels of HCB or PCP at any time point. 
Fig. 2. Effect of the dose of PCP on serum FT4 levels . 
• 
0.001 0.01 0.1 
dose of PCP [mmot/kg] 
Single Lp injections of different doses of PCP were given to groups of rats (N=4). Blood was 
collected 6 h after administration of PCP. FT4 levels in serum were determined with a RIA. 
Occupancy of serum binding proteins. 
Sera of animals exposed to 3.5 mmol HCB/kg for 4 weeks did bind 
significantly less T4 (20 % less) than sera of control animals, indicating partial 
occupancy of binding sites as a consequence of dosing with HCB (Table 3). 
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Table 2. HCB and PCP concentrations in serum of animals exposed to HCB 
Dose of HCB Dosing period HCB (umol/L) PCP (umol/L) 
(mmol/kg) (weeks) 
0.0 2 DL DL 
0.9 2 9.0 :!: 0.9 1.1 :!: 0.51 
1.7 2 14.5 :!: 3.3 1.7 :!: 0.58 
2.6 2 23.6 :!: 4.0 2.7 :!: 0.45 
3.5 2 23.2 :!: 2.3 2.6 :!: 0.52 
3.5 4 49.0 :!: 8.7 10.4 :!: 3.25 
Groups of rats (N=4-5) were orally dosed three times a week with HCB for a period of 2 or 4 
weeks. Within 24 h after the last dose, blood was collected by tail bleeding. HCB and PCP 
concentrations in serum were analyzed by HPLC. DL, Detection limit (see Materials and Methods). 
Table 3. Occupancy of binding sites after HCB-dosing 
Incubation N cpm % inhibition 
conditions 
HCB sera 5 37463 :!: 1321" 20 
Control sera 5 46662 :!: 866 0 
Control sera + 2 3083 :!: 194 93 
T4 (1OO.uM) 
Sera were obtained from animals dosed with 3.5 mmol HCB/kg for 4 weeks or without HCB. 
Binding of a standard amount of [125[]T4 to serum binding proteins was determined as described 
in the Materials and Methods. Significance: * p<O.05 
PCP levels in serum after PCP treatment 
The relationship between the dose of PCP administered and the 
concentration of PCP in serum reached, as determined by HPLC analysis, 
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was found to be linear (Fig.3) up to an administered dose of 100 ,umol/kg. 
DISCUSSION 
The results of the present experiments demonstrate that both HCB and 
its major metabolite PCP are able to produce a decrease in serum thyroid 
hormone levels. HCB produced significant reductions of TI 4 in a dose-
dependent manner (2 or 4 weeks exposure), while levels of TI3 were not 
found to be substantially altered. However, in short term experiments (2 
weeks) there appeared to be no large dose-dependent effect on FT4, and 
hence on TSH levels (because the TSH respons is to FT 4 rather than to 
TI4). During longer exposure to HCB (4 weeks), a greater reduction of TI4 
levels was observed, including decreased FT 4 and hence increased TSH 
levels. An explanation may be that during the shorter period (2 weeks) the 
buffering capacity of serum binding proteins on T 4 is still large enough to 
compensate the FT 4 pool. With prolonged exposure this capacity may 
become exhausted through competitive effects of PCP, the FT41eveis can no 
longer be maintained and therefore TSH levels go up. TI3 levels have hardly 
been observed to be altered with PCBs, dioxins, chlorinated benzenes etc. 
These observations confirm and extend results of other investigators (4-6) 
who also found decreased TI 4 levels but no significant alterations in TI3 
serum levels by HCB. Recently however, evidence had been obtained for 
HCB-induced significant reductions of plasma TI3 levels (26). The 
hypothalamus-pituitary axis is probably not impaired as indicated by an 
increased TSH response, while preliminary results have shown evidence for 
an increased activity of the thyroid gland as appeared histologically by 
hyperplasia in combination with increased iodine uptake in the thyroid. The 
combination of decreased TI 4 and FT 4 levels in sera and an increased TSH 
response after subchronic treatment with HCB suggest the condition of 
hypothyroidism. 
Repeated dOSing with HCB leads to induction of microsomal enzymes, 
e.g. P450 (11), ethoxyresorufin-deethylase (11) and UDPGT levels (12). 
Enhanced activity of several UDPGTs have recently been shown to give rise 
to increased levels of T 4-glucuronides and to an increased bile flow (12), the 
combined effect could lead to a rapid removal of T4 from the circulation (12). 
A further consequence of hepatic microsomal enzymatic activity is a 
build-up in serum of PCP, the major metabolite of HCB (17-19). PCP has 
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been causally implicated in HCB-induced reductions of thyroid hormone 
levels because of its greater effectiveness in reducing TT4 serum levels (20). 
The present experiments confirm the rapid decrease of TT 4 serum levels in 
animals exposed to PCP. In addition, FT4 levels in serum were also equally 
affected. No significant alterations of TSH levels were observed, but the time 
period of 6 h may not be long enough for proper operation of the hypo-
thalamus-pituitary-thyroid feed-back mechanism. 
Fig. 3. Relationship between serum PCP levels and administered dose. 
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Different doses of PCP were injected Lp. and blood was collected 6 h later. PCP concentratio 
n in serum was analyzed by HPLC. These results represent combined data from tINe independent 
animal experiments. 
In the present study, evidence for significant competitive interactions 
(19.7 % competition in the standard gel filtration assay) was observed in sera 
of animals dosed with HCB. In contrast, no a~erations in serum binding ofT4 
in sera of animals exposed to HCB were reported using an electrophoretic 
technique (6). Possible differences in sensitivity of the techniques being 
applied may account for the different findings. In earlier studies it was found 
that there was very little binding of HCB to T 4-binding sites of serum 
proteins. PCp'however, is a very avid binder of these sites. Among the serum 
binding proteins PCP has relatively the highest binding to TTR, even higher 
than T 4 itself, followed by albumin and lowest binding to TBG. By Scatchard 
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analysis it is apparent that PCP alters the affinity of T 4-binding and not the 
number of binding sites on serum proteins (21,22,25,32). 
One of the unresolved issues concerns the question to what extent the 
possible mechanisms, (i.e competitive interactions and increased 
metabolism), are involved in the decrease of thyroid hormone by HCB and 
related polyhalogenated aromatics. The present experiments allow an 
estimation of the respective contribution of either of these mechanisms. It 
was possible to estimate the contribution of PCP to the decrease of TT 4 
levels through competitive interactions, because, relationships between 
administered doses of PCP versus serum concentrations of PCP on the one 
hand (Fig.3) and versus serum TT4 levels on the other were established 
(Fig.1). After dosing for 4 weeks with 3.5 mmol HCB/kg, PCP levels in serum 
reached 0.01 mmol/I (Table 2). This serulTl level of PCP would correspond 
with an administered dose of 0.0044 mmol/kg PCP (by extrapolation in Fig. 
3) that would be able to induce a decrease of 19.5 % in serum TT 4 levels 
(and a marginal decrease of FT4levels) through competitive interactions (by 
extrapolation in Fig. 1). Since the present data showed a maximum reduction 
of TT 4 levels of 41 % with a sub-chronic dosing of 3.5 mmol HCB/kg (Table 
1) it can be calculated that PCP may decrease TT4 levels through 
competition at the hormone binding protein level by about 48 % (i.e. 19.5/41 
x 100 %). The remaining 52 % decrease of TT4 levels is attributed to other 
causes such as increased hepatic metabolism. At the earlier time of 2 weeks, 
serum levels of PCP were not high enough to cause a decrease of TT41eveis 
by competitive interactions with thyroid hormone binding proteins in serum 
and the effect on TT41eveis may be caused solely by the metabolic pathway. 
The present findings suggest that the decrease of T 4 levels by repeated 
dosing of HCB may initially be caused by induction of metabolic pathways 
for T4 only. With prolonged dosing, HCB accumulates, for instance, in the 
liver. As hepatic microsomal metabolism is also increased, PCP levels in the 
circulation can reach levels that are high enough to compete with thyroid 
hormone for binding sites of thyroxine binding proteins such as TTR and 
albumin (21,22,25,26). In this phase both competitive interactions and 
metabolism work in conjunction to lower T 4 serum levels. As far as we know, 
this may be the first example of a common effect (decrease of serum TT4 
levels) caused by parent compound and metabolite at the same time through 
different and independent mechanisms. 
131 
REFERENCES 
1. Courtney KD, Hexachlorobenzene (HCB):a review. Environ Res. 20, 225--246, 1979, 
2. Peters HA, Gockmen A, Cripps OJ, Bryan GT and Dogramaci r. Epidemiology of 
hexachlorobenzene-induced porphyria in Turkey. Arch. Neurol. 39: 744-749, 1982. 
3. Cabral JRP and Shubik P, Carcinogenic activity of hexachlorobenzene in mice and 
hamsters. In: Hexachlorobenzene: Proceedings of an International Symposium. !ARC 
Scientific Publications. 77, 411-416, 1986. 
4. Rozman K, Gorski JR, Rozman P and Parkinson A, Reduced serum thyroid hormone levels 
in hexachlorobenzene induced porphyria Toxico!. Lett. 30: 71-78,1986. 
5. Kleiman de Pisarev DL, Carmen Aies de Molina MO and San Martin de Viale Le, Thyroid 
function and thyroxine metabolism in hexachlorobenzene-induced porphyria. Biochem. 
Pharmacol. 39: 817-825, 1990. 
6. Kleinman de Pisarev DL, Sancovich HA and Ferramola de Sancovich AM, Enhanced 
thyroxine metabolism in hexachlorobenzene intoxicated rats. J. Endocrino!. Invest. 12: 767-
n2,1989. 
7. Wassermann 0, Wassermann M, Simi Cucos MSC and Ojavaherian M, Thyroid gland 
changes in rats receiving polychlorinated biphenyls. In: Pesticides and the environment: A 
Continuing Controversy 2. (Ed. Deichman WB), pp 151-161. Intercont: Medical Book Co, 
New York, 1973. 
8. Bahn AK, Mills JL, Snyder PJ, Gann PH, Houten L, Bialik 0, Hollman A and Utiger RD, 
Hypothyroidism in workers exposed to polybrominated biphenyls. New Engl.J.Med. 302: 31-
33, 1986. 
9. Byrne JJ, Carbone JP and Hanson EA, Hypothyroidism and abnormalities in the kinetics of 
thyroid hormone metabolism in rats treated chronically with polychlorinated biphenyl and 
polybrominated biphenyl. Endocrinology 121: 520-527, 1987. 
10. Van den Berg KJ, Zurcher C and Brouwer A, Effects of 3,4,3',4'-tetrachlorobiphenyl on 
thyroid function and histology in marmoset monkeys. Toxicol.Lett. 41: 77-86, 1988. 
11. Van Ommen B, Hendriks W, Bessems JGM, Geesink G, Muller F and van Bladeren PJ, The 
relation betvveen the oxidative biotransformation of hexachlorobenzene and its 
porphyrinogenic activity. Toxico!. Appl. Pharmacol. 100: 517-528,1989. 
12. Van Raaij JAGM, Kaptein E, VisserTJ and van den Berg KJ, Increased glucuronidation of 
thyroid hormone in hexachlorobenzenetreated-rats. Biochem. Pharmacol. 45:627-631,1993. 
13. Bastomsky CH, Effects of a polychlorinated biphenyl mixture (arochlor 1254) and DDT on 
biliary thyroxine excretion in rats. Endocrinology 95: 1151-1155,1974. 
14. Beetstra JB, van Engelen JGM, Karels P, van der Hoek HJ, de Jong M, Docter R, Krenning 
EP, Hennemann G, Brouwer A and Visser TJ, Thyroxine and Triiodothyronine are 
glucuronidated in rat liver by different UDP-glucuronyltransferases, Endocrinology 128: 741-
746,1991. 
15. Lucier GW, McDaniel OC and Hook GER, Nature of the enhancement of hepatic uri dine 
diphosphate glucuronyltransferase activity by 2,3, 7,8-tetrachlorodibenzo-p-dioxin. 8iochem. 
Pharmacol. 24: 325-334, 1975. 
16. Bastomsky, CH, Enhanced thyroxine metabolism and high uptake goiters in rats after a 
single dose of 2,3,7,8-tetrachlorodibenzo-p-dioxin. Endocrinology 101: 292-296, 1977. 
132 
17. Koss G, Koransky A and Steinbach K. Studies on the toxicology of hexachlorobenzene.11. 
Identification and determination of metabolites. Arch. Toxico!. 35: 107~114, 1976. 
18. Van Ommen BV, Adang AEP, Brader L, Posthumus MA, Muller F and Van Bladeren PJ, The 
microsomal metabolism of hexachlorobenzene. Biochem. Pharmacol. 35: 3233--3238, 1986. 
19. Van Ommen BV, van Bladeren PJ, Temmink JHM and Muller F, Formation of 
pentachlorophenol as the major product of microsomal oxidation of hexachlorobenzene. 
Biochem. Biophys. Res. Commun. 126: 25-32, 1985. 
20. Van Aaaij JAGM, Van den Berg KJ, Bragt PC, Engel A and Notten WRF, Effects of 
hexachlorobenzene and its metabolites pentachlorophenol and tetrachlorohydroquinone on 
serum thyroid hormone levels in rats. Toxicology. 67: 107-116, 1991. 
21. Van den Berg KJ, Interaction of chlorinated phenols with thyroxine binding sites of human 
transthyretin, albumin and thyroid binding globulin. Chern. Biol.lnteract. 76: 63--75, 1990. 
22. Van den Berg KJ, van Raaij JAGM, Bragt PC and Notten WAF, Interactions of halogenated 
industrial chemicals with transthyretin and effects on thyroid hormone levels in vivo. 
Arch.Toxicol. 65: 15-19, 1991. 
23. Brouwer A and Van den Berg KJ, Binding of a metabolite of 3,4,3',4'- tetrachlorobiphenyl 
to transthyretin reduces serum vitamin A transport by inhibiting the formation of the protein 
complex carrying both retinol and thyroxine. Toxicol. Appl. Pharmacol. 85: 301-312, 1986. 
24. Brouwer A, Inhibition of thyroid hormone transport in plasl')1a of rats by polychlorinated 
biphenyls. Arch Toxicol Sup pI. 13: 440-445, 1989. 
25. Den Besten C, Vet JJAM, Besselink H, Kiel GS, van Berkel BJM, Meems R and Van 
Bladeren PJ, The liver, kidney and thyroid toxicity of chlorinated benzenes. Toxicol. Appl. 
Pharmacol. 111: 69-81, 1991. 
26. Den Besten C, The relationship between biotransformation and toxicity of halogenated 
benzenes: nature of the reactive metabolites and implications for toxicity. Thesis, 
Wageningen, The Netherlands, 1992. 
27. McKinney JO, chae K, Oatley JS and Blake CCF. Molecular interactions of toxic chlorinated 
dibenzo-p-dioxins and dibenzofurans with thyroxine binding prealbumin. J. Med. Chern. 28: 
375-381. 1985. 
28. Rickenbacher U, McKinney JO, Oatley SJ and Blake CCF, Structurally specific binding of 
halogenated biphenyls to thyroxine transport protein. J. Med. Chern. 29: 641-648,1986. 
29. McKinney JO. Fannin R. Jordan S. Chae K, Rickenbacher U and Pederden L, 
Polychlorinated biphenyls and related compound interactions with specific binding sites for 
thyroxine in rat liver nuclear extracts. J. Med. Chem. 30:79-86, 1987. 
30. McKinney JO. Fawkes J, Jordan S, Chae K. Oatley SJ, Coleman RE and Briner W, 2,3,7,8-
tetrachlorodibenzo-p-dioxin (rCOO) as a potent and persistent thyroxine agonist: 
Amechanistic model for toxicity based on molecular reactivity. Environ. Health. Perspect 
61 :41-53. 1985. 
31. Cody V, Conformational analysis of environmental agents:use of X-ray crystallographic data 
to determine molecular reactivity. Environ. Health Perspect. 121 :52Q..S27, 1985. 
32. Van Raaij JAGM, Van den Berg KJ and Notten WRF, Hexachlorobenzene and its metabolites 
pentachlorophenol and tetrachlorohydroquinone: interaction with thyroxine binding sites of 
rat thyroid hormone carriers ex vivo and in vitro. Toxico!. Lett. 59: 101-107, 1991. 
133 

CHAPTER VIII 
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ABSTRACT 
[n the present study the effects of hexach[orobenzene (HCB) and the metabolite 
pentachlorophenol (PCP) were investigated w~h respect to uptake ofthyroxine (T4) into 
cerebrospinal fluid (CSF), and brain structures of rats. [,25[]T4 was taken up into CSF 
of control rats by a relatively slow process, reaching a steady state after about 3 h. 
Both repeated dosing of HCB and single doses of PCP caused decreased uptake of 
[,25[]T4 into CSF, total brain tissue as well as specific brain structures, such as occip~a[ 
cortex, thalamus, and hippocampus. Mhough HCB-treatment caused a build-up of 
HCB and PCP levels in serum, in brain only HCB was present in significant amounts 
(t6 % of the serum level). [n CSF, both HCB and PCP concentrations were both below 
detection levels. Separate experiments with PCP showed, however, a dose- and time 
dependent uptake of PCP into CSF. 
The present results indicate that PCP and the parent compound HCB are able to 
affect brain supply of T4. This may have consequences for an adequate development 
of the brain or proper brain function in adults. The exact mechanisms of interference 
of PCP and/or HCB in brain uptake of T4 remain to be established. 
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INTRODUCTION 
From several studies it has become clear that hexachlorobenzene (HCB), 
which is produced as a by-product in industrial processes and formerly used 
as a fungicide, may cause disturbances of thyroid homeostasis of several 
species including humans (1-6). Other chlorinated aromatics such as 
polychlorinated biphenyls (PCBs), polybrominated biphenyls and dioxins 
induce similar effects (7-12). In fact, reductions of serum thyroid hormone 
levels are among the most sensitive indicators of exposure to these 
compounds in experimental studies (6,12,13). 
A major mechanism responsible for decreases of thyroxine (T 4) in the 
circulation after exposure to HCB or PCBs appears to be increased 
metabolism of T4 through an increased biliary clearance (4, 14-19) and 
induction of several types of T4 UDP-glucuronyltransferases (4,20-22). 
Interierence of pentachlorophenol (PCP), the major oxidative metabolite of 
HCB (23-26) with T 4-binding to serum proteins has also been found to play 
a role (27-29). In vitro studies demonstrated that this interaction was of a 
competitive nature, and that the highest affinity was observed with 
transthyretin (TTR) (28,30), a major transport proteinforT4 in rats. Additional 
evidence for a competitive mechanism was also obtained from in vivo and ex 
vivo studies (3,5,29). Recent evidence suggests that after repeated exposure 
of rats to HCB both types of mechanisms, i.e. enhanced metabolism by HCB 
and competitive interactions by the metabolite PCP, may operate 
independently and to an equal degree in reducing serum T4 levels (5). 
As a consequence of decreased peripheral thyroid hormone levels, 
target organs and tissues may be insufficiently supplied with thyroid 
hormone. Of special interest is the brain because it has been suggested that 
TTR might playa role for the transport of T 4 through the blood-cerebrospinal 
fluid (CSF) barrier (31-33). The choroid plexus forms part of the blood-CSF 
barrier and a considerable amount of data indicate that TTR is newly 
synthesized by the epithelial cells of rat and human CP independently from 
hepatic production of TTR (3441). In addition, evidence for a saturable 
transport system for T3 in the blood-CSF barrier (42) has been described. 
HCB and/or PCP could alter brain supply of thyroid hormones through 
various routes, e.g. via decreased blood levels or via interierence with 
transport systems. Alternatively, transport into the CSF and the brain of 
xenobiotic compounds that have a high affinity for TTR, e.g. PCP, might be 
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facilitated. 
Thus far, little information is available concerning effects of these and 
other compounds with respect to the brain supply of thyroid hormones or 
their specific uptake into the brain. This could be relevant for the 
interpretation of neurotoxicity and developmental toxicity associated with 
halogenated aromatic compounds (43-46). 
The purpose of the present study was to investigate in an experimental 
rat model whether exposure to HCB or PCP would influence T4 uptake into 
CSF and brain structures. This was correlated with measurements of HCB 
and PCP in brain and CSF. Finally, entry of PCP into CSF was determined 
separately. 
MATERIALS AND METHODS 
Chemicals 
[, 251]T 4 (SA 1500 !,Ci/!,g), was obtained from Amersham (England), HCB 
and PCP from Aldrich Company (Brussels, Belgium). 
Animals, housing and treatment 
In all experiments, male WAG-RIJ rats of about 14-15 weeks old, 
weighing 200-250 g were used. They were housed in groups of 3-4 on a 12 
h light-dark cycle with free access to food and water. For experiments with 
HCB, groups of rats (N=3-5) were repeatedly treated (three times a week) 
with an emulsion of HCB (40 mg/ml, 0.5 % Tween-20 in water), or vehicle 
(control animals) by gavage for two (exp 1) or four weeks (exp 2), using 
different doses (0-3.5 mmol HCB/kg). Following the last dose (day 14 and 
day 46 of exp 1 and exp 2 respectively), brain uptake ofT4 was determined. 
In experiments with PCP, different doses (0-0.10 mmol/kg), as a solution in 
corn oil (1 m~ were administered i.p to groups of rats (N=3-4). Control 
animals received corn oil only. 
Uptake of T4 into CSF 
['25I]T 4 from a stock solution in 70 % ethanol and 30 % water was gently 
concentrated by a nitrogen flow to remove ethanol. The remainder was taken 
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into PBS (8 mM Na"HP04.2Hp, 1.5 mM KH2P04 , 140 mM NaCI, 2.5 mM KCI). 
In order to characterize the uptake ofT4 in the CSF, rats were brought under 
ether anaesthesia, and the jugular vein was prepared for injection of 5-1 0 "Ci 
[, 25I]T4 (200 -300 "Q. The open wound was closed with special woundclips. 
For collection of CSF, puncture of the cisterna magna was done at several 
times (0.5-24 h) after injection. Only CSF samples not contaminated with 
blood were further analyzed. In all experiments, radioactivity in CSF was 
determined by gamma counting. 
Uptake of T4 in brain 
Uptake of T4 in brain structures was determined by i.p. injection of 
animals with 25 "Ci [,25I]T4 in 1 ml of saline. Approximately 1 h (exp 1) or 6 
h (exp 2) later, the animals were killed by decapitation for isolation of brains. 
Brains were dissected (or not) in several brain structures, e.g occipital cortex 
(OC), hippocampus (HP) and thalamus (TH). Structures were weighed and 
radioactivity was determined in a gamma counter. 
Tissue levels of HCB and PCP 
HCB and PCP concentrations in CSF and sera from exposed animals 
were analyzed by HPLC as described earlier (3). For determination of brain 
levels of HCB and PCP, brains were isolated and homogenised in 4 volumes 
of cold saline. HPLC analysis was carried out as described before (3) except 
that HCB was extracted with ethylacetate (5 mil, and PCP with n-hexane (4 
mQ under acidic conditions. The detection limit for analysis of PCP in sera or 
CSF was 0.14 "mol/l and for HCB 0.35 "mol/I, with recoveries of 100 %. The 
detection limit for analysis of PCP in brain homogenates was 0.05 nmol/g wet 
weight tissue, and for HCB 0.16 nmollg, with recoveries of 97 % and 92 % 
respectively. 
Statistical evaluation 
In order to determine differences between control and experimental 
animals, statistical evaluation was done with Student's t-test. 
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RESULTS 
Uptake of radio labelled T4 into CSF was first examined in non-treated 
control animals. The kinetics revealed a gradual increase of radioactivity into 
CSF during the first hours after injection (Fig.1). The highest levels in CSF 
were found between 3 and 7 h and thereafter CSF radioactivity slowly 
declined. 
When ['2'I]T 4 was administered to rats after repeated treatment with two 
different doses of HCB for two weeks, significantly decreased amounts 
Fig. 1. Uptake of T4 into CSF. 
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C25I]T4 was administered i.v. to rats (N=3-4). At several times after injection, CSF was sampled 
and radioactivity in a volume of 100.u1 was determined. Results are expressed as mean ± SEM. 
of label in CSF were observed (30 % and 37 % decrease respectively, 
p<0.05) compared to control values but no clear dose-response relationship 
was found (Table 1). 
Treatment of rats with a single injection of PCP, did result in a dose-
dependent decrease of uptake of [,2SI]T4 into CSF (34-75 % decrease, Table 
2). 
The effect of HCB-treatment on the uptake of ['2SllT 4 in whole brain 
tissue and selected brain structures is shown in Table 3. In whole brain 
tissue, significant reductions (by:!: 46-55 %, p<O.05) in the content of label 
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Table 1. Effect on uptake of T 4 into CSF in rats dosed with HCB 
Dose CSF Percent 
(mmol/kg) 1) (dpm/1 00 I'Q Change 
0 826.9 ± 98.0 
2.6 524.2 ± 74.2" ·37 
3.5 582.5 ± 124.2" -30 
Groups of rats (N=3-5) were repeatedly dosed with HCB or vehicle as indicated for a period of 
2 weeks. Following the last dose (day 14), C25~T4 was injected i.v., CSF was collected after 1 
h and animals were exsanguinated. Radiolabel in CSF was determined by gamma counting. 
Results are expressed as mean values ± SO. Statistical significance: * p<O.OS. 
1) Dose in mg/kg: 750 and 1000 respectively. 
Table 2. Effect on uptake of T 4 into CSF in rats dosed with PCP 
Dose CSF Percent 
(mmol/kg) 1) (dpm/1 00 1'1) Change 
0 670.8 ± 105.5 
0.026 441.7 ± 29.1" ·34 
0.052 266.2 ± 52.6" ·60 
0.105 165.2 ± 18.1" ·75 
Groups of rats (N=3-4) received a single injection of different doses of PCP i.p. After a period 
of 4 h following dosing, [125JJT4 was injected i.v., CSF was collected after another 2 hand 
animals were exsanguinated. Radiolabel in CSF was determined by gamma counting. Results 
are expressed as mean values ± SO. Statistical significance: 7: p<O,05. 
1) Dose in mg/kg: 7, 14 and 28 respectively. 
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were observed. In addition, strongly reduced levels of label (by ± 42-56 %, 
p<0.05) were found in each of the specific structures examined, e.g., 
occipital cortex, hippocampus and thalamus (fable 3). No specific 
differences in the magnitude of the reductions were found between the 
various brain structures on the one hand, and between brain structures and 
total brain tissue on the other. 
The effect of treatment with HCB on the accumulation of HCB and PCP 
in rat brain, CSF and in serum is shown in Table 4. After a period of 4 weeks, 
a substantial concentration of HCB could be measured in brain tissue. The 
concentration of PCP in brain, however, was below the detection limit. In 
CSF, neither HCB nor PCP were found in concentrations above the detection 
limit. In serum there was a time-dependent accumulation of HCB as well as 
of PCP. PCP levels in serum were on the average 11 % of the serum HCB 
Table 3. Effect on uptake of T 4 in total brain and brain structures in rats 
dosed with HCB 
Dose Total Brain Brain structures 1} 
OC HP TH 
(mmol/kg)2) dpm/mg dpm/mg dpm/mg dpm/mg 
0.0 9.90 ± 0.08 50.0 ± 6.3 57.7 ± 19.7 67.7 ± 20.4 
2.6 5.35 ± 1.28" ND ND ND 
3.5 4.46 ± 1.87" 22.2 ± 5.5" 30.6 ± 6.9" 39.2 ± 17.3" 
Groups of rats (N=3-5) were repeatedly treated with different doses of HCB for a period of 2 
weeks (for total brain) or 4 weeks (brain structures). Following the last dose, [125[]T4 was 
administered, and brains were isolated and dissected, or not (see methods for details). 
Differences in radiolabel levels in total brain and brain structures of control animals are due to 
different amounts of total label injected within two separate experiments. Results are expressed 
as mean values ± SD. Statistical significance: * p<O.05. 
1) ec, occipital cortex, HP, hippocampus, and TH, thalamus. 
2) Dose in mgfkg: 750 and 1000 respectively. ND. not determined. 
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concentrations after a 2 week exposure period and increased to 22 % if the 
exposure period was prolonged to 4 weeks. The HCB concentration in brain 
tissue (Table 4) was about 16 % of the HCB levels in serum after exposure 
to 3.5 mmol HCB/kg for a period of 4 weeks. 
Next it was investigated whether the blood-CSF barrier would pose a 
strict limitation for entry of PCP into CSF. Different doses of PCP up to 64 
"mol/kg (17 mg/kg = 1/3 LDso) were given as a Single dose to rats and PCP 
levels were determined in CSF after 6 h by HPLC. The results, shown in 
Fig.2, demonstrate that uptake of PCP into CSF was linearly related to the 
administered dose. 
The time course of PCP uptake into CSF (Fig.3), following a single dose 
of 64 "mol/kg, indicates a gradual increase to a steady state level that was 
achieved after about 6 h. Thereafter, PCP levels in CSF declined and, after 
24 h, were essentially below the detection limit. 
Table 4. HCB and PCP concentrations in brain, CSF and serum of rats 
eXQosed to HCB 
Dosea CSF Brain Serum 
Mmol HCB/kg HCBb PCpb HCB' PCP' HCBb PCpb 
1.7 < 0.2 <0.1 NO NO 15.5 ± 2.8 1.8 ± 0.57 
2.6 < 0.1 <0.1 NO NO 23.6 ± 4.0 2.7 ± 0.45 
3.5 < 0.1 <0.1 NO NO 23.2 ± 2.3 2.6 ± 0.52 
3.5" NO NO 6.0 ± 1.1 <0.05 38.5 ± 7.2 8.5 ± 3.57 
Groups of rats (N=3-5) were repeatedly treated with different doses of HCB for a period of 2 or 
4 (*) weeks. HCB and PCP concentrations in CSF, brain and serum were determined by HPLC 
analysis as described in Materials and Methods. Levels in brain are expressed on the basis of 
wet weight. Results represent mean values ± SO. ND, Not determined. 
a) Dose in mg/kg: 500, 750 and 1000 respectively. b) concentration in,umol/l. c) concentration 
in nmol/g. 
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DISCUSSION 
A vast amount of data is available now to indicate reductions of thyroid 
hormone levels, and more specifically T 4, in experimental studies following 
exposure to halogenated aromatic compounds such as HCB (2,5,18,27). One 
of the consequences of decreased plasma levels ofT4 may be that in certain 
target tissues levels of the biological active T3 are not adequately met. This 
may in particular hold for the brain as a target organ since more than 90 % 
of T3 content of the brain is derived from intracerebral conversion of T 4 to 
T3 by deiodinating enzymes, rather than from plasma T3 (47,48). In view of 
this, levels of T3 in the brain are dependent on the supply of T 4 from the 
circulation as well as upon activity of type II 5' -deiodinase. 
The results from the present study indicate that exposure of rats to a 
polyhalogenated aromatic compound such as HCB has implications for a 
proper supply of T4 to target tissues such as the brain. A repeated exposure 
Fig. 2. Dose-dependent uptake of PCP into CSF 
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Different doses of PCP were administered Lv. to rats (N=3-4). After 6 h, CSF was collected and 
PCP levels were determined by HPLC. Results are expressed as the mean values. 
regimen of rats to HCB did resu~ in a strongly impaired uptake of 
peripherally administered T4 into CSF (by 37 %). In addition, uptake of T4 
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was decreased by HCB in total brain tissue as well as in a few selected brain 
regions (by 42-56 %). Previously it has been shown that PCP, the major 
metabolite of HCB, was more effective in a~ering plasma levels of T 4 than the 
parent compound (3). The present results indicate that the same principle 
may apply for brain uptake of T 4 since single doses of PCP did cause a 
large reduction of T4 uptake into CSF (up to 75 %). 
Fig. 3. Time-dependent uptake of PCP into CSF 
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Rats (N=3-4) received a single dose of 0.064 mmol (17 mg) PCP/kg. At several times after 
administration. CSF was collected and PCP concentration was analyzed by HPLC. At 24 h. PCP 
concentration in CSF was < 0.2.umol/1. Results are expressed as mean ± SEM. 
The mechanism(s) by which HCB and PCP inhibit brain uptake of T 4 is 
not clear at present. With respect to T4 uptake into CSF it has been 
suggested that a separate pool of TIR, synthesized in the choroid plexus, 
is involved (33). Since PCP is known to interact with the T4-binding site of 
TIR, it could compete with T4 for uptake into CSF. Furthermore, the present 
results indicate that PCP may enter CSF (Fig.2 and 3), possibly facilitated by 
the same mechanism. By occupying TIR binding sites for T4 in CSF, PCP 
could further impair intracerebral distribution of T4. Using different 
compounds with binding ability to TIR, for example a synthetic flavenoid 
(EMD 21388), arguments for such a mechanism have been obtained (49). 
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Further studies with PCP are in progress to adress this aspect more 
specifically. It cannot be excluded at this stage, however, that impaired 
cerebral uptake of T 4 by HCB and PCP reflects to some extent the 
decreased plasma T4 levels. 
A reduced availabity of thyroid hormones in the brain may have 
consequences for the normal functioning of biochemical and physiological 
processes in the brain of adult and particularly juvenile animals. For example, 
insufficient levels of thyroid hormones during pre- and post natal 
development of the brain can result in decreased protein synthesis, 
decreased myelogenesis, disturbed maturation of synaptic plasma 
membranes, and disturbed ramification ofaxons in the brain (50, 51). 
Furthermore, dendritogenesis and regeneration of sympathetic neurons may 
be affected. Both processes depend on nerve growth factor (NGF), and it is 
known that thyroid hormones are regulating factors of NGF biosynthesis (51). 
If early postnatal replacement therapy with thyroid hormones is not applied 
in congenital hypothyroidism, all these phenomena may lead to impairment 
of intellectual performance. 
It has become clear that transfer of maternal T 4 via the placenta protects 
the fetus from deficiency of T 4, and possibly deficiency ofT3. Whether during 
pregnancy the intracellular availability of thyroid hormone of the fetal brain 
may be impaired by compounds such as HCB or PCP, depends possibly on 
the period of maternal exposure. For instance, it has been suggested that 
inadequate levels of maternal T 4 might result in damage to the developing 
fetal brain early in gestation (52). The maternal thyroid function and TSH 
response as a reaction of exposure to HCB in utero will for a large part 
determine fetal thyroid hormone status in blood and brain as well. In the fetal 
brain, the adaptive response in deiodinating capacity for local production of 
T3 from T 4 may be a factor that determines whether a deficiency of T3 in the 
developing brain will develop. For the fetus, deiodination in the brain is a 
very active and important process during a period of hypothyroidism (47), 
since maternal transfer of T3 to the fetus does not protect the fetus from T3 
deficiency (52). Recent studies with perinatal exposure of rats to PCBs have 
indicated decreased fetal and neonatal plasma levels of T 4 in association 
with increased type II 5'-deiodinase activity in brain tissue (53). 
In adults, disturbed brain function as a result of severe hypothyroidism 
becomes apparent from behavioral symptoms such as depression, paranoia 
and sleepiness. Studies in adult rats with hypothyroidism have demonstrated 
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morphological changes in the thyroid hormone sensitive pyramidal cells of 
the hippocampus (54), a neural area associated with cognitive processes. In 
view of the above mentioned general symptoms during hypothyroidism, it is 
possible that a reduced T4 supply to the adult brain might enhance the 
neurotoxicity of HCB or PCP. 
In conclusion, the reduction of serum T 4 levels by repeated 
administration of HCB or a single dose of the metabolite PCP appeared to 
directly affect the brain supply of T 4. This may have consequences for 
proper brain development in exposed juveniles and neurological functions 
in exposed adults. Additional studies are required to more precisely 
determine the mechanism of T 4 and PCP transport into CSF, including a 
possible role of TIR, and interference of PCP (HCB) in this process. 
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CHAPTER IX 
THYROXINE TRANSPORT INTO THE BRAIN: ROLE OF 
TRANSTHYRETIN (TTR) 
JAG.M. van Raaij'·2, C.M.G Frijters2, L. Wong Yen Kong2, K.J. van den 
Berg2 and W.R.F. Notten 1.2 
ABSTRACT 
1) Institute of Public Health and Social Medicine, 
Erasmus University Rotterdam, The Netherlands 
2) TNO Medical Biological Laboratory, Rijswijk, The Netherlands 
The role ofTTR in thyroxine (T4) transport into cerebrospinal fluid (CSF) and brain 
structures was studied using in vivo experiments. Rats received [,251JT4 i.v in the 
presence of compounds with affinity for the T4-binding s~e of transthyretin (TTR), and 
uptake of [, 251JT4 in CSF was determined. No significant decrease in uptake was 
obselVed in the presence of either pentachlorophenol, 2,4,5-trichlorophenol, 2,4-
dichlorophenol, hexachlorophene or cold T4. In contrast, significant increases were 
obselVed w~h 2,4,5-trichlorophenol (33 %), 2,4-dichlorophenol (36 %) or bromoxynil 
(27 %). Inhibitors of transport systems for v~amins and organic acids in the choroid 
plexus (CP) such as ascorbate, salicylate or probenecid did not impair T4 uptake into 
CSF. These results are interpreted in a diffusion model rather than in a transport model 
on the basis of TTR. 
T4 transport through the capillary blood brain barrier (BBB) was also investigated. 
Brain uptake indices (BUls) did not alter after carotid injections of [, 25ljT4 in the 
presence of an excess of cold T4 or pentachlorophenol. Add~ion of T4-binding serum 
proteins to the injection solution did lead to a decreased BUI ofT4. These obselVations 
indicate the absence of high affinity T4 transport systems in the BBB. T4 may enter the 
brain as a free molecule by a nonsaturable process. 
A model is proposed to interpret transfer from T4 from serum to CSF over the 
blood-CSF barrier on the basis of free T4 gradients. T4 uptake from serum through the 
BBB may be based on the same principle. 
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INTRODUCTION 
It is well established that the brain requires an adequate supply with 
thyroid hormone for proper cerebral development and functioning. Thyroid 
hormones from the circulation have to pass various brain barriers, e.g. 
capillary blood-brain barrier (BBB) and/or blood-cerebrospinal fluid (CSF) 
barrier in order to be taken up into the brain compartment. 
The mechanisms involved in the transport of thyroid hormones across the 
different barriers are not completely understood. Although transport of 
triiodothyronine (T3) through the BBB appears to be carrier-mediated (1), the 
situation with respect to thyroxine (T 4) is less clear. Recently h has been 
suggested that T 4 transport through the blood-cerebrospinal fluid (CSF) 
barrier may involve transthyretin (TTR), a major serum thyroid hormone 
binding protein in mammals. This was based on the observation that high 
levels of i.v administered [,251]T 4 preferentially accumulated in isolated 
chOroid plexus (CP) , i.e a major CSF producing organ (2-5). Molecular 
biological studies have provided additional evidence that in the CP of rats, 
but also of humans, high levels of mRNA coding for TTR are produced 
indicating active synthesis of TTR (6-10). In CSF, a high proportion of T4 
appears to be bound to TTR (11,12). 
A more active role of TTR in transport of T 4 from blood to the brain has 
been proposed in a model by Schreiber et al (3). In this model TTR, having 
a high affinhy for T4 and being synthesized in the CP ephhelial cells and 
excreted in the CSF, transports T 4 from the bloodstream to the brain. 
Pardridge has advanced the hypothesis that plasma protein-binding may 
facilitate transport of thyroid hormones into tissues via microcirculatory 
barriers (1,13,14). 
Few experimental in vivo data are available to substantiate a TTR-based 
model for transport of T 4 into brain. Recently it was shown that T 4 covalently 
bound to TTR hardly entered CSF when administered i.v.(15). The results of 
this study further indicated the existence of separate and independent pools 
for hepatic- and CP-derived TTR. Furthermore, h was suggested that binding 
to TTR in the CP might be more important for transport of T4 to the brain 
than binding to circulatory TTR. Circumstantial evidence using compounds 
that bind to the T 4-binding site of TTR suggests also some role of TTR in 
brain transport of T 4. For instance, a synthetic flavonoid (EMD 21388) was 
found to decrease TTR binding of T4 in CP and CSF as well as uptake ofT4 
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in CSF and brain structures (15). 
In vivo treatment of rats with pentachlorophenol (PCP) has recently been 
observed to result in reduced uptake of T 4 from blood into the CSF as well 
as in brain structures (16). In addition, PCP was found to be taken up into 
CSF with similar kinetics as T4 (16). PCP has been shown to interact 
competitively with the T4-binding site of TTR at a higher affinity than T4 itself 
(17). 
In the present communication, an attempt was made to clarify the 
participation of TTR in transport of T 4 and xenobiotics such as PCP through 
the blood-CSF barrier. For this purpose, experiments were done to 
investigate whether various compounds that are known to interact with the 
T4-binding site of TTR competed directly with uptake of T4 into CSF. In 
addition to the blood-CSF barrier, attention was focussed on the BBB in 
order to establish an eventual role of TTR. 
MATERIALS AND METHODS 
Chemicals 
L_[,25IJT4 (specific activity 1500 pCi/pg), ['HJ-H,o (specific activity 5 
mCi/ml) and ['HJinulin (specific activity 442 pg/mg) were obtained from 
Amersham, England. Human serum albumin (HSA) , thyroxine binding-
globulin (TBG) , human transthyretin (TTR), L-thyroxine and 2,4,5-
trichlorophenol were obtained from Sigma Chemical Co (St Louis, MO, 
U.S.A). Salicylic acid, pentachlorophenol, bromoxynil and 2,4-dichlorophenol 
were obtained from Aldrich (Brussels, Belgium). Probenecid and 
hexachlorophene were purchased from Serva (Heidelberg, Germany). 
Ascorbinic acid was obtained from Merck (Darmstadt, Germany). 
Animals and housing 
Male WAG/RIJ rats, weighing 200-300 g were used. The rats were 
housed in groups of 3-4 on a 12 h light-dark cycle with free access to food 
and water. 
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Brain uptake of T 4 
For determination of T4 uptake in CSF, rats were brought under ether 
anaesthesia and the jugularic vein was exposed for injection. [, 251]T 4 was 
taken into PBS (8 mM Na,HPO •. 2H20, 1.5 mM KH2PO., 140 mM NaCI, 2.5 
mM KCI) to 25-50 pCi/ml. The animals were injected in the jugularic vein with 
200 pi of [, 251]T 4 in the presence of competing compounds (0-3000 pM in 
PBS). Control rats received [, 251]T4 in PBS only. After injection, the open 
wound was closed with woundclips. CSF samples were taken by cisterna 
magna punction. Only CSF samples not contaminated with blood were 
further analyzed. Radioactivity in CSF was determined by a gamma counter 
and was expressed as dpm/1 00 pi CSF. 
The Oldendorf procedure (18-20) was used to investigate transport of T 4 
through the BBB. Briefly, rats were brought under anaesthesia with 0.1 ml 
hypnorm (i.e. 0.2 mg fentanyl/ml) s.c and 0.2 ml hypnorm i.m. The carotid 
artery of animals was exposed for rapid injection of a 200 pi sample of 
mixture A. Mixture A was Krebs-Ringer buffer (127 mM NaCI, 3 mM KCI, 2 
mM CaCI2 , 2 mM MgSO., 1.25 mM NaH2PO., 10 mM glucose, 26 mM 
NaHC03, pH 7.4), containing 2.5 -5.10' dpm T4/ml (1-2pCO and ['25I]T4/ml 
and 25.10' dpm 3H,o/ml (10 pCO. The experimental animals were injected 
with 200 pi mixture A containing different concentrations of T4- binding 
proteins, cold T4 or PCP. After a 15 sec period, to allow unidirectional flow 
into the brain, the animals were decapitated. Brains were dissected into 
striatum, occipital cortex, and thalamus. Dissection was done at the side 
ipsilateral to the injected bolus. The structures were weighed, dissolved in 
tissue solubilizer (Soluene, Packard) whereafter radioactivity was determined 
by double-isotope liquid-scintillation counting with quench correction. The 
brain uptake index (BUI) was calculated from the expression: 
BUI= dpm/mg T4/3H in tissue .100 
total dpm T4/3H 
In order to estimate the contribution of arterial contamination in brain 
tissue, [3H] inulin was used because this protein is not supposed to cross the 
blood brain barrier (21). About 5.10' dpm of the isotope was injected. After 
decapitation, the brain was dissected and blood was collected. Radioactivity 
in tissues was determined as described above. The contribution of tracer in 
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serum in the dissected brain structures was found to be < 5 %. 
Statistical evaluation 
In all experiments, statistical evaluation was done with Student's t test, 
and results expressed as mean ± sd, except in figure 1, where mean ± sem 
(standard error of the mean) is presented. 
RESULTS 
The time course of T 4 levels in CSF of control animals is presented in 
Fig.1. ['25I]T 4 uptake into CSF increased for a period of 1.5 h and then 
remained at a steady state for at least 1 h. The effect of excess PCP (3000 
pM) on the kinetics of [,251]T 4 in CSF is also given in Fig.1. It appeared that 
the uptake of [,251]T4 into CSF was not inhibited in animals dosed with PCP, 
compared with controls. 
Fig.1. Time course of r' 251]T4 levels in CSF of rats in the presence of 
pentachlorophenol. 
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Uptake ofT4 into CSF without of with 3000 pM PCP was determined as reported in Materials and 
Methods. Results are expressed as mean ± sem. 0-. = Controls; IHiIIl = PCP. 
Other compounds, previously shown to interact with the T 4-binding site 
of TIR, such as 2,4-dichlorophenol or 2,4,5-trichlorophenol (Fig.2B), 
hexachlorophene (2,2'-methylenebis-(3,4,6-trichlorophenoQ (Fig.2C), and 
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bromoxynil {3,5-dibrom0-4-hydroxybenzonitriQ (Fig.2D) were not able to 
compete effectively with T4 for entry into CSF. In contrast, T4 uptake into 
CSF was found to be slightly increased in the presence of 2,4-dichlorophenol 
or 2,4,5-trichlorophenol (Fig.2B), and bromoxynil (Fig.2D). Furthermore, the 
uptake of [,25IJT 4 into CSF was not inhibited in the presence of cold T 4 
(Fig.2E). 
A summary of the competing ability of these chemicals with T 4 for 
binding to TTR, the relative binding affinities of these chemicals for the T 4-
binding site of TTR and their effect on T4 uptake into CSF is given in Table 
1. The results show essentially an absence of a relationship between the 
ability to occupy binding sites of TTR and effect on T4 uptake into CSF. 
It is well established that the blood-CSF barrier also contains transport 
systems in the choroid plexus for a number of vitamins and organic acids, 
for example ascorbate and salicylate. Other active transport systems in the 
choroid plexus deal with efflux of specific compounds, e.g. neurotransmitter 
metabolites (22-26). It was investigated whether transport of T4 into or out 
-
Fig.2. Effect of TTR-binding compounds on uptake of T 4 into CSF 
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Rats were Lv. injected with C251]T4 in the presence of different concentrations of 
pentachlorophenol (A), (P1, P2 and P3: 333,1000 and 3000}tM resp.). 2,4-Dichloropheno[ (01: 
600 I'M) and 2,4,S-Trichlorophenol (8), (fR: 600 I'M), Hexachlorophene (C), (H: 30 I'M), 
Bromoxynil (0), (81 and 82: 300 and 3000 I'M resp.), andT4 (E), (f: 500 I'M). CSFwas sampled 
after 1 h (T4), 2 h (2,4-Dichlorophenol and 2.4,5-TrichlorophenoQ or 3 h (pentachlorophenol, 
hexachlorophene and bromoxynil). C= control values, Statistical significance: * p<O.05. 
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of the CSF could be linked to any of the systems involved in the transport of 
vitamins, organic acids or efflux. Using representative compounds for each 
of these systems, e.g. salicylate (Fig. 3A), probenecid (Fig. 3S) and 
ascorbate (Fig. 3C), neither one of these compounds was found to 
significantly affect levels of radiolabelled T4 in CSF. 
The effect of various serum binding proteins on the transport of T 4 
through the SSS was determined using the single pass procedure (18-20). 
Addition of TTR to the incubation medium did not result in enhanced brain 
uptake of T4 (Table 2). Rather, a tendency towards decreased SUI of T4 was 
observed. With the highest amount of TTR (30l'g) a significant decrease in 
SUI (by 32 %, p<O.OS) was found in striatum. In the presence of thyroxine 
binding globulin (TSG) a significant decrease in SUI of T 4 was observed in 
striatum, occipital cortex and thalamus (by:!: 34 - 41 %, p< O.OS). With 
albumin added to the incubation medium the effect on SUI of T 4 was less 
pronounced with a tendency to decreased SUI at the highest concentration 
(statistically not significant). 
Finally, it was investigated whether SUI of T4 could be altered by an 
Table 1. Compounds binding to TTR and their effect on T 4 uptake into CSF 
Compound Competing Relative [, 25I]T4 Uptake 
effectal in affinityb) into CSF 
vitro (%) 
Pentachlorophenol 96 1.7 Not inhibited') 
2,4,S-trichlorophenol 94 0.1S Increased') 
2,4-dichlorophenol 94 0.003 Increased') 
Hexachlorophene 93 0.7 Not inhibited3) 
Sromoxynil 87 ND Increased') 
T4 98 1 Not inhibited4) 
a) Competition of compounds with T4 for binding to TTR in vITro was determined as described 
~reviously (17). 
) Data on relative affinity of compounds for the T4-binding site of TTR were taken from Van den 
Berg et al (1991). (27). ND, Not determined. 1) at 3000 pM; 2) at 600 ,uM; 3) at 30 ,uM; 4) at 500 pM. 
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excess of unlabelled T4. The results, shown in Table 3, indicate that the SUI 
of [, 251]T4 was not found to be significantly decreased by an excess of 
unlabelled T4 or an excess of PCP. Rather a trend towards an upward SUI 
was observed, being significant for T4 with respect to uptake in the thalamus 
(p< 0.05). 
DISCUSSION 
In vitro studies of transport of T 4 through the blood-CSF barrier have 
suggested that T 4 may be directly transported via TTR-mediated systems 
localised in the CP (2,3). Several observations from the present study bring 
into question the in vivo relevance of TTR as a possible membrane transport 
carrier molecule for the CSF-uptake of T4. T4 uptake into CSF was found to 
be unaffected in the presence of an excess of several compounds such as 
T4 itself, PCP, 2,4,5-trichlorophenol, 2,4-dichlorophenol, hexachlorophene 
and bromoxynil (Fig. 2) that were known to interact specifically with the T 4-
binding site of TTR (Table 1). PCP has previously been shown to have an 
even higher affinity for that site than T4 (17). 
Fig.3. Effect of salicylate, probenecid and ascorbate on uptake of T4 into 
CSF 
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Rats were Lv. injected with [12511T4 inthe presence of salicylate (A), (S: SOOpM), probenecid (8), 
(P: S00ftM), or ascorbate (e), (A: 500ftM). One hour later, CSF was sampled. Radioactivity was 
determined. C= control values. 
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If TTR was a rate limiting factor of T4 uptake into CSF, inhibition of T4 
uptake would have been proportional to the interacting capacities of these 
compounds. Furthermore, in the rat model T4 uptake into CSF over the 
blood-CSF barrier was a fairly slow process that required several hours to 
reach a steady state (Fig.1). The final ratio of accumulation of T4 in CSF 
versus blood has previously been found to be much smaller than unity (16). 
Also these data are not in favor of an active transport of T 4 through the 
Table 2. Effect of T4-binding proteins on brain uptake of T4 
Binding BUI (ST) BUI (OC) BUI (TH) 
protein (etg) 
TTR 
0 33.6 :!: 5.7 38.9 :!: 11.5 39.5 :!: 13.9 
7.5 30.7 :!: 2.7 28.3 :!: 3.0 39.4 :!: 4.5 
15 29.2 :!: 2.6 NO 25.0 :!: 3.3 
30 22.8 :!: 4.4' 22.2 :!: 0.9 21.0 :!: 1.7 
TBG 
0 13.6 :!: 0.9 12.8 :!: 1.6 11.2 :!: 0.7 
6.6 8.0 :!: 2.6' 8.2 :!: o§ 7.4 :!: 2.1' 
Albumin 
0 40.1 :!: 15.4 35.3 :!: 9.9 27.5 :!: 7.1 
15 29.2 ± 5.0 35.1 :!: 6.3 27.7 ± 6.2 
45 33.4 ± 8.5 30.4 ± 10.8 25.9 ± 1.4 
[125[]T4 in the presence of different amounts of T4-binding serum proteins was injected into the 
carotid artery of rats. The Brain Uptake Index (SUQ was determined in different brain structures 
(ST, striatum; ~C, occipital cortex; TH, thalamus) as described in the Methods section. NO, not 
determined. Significance: "', p<O.05. 
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the blood-CSF barrier, where a ratio higher than unity would have been 
expected. Using a somewhat different approach, Chanoine et al (15) recently 
observed that T 4 covalently bound to TTR was hardly taken up into CSF and 
brain as compared to unbound T4. This strongly indicates that at least 
circulatory TTR is not a facilitating factor in blood-CSF transport of T4. 
Table 3. Effect of competing T4 and PCP on brain uptake of radiolabelled T4. 
Competing SUI (S1) 
compound 
SUI (OC) SUI (TH) 
(uM) 
T4 
o 
0.8 
4 
20 
PCP 
25.3:!: 3.7 31.0 :!: 5.5 23.9:!: 1.5 
28. 7:!: 7.7 32.8 :!: 7.9 26.6:!: 5.3 
27.1 :!: 5.8 26.9:!: 1.7 25.8:!: 1.0 
29.3:!: 3.2 32.4 :!: 2.2 32.3:!: 2.4" 
o 25.2:!: 7.3 24.9 :!: 2.4 24.4:!: 5.0 
1877 28.7:!: 12.6 26.2:!: 6.2 33.2:!: 13.5 
C251]T4 in the presence of different concentrations of unlabelled T4 or PCP was injected into the 
carotid artery of rats. The Brain Uptake Index (BUQ was determined in different brain structures 
(ST, striatum; OC, occipital cortex; TH, thalamus) as described in the Methods section. 
Significance: *, p<O.05. 
In the CP, several systems are involved in the transport of nutrients, e.g. 
amino acids, vitamins, nucleosides etc. as well as a specific system for 
removal of toxic organic acids, such as biogenic amines and their acidic 
metabolites (22-26). Specific compounds acting on these systems, for 
example ascorbate, salicylate and probenecid, were not very effective in 
lowering T4 uptake into CSF (Fig. 3), suggesting that neither of these 
transport systems may be involved in T4 transport into or out of the CSF. A 
rather consistent finding was a tendency for somewhat increased T 4 levels 
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in the presence of high concentrations of PCP, 2,4-dichlorophenol, 2,4,5-
trichlorophenol and bromoxynil. It cannot be excluded that these compounds 
may inhibit efflux of T 4 from the brain, a process in which TTR mayor may 
not participate. This efflux system is supposedly different from the organic 
acid type of efflux system that is inhibited by probenecid (an alternative 
explanation based on FT4 gradients is given below). Taken together, the 
present results with respect to the in vivo mechanism of T 4 uptake from 
blood into CSF tend to exclude several possibilities for carrier-mediated 
transport systems and leaves the option of uptake by diffusion. 
The role of transport systems lor T4, and the involvement of T4-binding 
proteins, TTR in particular, was also studied with respect to the BBB using 
a single pass unidirectional flow (18-20) technique. The results indicate that 
neither TTR nor any other T 4-binding proteins, such as TBG or albumin, did 
facilitate T4 uptake through the BBB into various brain structures, e.g. 
striatum, thalamus and occipital cortex. In contrast, with TTR as well as TBG 
the BUl of T4 into brain structures was decreased as compared to uptake of 
T4 alone (Table 2). The suggestion from these results is that serum binding 
proteins rather act merely as circulatory buffers of T 4 than that they are 
involved in the passage 01 T 4 over the BBB into various brain structures. A 
further suggestion from these findings is also that only Iree T 4 molecules 
pass are able to pass the cerebral capillaries of the brain. The inability of an 
excess T4 to decrease effectively the BUI of radiolabelled T4 tend to 
eliminate possibilities for the existence of carrier-mediated transport systems 
for T 4 in the cerebral capillaries that form the blood-brain barrier. This leaves 
the alternative of uptake by diffusion. 
On the bases of the foregoing results, a revision of the Schreiber model 
is proposed regarding a TTR-based transport system lor T4 into CSF. T4 
bound to TTR or other serum binding proteins is delivered as a complex or 
as free T 4 (FT 4) through the fenestrated endothelial cells into the stroma of 
the CPo In the stroma there exists a normal equilibrium between the TTR-T4 
and FT4. Transport of FT4 takes place across the basolateral and apical 
membranes of the epithelial cells that constitute the CP to reach the CSF. 
The mechanism of transport may involve a process of diffusion on the basis 
of lipid partioning. During passage 01 the epithelial cells, T 4 is not able to 
interact with TTR that is newly synthesized, for as yet unknown reasons that 
may have to deal with intracellular sequestration and/or processing of TTR. 
Only in the CSF complexes are allowed to be formed of FT4 and newly 
synthesized TTR. I n this model there is no active role of plasma- or CP-
derived TTR involving transport of T4 into CSF. The driving force could be 
the rate of CSF production and the continuous CSF flow that should create 
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a concentration gradient of FT4 between the blood and CSF compartment. 
The differential effects observed with respect to T 4 uptake into CSF after 
pretreatment of rats with PCP (16) compared with simultaneous addition of 
PCP (this paper) may be explained with this new model. Pretreatmem of 
animals with PCP was previously found to result in strongly decreased blood 
levels of TT4 and FT4 (28) as well as decreased uptake of T4 imo CSF (16). 
The kinetics of this process have revealed a maximum decrease after about 
6 h (29). The decreased FT41evels, of course, lowerthe inward gradient, e.g. 
direction CSF, and hence the rate of diffusion. If PCP is added 
simultaneously or is present for only a limited amount of time, the FT 4 
concentration gradient is insufficiently lowered to decrease T4 flow into CSF. 
Rather the opposite effect may occur because the strong competitive effect 
of PCP with the T 4-binding site of TTR in particular may lead to temporarily 
increased serum FT 4 levels, an increased FT 4 gradient and enhanced inflow 
of T4 into CSF. The apparant increase in T4 CSF uptake by 2.4,5-
trichlorophenol, 2.4-dichlorophenol and bromoxynil may also be explained on 
this basis. Using the T4 flavonoid analog (EMD 21388), with affinity for the 
T 4-binding site of TTR, it could be shown that T 4 transfer from serum to CSF 
was dependent on the serum FT4 level (15). 
Since the present results indicate that also uptake of T 4 through the BBB 
takes place by a diffusion process, the FT4 concentration gradient from 
blood to brain over the BBB may be a determining factor for T 4 uptake into 
brain structures. The decrease in both serum TT 4 and FT 4 levels and T 4 
uptake in brain structures as previously observed in animals that had been 
repeatedly dosed with hexachlorobenzene (16) may be interpreted according 
to this concept. 
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EVALUATION 
During the investigations presented in this thesis, evidence for two 
mechanisms for hexachlorobenzene (HCB)-induced reduction of thyroxine 
levels in the circulation of rats was obtained. 1: Enhanced thyroxine-
metabolism caused by HCB (Chapter VI). 2: Competitive interaction of 
pentachlorophenol (PCP), a major metabolite of HCB, with the thyroxine-
binding sites of serum proteins (Chapter N and V). It was estimated that in 
rats exposed to HCB, nearly half of the reduction of serum total thyroxine 
was caused by interaction of PCP with the thyroxine-binding sites of serum 
proteins (Chapter VII). The other half of the reduction is probably caused by 
an enhanced metabolism of thyroxine. Effects of HCB on the synthesis of 
thyroxine in the thyroid gland may not be exluded. 
Exposure of rats to HCB or PCP did also result in reductions of thyroxine 
levels in the cerebrospinal fluid (Chapter VI/I). This phenomenon could 
probably not be attributed to specific interference of PCP with transthyretin 
in the cerebroventricular organs for the following reason: when radiolabelled 
thyroxine was simultaneously administered with PCP, no decrease of 
thyroxine uptake into the cerebrospinal fluid was found (Chapter IX). 
Comparable results were found (no blockade of thyroxine uptake) with other 
aromatic halogenated hydroxylated compounds (AHHs) having a high affinity 
for the thyroxine-binding site of transthyretin. Furthermore, transport of 
radiolabelled thyroxine through the capillary blood brain barrier was not 
inhibited by excess PCP or thyroxine (Chapter IX). These findings could not 
be explained with existing models involving thyroxine transport from blood 
to the brain (Chapter I). 
A new model for thyroxine transport is proposed in this thesis (Fig.1), 
which explains the results on thyroxine transport in the rat brain obtained 
during the investigations underlying this thesis. This model is based on that 
of Schreiber et al (1990), who postulated that transthyretin derived from the 
choroid plexus was responsible for thyroxine transport from the blood to the 
rat brain. This hypothesis was based on a high-capacity uptake of 
radiolabelled thyroxine in the choroid plexus, a major part of the blood-
cerebrospinal fluid barrier (see review Chapter I), after systemic 
administration. It is possible that this observation is caused by binding of the 
label to transthyretin at the apical side (cerebrospinal fluid side) of the 
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choroid plexus, since the epithelial cells possess the capacity to reabsorb 
apically proteinaceous material from cerebrospinal fluid (Olsson et ai, 1973, 
Smith et ai, 1964). Furthermore, in a recent study, it was suggested that T4 
reaches the brain primarily through the blood-brain barrier and not via the 
choroid plexus (Slay et ai, 1993). This statement was based on a decreased-
and an increased uptake of [,25]T 4 in the choroid plexus and cerebral cortex, 
respectively, after treatment of rats by cycloheximide and an i.v. injection of 
[,25JT4. 
In contrast with the hypothesis of Schreiber (1990), the postulated model 
(Fig.1) implies no role of transthyretin in the epithelial cells of the chOroid 
plexus. In this model, transthyretin, transthyretin-thyroxine complexes and free 
thyroxine pass the fenestrated capillaries of the choroid plexus (passive 
transpon) as a first step. The complexes, and also transthyretin are able to 
return to the blood by the same route. In the stroma of the choroid plexus, 
there exists an equilibrium between free thyroxine and the transthyretin-
thyroxine complex (comparable with the equilibrium in blood). Free thyroxine 
crosses the basolateral and apical membranes of the epithelial layer 
respectively by lipid panitioning, whereafter the cerebrospinal fluid is reached. 
In this companment, free thyroxine binds to transthyretin which has been 
produced by the choroid plexus. Thyroxine-transthyretin complexes may 
interact with transthyretin receptors of the neuronal and glial membranes in 
brain tissue. 
When serum thyroxine-protein complexes make a contact with the blood 
side of endothelial membranes of the capillary blood brain barrier, thyroxine-
binding proteins will deliver free thyroxine into the extracellular space of the 
brain (Fig. 1). Thereafter, free thyroxine migrates slowly from the extracellular 
space of the brain, where free thyroxine reaches the membranes and 
cytoplasm of the brain cells (neurons or glial cells). Otherwise, free thyroxine 
migrates funher into the cerebrospinal fluid (where free thyroxine is bound to 
transthyretin) after free passage of the ventricle wall. 
In the postulated model, the possible function of transthyretin produced 
by the choroid plexus is 1) a carrier for thyroxine in the cerebrospinal fluid for 
an efficient delivery of thyroxine into the extracellular and/or intracellular 
companment of the brain and 2) to allow transfer of thyroxine into the brain 
cells using transthyretin receptors on membranes. In any case, there is still 
no evidence that transthyretin is able to interact with free thyroxine in the 
intracellular companment of the epithelial cell. This may imply an intracellular 
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processing of transthyretin in such a manner that thyroxine molecules are not 
able to reach binding sites of intracellular transthyretin. The main rate-limiting 
step responsible for the cerebrospinal fluid-thyroxine levels may probably be 
the rate of cerebrospinal fluid secretion by the epithelial choroid plexus-cells, 
and not the level of epithelial transthyretin. 
Fig. 1. Hypothesis for transport of thyroxine from the blood to the brain 
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1) transthyretin produced by the choroid plexus 
Possible interactions of AHHs with transthyretin in the cerebrospinal fluid 
or with transthyretin receptors on membranes may explain neurotoxic 
properties of AHHs by disturbances of mammalian intracerebral thyroxine 
concentrations. When a possible neurotoxic compound enters the 
cerebrospinal fluid after crossing the epithelial cells of the choroid plexus as 
free molecules, it may compete with free thyroxine for the thyroxine-binding 
site of transthyretin in the cerebrospinal fluid. Such a compound may also 
interact with transthyretin receptors on neuronal- and glial transthyretin 
receptors. As a consequence, this may result in a disturbance of the 
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intracellular availability of thyroxine in the neuronal and glial cells. Effects of 
AHHs related to interactions with transthyretin in the brain should be of more 
significance in fetal or neonatal species since AHHs may enter the brain 
more easily because the blood-brain barrier is not always fully developed 
during the pre-and postnatal period (Johanson et ai, 1976, Johanson, 1980, 
1989). An a~ered thyroid hormone status in the mammalian brain induced by 
AHHs during critical periods of brain growth and development may act 
negatively because these processes are essentially dependent on thyroid 
hormones (see review of Chapter f). Experimental studies involving 
interactions of AHHs with intracerebral transthyretin of juvenile animals could 
be helpful to understand mechanisms of induced developmental 
neurotoxicity by local hypothyroidism. 
Possible implications for humans exposed to aromatic halogenated 
hydrocarbons 
The percentage of thyroxine bound to human thyroxine-binding globulin 
in blood is 6-fold, and the affinity of thyroxine for this protein is 100-fold 
higher compared with transthyretin (Chapter f). Therefore, in humans 
exposed to AHHs, thyroxine-binding globulin in the circulation will prevent 
fluctuations of free thyroxine resulting from displacement of T4 from 
transthyretin. Decreased serum thyroxine levels based on interactions of 
AHHs with the thyroxine-binding site of transthyretin may playa significant 
role at the moment that thyroxine-binding sites of all serum thyroxine-binding 
globulin molecules are occupied. However, transthyretin transports only 10-
15 % of circulating thyroxine which implies that the highest possible 
decrease of free T4 due to interactions of AHHs with the thyroxine-binding 
site of transthyretin and removal from the circulation, will be 10-15 %. 
In view of the relevance for risk assessment in occupational tOXicology, 
research is necessary to examine industrial compounds with a high affinity 
forthyroxine-binding globulin. Examples of relationships between interactions 
of industrial compounds with thyroxine-binding globulin and reduced 
thyroxine levels in serum are scarce. However, some pharmacologically 
important drugs, such as salicylate, or the anticonvulsant diphenylhydantoin 
and oleate, which possess a high affinity for the thyroid hormone-binding site 
of human thyroxine-binding globulin (Oppenheimer et ai, 1962, Larsen, 1972, 
Savu et ai, 1989), are able to reduce plasma thyroid hormone levels 
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(Molholm Hansen et ai, 1974, De Sandro et ai, 1991, Davies et ai, 1991). 
Interactions of AHHs with transthyretin in the brain may have implications 
for thyroid hormone homeostasis in the brain of humans exposed to AHHs, 
because 44 % of thyroxine is bound to transthyretin in cerebrospinal fluid 
(Hagen et ai, 1973). Herbert and coworkers (1986) report even a percentage 
of :!: 80 % bound T4 to human transthyretin in this fluid. If AHHs, such as 
PCP, penetrate the blood brain-and/or blood cerebrospinal fluid barriers and 
reach transthyretin in the cerebrospinal fluid, interaction with the thyroxine-
binding site is possible. Hence, it may be expected that thyroxine levels in 
the cerebrospinal fluid and brain will change, i.e. free and bound levels will 
probably increase and decrease, respectively. Whether these interactions, or 
those with cellular membrane transthyretin receptors will occur, depend 
probably on 1) the penetrating capacity ofthe AHHs through the membranes 
(Neuwelt, 1989) of the capillary blood brain barrier and of the endothelial and 
epithelial membranes of the choroid plexus, 2) the rate of migration of AHHs 
from the extracellular space of the brain to the cerebrospinal fluid, and 3) the 
concentrations of the AHHs reached in the cerebrospinal fluid. 
AHHs as parent compounds will probably pass membranes of the blood-
brain barrier more easily than the associated hydroxy-compounds, because 
the latter possess in general a less lipophylic character (compare HCB 
versus PCP), (Chapter V1I0. The presence of cytochrome P450-mediated 
activity in the human brain (Vijayalakshmi et ai, 1990), may possibly result in 
conversion of the parent compounds (Ravindranath et ai" 1989) into 
hydroxylated compounds (e.g. the biotransformation of HCB into PCP). 
Whether these compounds interact with transthyretin (receptors) in the 
brain and hence disturb thyroxine homeostasis in the brain may be an 
interesting topic for future investigations. 
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SUMMARY 
During various industrial processes (incinerations, production of 
pesticides), aromatic halogenated hydrocarbons (AHHs) such as 
hexachlorobenzene (HCB), polychlorinated biphenyls (PCBs), and 
polychlorinated dibenzo-p-dioxins (PCDDs) are still released into the 
environment. These highly persistent compounds may act negatively on the 
health of humans via occupational- or environmental exposure. The major 
general toxic effects of PCBs and related AHHs in humans are: headache, 
loss of weight, loss of appetite, abdominal pain and nausea. More specific 
effects include dermal lesions (chloracne), disturbed hepatic function 
(enlargement, hepatocellular necrosis), and reduction of sensory and motor 
nerve condition velocity (peripheral). 
Toxicological studies in various animal species report ''wasting syndrome" 
(loss of fat), thymic atrophy, impaired reproduction, disturbed embryonal 
development and dysfunctioning of the central nervous system. Other toxic 
effects of AHHs include disturbances on vitamin-and hormone levels. 
During the last ten years, much attention has been given to effects of 
PCBs and dioxins on thyroid hormone status (Chapter I). A number of animal 
studies demonstrated that these compounds were able to induce reductions 
of thyroid hormone levels in blood. Decreased plasma thyroxine (f4) levels 
were detected in humans, who had consumed food contaminated with HCB. 
Prolonged inadequate thyroid hormone levels (for example in 
hypothyroidism) in organs, such as the brain, may lead to disturbances of 
biochemical processes in organs, such as the brain (Chapter I). In particular, 
brain growth and development during the fetal and neonatal stage is strongly 
dependent on the availability of thyroid hormone. 
In this thesis, mechanisms are identified which may clarify the 
phenomenon of AHHs-induced reductions of T 4 levels in blood and brain of 
rats. In addition, it is described whether AHHs are able to influence supply 
of T 4 to the brain, and whether interactions of these compounds with T 4 
transport systems localised in the blood-cerebrospinal barrier or capillary 
blood-brain barrier are involved. HCB was chosen as a model compound 
because of its relatively simple chemical structure and the physico-chemical 
characteristics shared with PCBs; Also the thyroid and neurotoxicological 
properties of HCB are analogous with those of PCBs; Furthermore, 
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pentachlorophenol (PCP), an important metabolite of HCB, possibly interferes 
with T 4-binding serum proteins. 
The first experiments were designed to characterize effects of HCB on 
the thyroid gland and thyroid hormone levels (Chapter If). Repeated 
administration of HCB to rats for a period of 4 weeks resulted in reductions 
of total T 4 (IT 4) levels in the serum. The total T3 (IT3) levels in serum were 
only decreased in the second and third week of dosing. The thyroid gland 
of rats exposed to HCB had an increased iodine uptake (± 5.5-fold) and was 
clearly hyperplastic compared with controls. These phenomena indicated that 
the hypothalamus-pituitary-thyroid axis was probably not impaired by HCB. 
During prolonged exposure, a gradual build up of PCP levels in serum was 
demonstrated. Cytochrome P450-1 A 1 appeared to be induced by HCB, since 
microsomal hepatic ethoxyresorufin-O-deethylase activity was increased in 
exposed animals (13-fold) compared with controls. Taken together, it was 
concluded that exposure of rats to HCB resulted in a hyperactive thyroid 
gland and reductions of thyroid hormone levels. 
Experiments were performed to investigate whether the reduced serum 
thyroid hormone levels by HCB could be attributed to HCB itself, or to its 
major metabolite PCP (Chapter /If). A single dose of HCB had no significant 
effects on TT4 or TT3 within a period of 24 h post exposure. In contrast, an 
equimolar dose of PCP resulted in a decrease of ± 60 % of TT4 levels in 
serum. Furthermore, TT3 levels in serum were slightly decreased by PCP. A 
clear inverse relationship was found between the kinetics of serum PCP and 
TT4 levels. The results suggested that PCP might be causally involved in 
decreases of TT4 levels induced by HCB. 
In Chapter N, results are described which show to what extent hormone 
displacement from serum proteins is involved in the PCP-induced reductions 
of serum TT4 levels. Occupancy of T4-binding sites of serum proteins 
occurred in sera from rats exposed to PCP, but was hardly detectable in sera 
from rats exposed to HCB. Competing ability towards T4 was found in serum 
extracts from PCP-, but hardly from HCB-exposed rats. It was also found that 
PCP had a higher potency to interact with T4-binding sites of serum proteins 
than HCB. These results implied that PCP, as metabolite of HCB, might be 
a major causal factor in HCB-induced reductions of serum TT 4 levels, 
possibly through interaction with T4-binding serum proteins. 
Not only PCP and other chlorophenols, but also other groups of industrial 
compounds, such as nitrophenols, phenoxy acids, chlorobenzenes and 
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DDTs competed with T4 for binding to transthyretin (ITR) (Chapter \I). Some 
of these compounds were also able to cause reductions of TT 4 levels in 
blood. It could be postulated that the ability of a variety of industrial 
compounds to interact with the T4-binding site of TTR might be related to 
their potential to reduce TT 4 levels in blood. 
Exposure of rats to HCB can result in increase of biotransformation 
processes by induction of cytochrome P450 (phase I reaction). Induction of 
phase II (conjugation) enzymes by HCB may also occur. Therefore, reduced 
serum TT 4 levels caused by HCB might also be attributed to an enhanced 
metabolism of T 4. It was found that the activity of the T 4-UDP-
glucuronyltransferase (f 4-UDPGT) activity in hepatic microsomal fractions of 
rats repeatedly exposed to HCB was increased by a factor 5 compared with 
controls (Chapter Vf). Furthermore, an almost 3-fold higher production ofT4-
glucuronides in bile was caused by HCB. A decrease of the TT 4 levels in 
serum by increased activity of the hepatic type 1 deiodinase was excluded 
since HCB inhibited this enzyme. The results indicated that exposure of rats 
to HCB leaded to enhanced metabolism of T 4 (by increased 
glucuronidation), which might contribute to decreased serum TT4 levels. 
Separate experiments (with HCB or PCP) were designed to estimate the 
contribution of competitive interaction of PCP with serum T 4-binding proteins 
in decreased TT4 levels caused by HCB (Chapter Vlf). It appeared that a 
linear relationship existed between the administered dose of PCP and serum 
levels of PCP. It was also found that the amount of PCP-induced reductions 
of serum TT41eveis was dependent on the administered dose of PCP. Using 
these data, it was concluded that after repel'ted exposure of rats to HCB 
(with known HCB and PCP levels in serum), 48 % of the total reduction of 
TT 4 in serum was related to interactions of PCP with T 4-binding serum 
proteins. The other part of the reduction might be associated with an 
increased metabolism of T4 by HCB, although other unknown mechanisms 
could be involved (for instance a direct effect of HCB on the synthesis of T 4 
in the thyroid gland). 
In Chapter VIII, the consequences of exposure of rats to HCB or PCP with 
respect to the T 4 uptake into cerebrospinal fluid (CSF) and brain (structures) 
are described. It was found that repeated oral exposure of rats to HCB 
caused a lowered uptake of administered labelled T 4 into CSF and various 
brain structures, compared with controls. A single Lp. dose of PCP resulted 
in a dose-dependent decrease of T4 uptake into CSF. Since HCB and/or 
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PCP were able to decrease T4 uptake into CSF, these compounds may act 
negatively on T 4-dependent processes in the mammalian brain. 
Experiments were set up to investigate whether a diminished T4 uptake 
into CSF caused by PCP, might be attributed to specific interlerence of PCP 
with T 4 transport systems localised in the blood-CSF or capillary blood-brain 
barriers (Chapter IX). Attention is paid to the question whether the interaction 
of PCP with plasma and/or brain TTR might be responsible for the reduced 
T4 uptake into the CSF. In addition, it was investigated whether T4 transport 
to the brain along the cerebroventricular organs (such as choroid plexus) 
involved transport systems for organic acids or vitamins. It appeared that 
simultaneous systemic administration of labelled and excess cold T 4, PCP 
and other TTR-binding compounds, did not impair T 4 uptake into CSF ifirst 
part of Chapter IX). Similarly, T4 uptake into CSF could not be inhibited by 
inhibitors of organic acid transport (probenecid, salicylate) or vitamin 
transport (ascorbate). The results implied that transport of T4 into CSF was 
not based on a TTR-mediated system, nor on several other specific transport 
systems of the choroid plexus. Also, these results may be interpreted as 
transfer of T 4 through blood-CSF barriers as a free molecule, with a diffusion 
gradient as a driving force. 
Finally, experiments were done in order to study whether transport of T 4 
through the capillary blood brain barrier is based on high affinity systems 
(second part of Chapter IX). Using carotid injections of labelled T4 with an 
excess of cold T4 or PCP, no signfficant alterations of "brain uptake indices" 
(BUls) were found. Addition ofT4-binding proteins (ITR, albumin, orTBG) to 
the injection mixture resulted in decreased BUls of T 4 in various brain 
structures. These observations suggested that again only free T 4 fractions 
were available for rapid transport through the capillary blood brain barrier, 
based on dfffusion processes. 
Whether HCB-or PCP (or other AHHs)-induced reductions of TT4 levels 
act negatively on brain functions of adult mammals (also humans) could be 
an issue for further research. In any case, thyroid hormones are 
indispensable for a normal growth and development of the brain during the 
fetal and neonatal stage of humans and animals. Therefore, in view of 
possible effects of AHHs on thyroid hormone concentrations (maternal, fetal, 
neonatal, see Chapter fj, investigations of the consequences of pre-and post 
natal exposure of AHHs to brain functions of young human infants seems 
even more appropriate. 
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SAMENVATTING 
Bij veel industriele processen (verbrandingen, pesticiden productie) 
kunnen gehalogeneerde aromatische verbindingen (AHHs), zoals 
hexachloorbenzeen (HCB), polychloorbiphenylen (PCBs) en dioxinen 
(PCDDs) vrij komen in de omgeving. Deze verbindingen bezitten de 
eigenschap om sterk te persisteren in lichaamsweefsel, en kunnen de 
gezondheid van mensen die beroepsmatig of via het milieu worden 
blootgesteld, negatief beinvloeden. De belangrijkste algemene toxische 
effecten van PCBs en gerelateerde gehalogeneerde aromatische hydro-
carbonzuren zijn bij de mens: hoofdpijn, gewichtsverlies, eetlustverlies, 
buikpijn en misselijkheid. De meer specifieke effecten zijn: huidlaesies 
(chloracne), leverfunctiestoomissen (vergroting, hepatocellulaire necrose), 
en afname in sensorische en motorische zenuwgeleidingssnelheid (perifeer). 
Toxicologische studies bij verschillende diersoorten rapporteren "wasting 
syndroom" (verlies van lichaamsvet), thymusatrofie, verslechterde 
reproductiecapaCiteit, gestoorde embryonale ontwikkeling en afwijkend 
functioneren van het centrale zenuwstelsel. Andere toxische effecten van 
AHHs zijn verstoringen van vitamine- en hormoon spiegels. 
Gedurende de laatste tien jaren is veel aandacht geschonken aan 
effecten van PCBs en dioxinen op de schildklierhormoon status (Hoofdstuk 
I). Een aantal dierstudies hebben laten zien dat deze verbindingen in staat 
zijn om dalingen van schildklierhormoon spiegels in bloed te induceren. Bij 
mensen, die voortdurend waren blootgesteld aan HCB (via gecontamineerd 
voedseQ zijn dalingen van plasma thyroxine (T 4) spiegels beschreven. Een 
chronisch tekort aan schildklierhormoon (bijvoorbeeld bij hypothyroidie) kan 
een aanleiding zijn tot verstoringen van biochemische processen in organen, 
zoals bijvoorbeeld de hersenen (Hoofdstuk I). In het bijzonder zijn groei en 
ontwikkeling van het brein tijdens de foetale en neonatale periode sterk 
afhankelijk van de beschikbaarheid van schildklierhormoon. 
In dit proefschriftworden enkele mechanism en opgehelderd, die mogelijk 
ten grondslag liggen aan door AHHs geinduceerde dalingen van T 4 spiegels 
in het bloed en in de hersenen van de rat. Ook wordt beschreven in hoeverre 
AHHs in staat zijn de T4 toevoer naar de hersenen te be'invloeden, en in 
hoeverre interacties van deze verbindingen met transportsystemen voor T 4 
in de bloed-hersenvocht of bloed-hersen barrieres hierbij betrokken zijn. HCB 
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is als modelstof gekozen om de volgende redenen: HCB heeft binnen de 
AHHs een relatief eenvoudige chemische structuur; de fysisch-chemische 
eigenschappen van HCB zijn vergelijkbaar met die van de PCBs; HCB 
beschikt over analoge eigenschappen wat betreft de schildklier-en 
neurotoxiciteitvan PCBs; Pentachloorfenol (PCP), een belangrijke metaboliet 
van HCB interfereert mogelijk met T4-bindende serum eiwitten. 
In hoofdstuk /I staan resultaten beschreven die de effecten van HCB op 
de schildklier en op schildklierhormoonspiegels karakteriseren. Na herhaalde 
blootstelling van ratten aan HCB gedurende een periode van 4 weken bleek 
dat in het serum de totale T 4 (IT 4) spiegels gedaald waren. De totale T3 
(IT3) spiegels in het serum waren eveneens gedaald, maar vanal ± 2 weken 
na de eerste blootstelling keerden de spiegels weer geleidelijk naar het 
"normale" niveau. De schildklier van de met HCB behandelde dieren was 
duidelijk hyperplastisch, en had een verhoogde iodium opname (± 5.5-
voudig) ten opzichte van de controle dieren. Deze bevindingen betekenen 
dat de hypothalamus-hypofyse-schildklier as waarschijnlijk normaal 
functioneert. Naarmate de blootstelling langer duurde, kon een geleidelijke 
opbouw van PCP in het serum aangetoond worden. Cytochroom P450-1 A 1 
bleek ge'induceerd te kunnen worden door HCB, zoals bleek uit een 13-
voudige toename van de microsomale ethoxy-resorufine-O-deethylase 
(EROD) activiteit in de lever ten opzichte van de controles. De conclusie kon 
getrokken worden dat blootstelling van de rat aan HCB leidt tot een 
hyperactiviteit van de schildklier en tot dalingen van schildklier-
hormoonspiegels. 
Experimenten werden uitgevoerd om te onderzoeken of de door HCB 
geTnduceerde dalingen van de TI 4 en TI3 spiegels veroorzaakt worden door 
HCB zelf, of juist door belangrijke metabolieten van HCB, zoals PCP 
(hoofdstuk 1If). Het bleek dat HCB niet in staat was significante veranderingen 
in TI4 en TI3 spiegels te veroorzaken binnen een periode van 24 uur na 
blootstelling. Echter, een equimolaire dosis van PCP leidde al binnen 2 uur 
na blootsteling tot een sterke daling van serum TI4 spiegels (± 60 %). 
Verder veroorzaakte PCP een lichte daling van TI3 spiegels. Ook bleek dat 
het verloop van de serum PCP concentraties duidelijk omgekeerd correleerde 
met het verloop van de serum TI 4 concentraties. Er is dus een mogelijkheid 
dat PCP causaal betrokken is bij de door HCB geinduceerde dalingen van 
TI4 concentraties in de circulatie. 
In hoofdstuk IV staan resultaten beschreven die laten zien in hoeverre 
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hormoonverdringing van serum eiwitten toe te schrijven is aan door PCP-
geinduceerde dalingen van TT 4 spiegels in serum. Bezetting van T 4-
bindingsplaatsen in sera kon aangetoond worden in ratten die blootgesteld 
waren aan PCP-, maar in veel mindere mate in sera die afkomstig waren van 
ratten die aan HCB blootgesteld waren. Ook bleken serum-extracten van de 
met PCP gedoseerde dieren een sterke competerende activiteit (vergeleken 
met T4) te hebben. In serum-extracten afkomstig van dieren die aan HCB 
blootgesteld waren was nauwelijks competerende activiteit aanwezig. Verder 
kon aangetoond worden dat PCP een veel sterker vermogen heeft om T4-
bindingsplaatsen te bezetten dan HCB. De resultaten suggereren dat PCP, 
als metaboliet van HCB, een belangrijke oorzaak kan zijn van de gedaalde 
TT 4 spiegels die door HCB geinduceerd kunnen worden, mogelijk door 
interacties met T 4-bindende serum eiwitten. 
Niet aileen PCP en anderen chloorfenolen, maar ook andere groepen van 
industriele stoffen, zoals bijvoorbeeld nitrofenolen, fenoxyzuren, 
chloorbenzenen en DOTs blijken te competeren met T 4 voor de T 4-
bindingsplaats van transthyretine (TTR), zoals blijkt uit resultaten die 
beschreven zijn in hoofdstuk V. Sommige van deze verbindingen blijken ook 
in staat te zijn om dalingen van TT4 spiegels te veroorzaken. De resultaten 
impliceren dat er een verband bestaat tussen het vermogen van sommige 
van deze verbindingen te binden aan TTR en hun vermogen om TT4 
spiegels te verlagen. 
Blootstelling van ratten aan HCB kan resulteren in toename van 
biotransformatie-processen door inductie van cytochroom P450 (lase I 
reactie). In het lichaam kan HCB mogelijk ook lase II (conjugatie) enzymen 
induceren, die mogelijk een rol spelen bij de door HCB-veroorzaakte 
dalingen van TT 4 spiegels. Wanneer namelijk ratten herhaaldelijk 
blootgesteld werden aan HCB, werd in de hepatische microsomale fracties 
een 5-voudige verhoging van de T4-UDP-glucuronyltranslerase (T4-UDPGT) 
activiteit ten opzichte van controles gevonden (Hoofdstuk VI). Verder was in 
de blootgestelde dieren de T 4-glucuronide uitscheiding in de gal bijna 3 
maal verhoogd. Afbraak van T 4 gebeurt ook via activatie van type 1 
deiodinase in de lever, maar blootstelling aan HCB veroorzaakte een 
remming van dit enzym. De mogelijke conclusie is dus dat blootstelling van 
ratten aan HCB leidt tot een verhoogd metabolisme van T4 (door toenmame 
van de glucuronidering), hetgeen kan bijdragen aan dalingen van de TT4 
spiegels. 
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Experimenten werden uitgevoerd (met HCB en PCP afzonderlijk) om in 
een situatie van gedaalde TT4 spiegels door inwerking van HCB een 
schatting te kunnen doen van het relatieve aandeel van interacties van de 
metaboliet PCP met T 4-bindende serum eiwitten en het metabolisme van T 4 
(hoofdstuk VII). Het bleek dat er een lineair verband bestond tussen de 
toegediende dosis van PCP en de ontstane spiegels van PCP in het serum. 
Verder kon aangetoond worden dat de hoeveelheid dalingen van de TT4 
spiegels afhangt van de toegediende dosis van PCP. Met behulp van de 
gegevens kon berekend worden dat na herhaalde blootstelling van ratten 
aan HCB (met bekende serum concentraties HCB en PCP), 48 % van de 
totale T 4 dalingen in he! serum te relateren is aan interacties van PCP met 
T4-bindende serum eiwitten. De rest van de totale T4 daling kan mogelijk 
gerelateerd worden aan een verhoogd metabolisme van T 4 geinduceerd 
door HCB, hoewel andere op dit moment onbekende mechanismen ook nog 
van belang kunnen zijn (bijvoorbeeld een mogelijk direct effect van HCB op 
de synthese van T4 in de schildklier). 
In hoofdstuk VIII worden de consequenties beschreven v~~r de normale 
opname van T4 in cerebrospinaal vocht (CSF) en hersen(strukturen) na 
blootstelling van ratten aan HCB of PCP. Wanneer HCB herhaaldelijk oraal 
gegeven werd, bleek dat de opname van toegediend gelabeld T 4 in het CSF 
en hersenstructuren duidelijk verminderd te zijn ten opzichte van de controle 
dieren. Ook een eenmalige dosering van PCP resulteerde in het CSF in een 
soortgelijk effect dat dosis- afhankelijk was. Omdat zowel HCB als PCP de 
opname van T 4 in de CSF doen dalen, kunnen deze stoffen dus mogelijk T 4-
afhankelijke processen in zoogdierhersenen nadelig be'invloeden. 
Of de door PCP veroorzaakte gedaalde T 4 opname in het CSF of 
hersenen gerelateerd kan worden aan specifieke interactie met T 4 
transportsystemen in de bloed-CSF 01 capillaire bloed-hersen barriere wordt 
beschreven in hoofdstuk IX. Hierin wordt onder andere aandacht besteed 
aan de vraag of interactie van PCP met plasma-en/of hersen-TTR 
verantwoordelijk zou kunnen zijn voor de gereduceerde T 4 opname in het 
CSF. Verder werd onderzocht of het transport van T4 via cerebroventriculaire 
organen (zoals choroid plexus) naar de hersenen, verloopt via het transport 
voor organische zuren of vitaminen. Het bleek dat indien overmaat 
ongelabeld (koud) T4, PCP, of andere TTR-bindende stoffen, simultaan met 
gelabeld T4 systemisch werd toegediend, de opname van T4 in het CSF niet 
geremd was (eerste deel van hoofdstuk IX). Hetzelfde fenomeen werd 
178 
gevonden met probenecid, salicylzuur of ascorbinezuur. Oe resultaten 
impliceren dat het transport van T 4 naar het CSF niet gebaseerd is op een 
door TTR-gemedieerd systeem, of op andere specifieke transportsystemen 
in de choroid plexus. Oe resultaten kunnen ge'interpreteerd worden door aan 
te nemen dat T 4 getransporteerd word over bloed-CSF barrieres als een vrij 
molecuul, met een diffusiegradient als de drijvende kracht. 
Aanvullende experimenten werden uitgevoerd om vast te stellen of het 
T 4 transport via de capillaire bloed hersen barriere naar de hersenen te 
verzadigen is (!aatste dee! hoofdstuk IX). Gebruik makende van carotis 
injecties van gelabeld T4 in aanwezigheid van koud T4 of PCP, kon gesteld 
worden dat het T 4 transport over deze barriere onverzadigbaar was, omdat 
de "brain uptake indices" (BUls) niet veranderden. Ook werd gevonden dat 
indien gelabeld T4 toegediend werd in een gebonden vorm (aan albumine, 
TTR of TBG), de BUls van T4 in diverse hersengebieden afnamen. Oil 
betekent mogelijk wederom dat aileen de vrije T 4 fractie via diffusie 
beschikbaar is voor transport over de cerebrale capillairen. 
Of de door HCB-of PCP (of andere AHHs) ge'induceerde dalingen van 
serum thyroxine spiegels negatief inwerken op hersenfuncties van volwassen 
zoogdieren (ook de mens) kan een relevante vraag zijn v~~r toekomstig 
onderzoek. Schildklierhormonen zijn in ieder geval onmisbaar voor een 
normale groei en ontwikkeling van de hersenen gedurende het foetale en 
neonatale stadium van mens en dier. Oaarom is het gezien de mogelijke 
effecten van AHHs op schildklierhormoonconcentraties (maternaal, foetaal, 
neonataal, zie Hoofdstuk /) wenselijk om onderzoek te doen naar de 
consequenties van pre-en post natale blootstelling van AHHs voor de 
hersenfuncties van zeer jonge kinderen. 
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Jeroen van Raaij is geboren te Bergen op Zoom op 20-07-1962. Na het 
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Immunologie (Prof.dr.R.E. Ballieux) en Endocrinologie (Prof.dr.J.L. van den 
Brande/dr. S. van Buul), en als bijvak Moleculaire biologie (Prof.drAD.M.E. 
Osterhaus/dr P. de Vries). 
In aansluiting op de studie deed hij electromyografisch onderzoek bij 
ponies') aan de afdeling Functionele morfologie van de faculteit der 
diergeneeskunde (Drs M. Jansen/Prof.dr.w. Hartman). Vanaf oktober 1989 
beg on hij met het in dit proefschrift beschreven onderzoek (o.l.v. dr.KJ. van 
den Berg, Medisch Biologisch Laboratorium te Rijswijk). Tijdens dit 
onderzoek volgde hij tevens de postdoctorale opleiding Toxicologie 
(SMBWO). Verder is hij co-auteur van 2 recente publicaties2,3) die in 
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FEBS Letters 315:65-68, 1993. 
3) Glucuronidation of thyroid hormone in rat liver: Effects of in vivo treatment with microsomal 
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T.J. Visser, E. Kaplein, H. van Toor, J.A.G.M. van Raaij, K.J. van den Berg, C.T.T. Joe, 
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NAWOORD 
Op de eerste plaats wi! ik iedereen bedanken die aan het tot stand 
komen van dit proefschrift hoe dan ook een bijdrage hebben geleverd. In het 
bijzonder wil ik mijn co-promotor dr. K.J. van den Berg en mijn promotor 
prof.dr.W.R.F. Notten bedanken. Beste Kor, Door jou, met wie ik waardevolle 
discussies heb gehad bij het beoordelen van experimenten en manuscripten, 
ben ik veel aspecten van de Toxicologie steeds meer gaan begrijpen en 
waarderen. Ik denk dat ik met de stelling "mijn leermeester" al een heel stuk 
van jou deskundigheid en betrokkenheid bij het onderzoek heb samengevat. 
Beste Wi!fried, jou wilde ik bedanken voor de positieve adviezen voor het 
onderzoek, en voar de mogelijkheid die ik kreeg om de opleiding tot 
Toxicoloog te volgen. 
Aan dr. ir. Peter Bragt, evenals dr. Wim de Kort en dr. Wim Bergers ben 
ik dank verschuldigd voor hun suggesties voor de inhoud van diverse 
gedeeltes van het proefschrift. Janny, ook jou moet ik zeer zeker bedanken 
voor de goede adviezen die jij me regelmatig hebt gegeven. 
Bij het practisch werk heb ik enorme steun gehad van vooral Roel Engel. 
Beste Roel, ik zie jou nog wei eens detectie-limieten halen van minder dan 
x attomol pentachlorophenol/liter in welke matrix dan ook. Met een haast 
onvoorstelbare nauwkeurigheid wist je in minimale volumina toch nog aardig 
scherpe "tjappers" tevoorschijn te toveren op het chromatogram. Ook wil ik 
mijn analisten John van Vlaardingen, Letitia Wong en Charles Frijters 
bedanken voor hun bijdrage in het experimentele werk. Beste John, vooral 
de canulaties van de galkanaaltjes bij de rat vond ik een technisch 
hoogstandje. Beste Letitia en Charles, tijdens het onderzoek heb ik nog nooi! 
zoveel gelachen als tijdens jullie aanwezigheid. Charles, je hield je steeds in 
als de getallenlijst van jou experiment al lang uit de teller verdwenen was 
door mijn toedoen. Ik waardeer het ten zeerste dat jullie altijd bereid waren 
voor mij de benodigde experimenten snel en vakkundig uit te voeren. Frans 
Luiten en Martin N eeleman wi! ik bedanken voor het leveren en verzorgen 
van de proefdieren die ik nodig had voor de experimenten. 
Hoofdstuk VI zou nooit tot stand gekomen zijn zonder medewerking van 
enkele mensen van de afdeling Interne Geneeskunde III van de Erasmus 
Universiteit van Rotterdam. Prof.dr.ir.T.J. Visser ben ik zeer erkentelijk voor 
de wetenschappelijke inbreng op het gebied van glucuronideringsprocessen 
van schildklierhormoon. Beste Theo, door jou ben ik veel meer gaan 
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begrijpen van processen die betrokken zijn bij de afbraak van 
schildklierhormoon. Verder dank dat je mij de gelegenheid hebt gegeven in 
het laboratorium de benodigde experimenten te doen. Dit laatste heb ik met 
veel plezier gedaan in samenwerking met analyste Ellen Kaptein, die met een 
uitzonderlijk geduld de experimenten wist te completeren. 
Dr. Jaap Kruse, dr. Chris Zurcher, Wim Meuling en Michel Boermans wil 
ik bedanken voor de hulp die ze geboden hebben bij het construeren en het 
tot stand komen van de grafieken en foto's. 
Dr. Graham Elliott en dr. Beverly Kulig ben ik erkentelijk voor hel 
corrigeren van stukken lekst op het gebied van de Engelse taal. 
Mijn ouders wil ik bedanken voor de enorme steun die ik van hen zo vaak 
ondervond, en als zeer waardevol ervaren heb. 
Beste allemaal, bedankt. Ik heb een boeiende en leuke promotielijd 
gehad. 
JEROEN 
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